Mechanisms by which di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate disrupt ovarian folliculogenesis and steroidogenesis by Hannon, Patrick
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 Patrick R. Hannon
 
 
 
 
 
MECHANISMS BY WHICH DI(2-ETHYLHEXYL) PHTHALATE AND MONO(2-
ETHYLHEXYL) PHTHALATE DISRUPT OVARIAN FOLLICULOGENESIS AND 
STEROIDOGENESIS 
 
 
 
 
 
 
BY 
 
PATRICK R. HANNON 
 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in VMS - Comparative Biosciences 
in the Graduate College of the  
University of Illinois at Urbana-Champaign, 2015 
 
 
 
 
 
Urbana, Illinois 
 
 
Doctoral Committee: 
 
Professor Jodi A. Flaws, Chair 
Professor Indrani C. Bagchi 
Professor Romana A. Nowak 
Assistant Professor Megan M. Mahoney 
 
ABSTRACT  
 Di(2-ethylhexyl) phthalate (DEHP) is a synthetic plasticizer used in the manufacturing of 
common polyvinyl chloride consumer, medical, and building products. Humans are exposed to 
DEHP on a daily basis because of its high production volumes, incorporation into widely used 
products, and its ability to leach out of the products. Daily exposure to DEHP results in 
measureable levels of the chemical and its metabolite mono(2-ethylhexyl) phthalate (MEHP) in 
human blood, urine, amniotic fluid, umbilical cord blood, breast milk, and ovarian follicular fluid 
samples. This is of public health concern because DEHP and MEHP are known endocrine 
disrupting chemicals and reproductive toxicants in the female.  
 The ovary is a primary regulator of the female reproductive and endocrine systems. Thus, 
proper regulation of ovarian function is required for reproductive health and steroid hormone 
controlled non-reproductive health. Two ovarian processes that are essential for normal ovarian 
function are folliculogenesis and steroidogenesis. Follicles are the functional units of the ovary 
containing the oocyte required for ovulation and fertilization and somatic cells responsible for 
synthesizing sex steroid hormones. Folliculogenesis is the process by which follicles undergo 
several irreversible developmental transitions starting from the most immature stage, the 
primordial follicle, to the most mature stage, the antral follicle. Steroidogenesis is the process by 
which somatic cells in the antral follicle enzymatically convert cholesterol to estradiol and other 
necessary precursor steroid hormones in a step-wise manner.  
 Improper regulation of ovarian folliculogenesis and steroidogenesis can lead to 
reproductive and non-reproductive complications. Specifically, aberrant regulation of 
folliculogenesis, indicated by an accelerated depletion or activation of primordial follicles, can 
lead to premature ovarian failure and infertility. This is because the primordial follicle reserve is 
set at birth and constitutes a female’s reproductive potential. Additionally, an increase in atresia, 
an apoptosis controlled process of follicular death, can also cause premature ovarian failure and 
infertility. Further, aberrant regulation of steroidogenesis, indicated by an inhibition of steroid 
hormone synthesis, can lead to infertility. This is because the hormones produced by the ovary 
act on the hypothalamus-pituitary-ovarian axis and the reproductive tract to regulate ovulation 
and the initiation of fertilization and pregnancy. Additionally, the hormones produced by the 
ovary act on non-reproductive tissues to regulate the cardiovascular, skeletal, and brain systems. 
Thus, defects in steroidogenesis are also associated with non-reproductive complications.  
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Very few studies have investigated the effects of environmentally relevant levels of DEHP and 
MEHP on ovarian folliculogenesis and steroidogenesis. Thus, the goal of my doctoral 
dissertation work was to investigate the ovotoxic effects of DEHP and MEHP on folliculogenesis 
and steroidogenesis and to elucidate the mechanisms by which these chemicals disrupt these 
essential processes. Specifically, I investigated whether and how DEHP and MEHP accelerate 
early folliculogenesis in vivo and in vitro. Further, I investigated how DEHP and MEHP disrupt 
the functionality of the antral follicle and inhibit estradiol production in adult antral follicles in 
vitro.   
I first tested the hypothesis that environmentally relevant levels of DEHP disrupt folliculogenesis 
in vivo by over-activating the phosphatidylinositol 3-kinase (PI3K) signaling pathway leading to 
the acceleration of primordial follicle recruitment. Factors within the PI3K signaling pathway are 
regulators of primordial follicle survival, quiescence, and recruitment. Specifically, factors that 
inhibit PI3K signaling maintain primordial follicle quiescence, and factors that drive PI3K 
signaling promote primordial follicle recruitment. I found that DEHP exposure for 10 and 30 
days accelerated primordial follicle recruitment, evident by a decrease in the percentage of 
primordial follicles and an increase in the percentage of primary follicles. Additionally, DEHP 
exposure for 10 and 30 days at doses that accelerate primordial follicle recruitment increased 
factors that drive PI3K signaling and decreased factors that inhibit PI3K signaling.  
I next tested the hypothesis that DEHP directly alters regulators of the cell cycle, apoptosis, and 
the steroidogenic pathway in antral follicles in vitro to disrupt antral follicle functionality. Antral 
follicles must grow, survive from atretic demise, and produce steroid hormones to function 
normally. I found that DEHP exposure initially increased the levels of cell cycle regulators in a 
compensatory manner; however, this compensation does not rescue the follicle from growth 
inhibition. Further, I found that DEHP exposure caused atresia by increasing the levels of pro-
apoptotic factors. In addition to the effects on growth and atresia, DEHP exposure also inhibited 
steroidogenesis. Specifically, DEHP exposure decreased the levels of precursor sex steroid 
hormones, in the relative absence of changes in steroidogenic enzyme levels, at time-points prior 
to decreasing estradiol levels.  
Further, I tested the hypothesis that MEHP directly mediates the DEHP-induced acceleration of 
primordial follicle recruitment in vitro, and MEHP directly inhibits the synthesis of sex steroid 
hormones in antral follicles in vitro via a different mechanism than DEHP. For the 
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folliculogenesis experiments, I found that MEHP exposure decreased the percentage of germ 
cells and increased the percentage of primary follicles by using a neonatal ovary culture system 
enriched in primordial and primary follicles. Similar to the mechanism in vivo, MEHP exposure 
also over-activated PI3K signaling by decreasing a PI3K inhibitor and increasing a PI3K 
activator. Meanwhile, DEHP exposure did not alter follicular dynamics or PI3K signaling 
factors. Thus, MEHP mediates the effects of DEHP on folliculogenesis in vivo. For the 
steroidogenesis experiments, I found that MEHP exposure inhibits estradiol production later then 
DEHP exposure. Specifically, MEHP exposure decreased the levels of steroidogenic enzymes, in 
the relative absence of prior changes in steroid hormone levels, at the same time-point in which 
estradiol levels are decreased. Thus, DEHP and MEHP differentially inhibit steroidogenesis in 
the antral follicle. Collectively, my doctoral dissertation data suggest that DEHP and MEHP 
disrupt ovarian folliculogenesis and steroidogenesis, which are essential processes for normal 
reproductive and non-reproductive health.       
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CHAPTER I 
Overview 
1.1 Overview 
Di(2-ethylhexyl) phthalate (DEHP) is a synthetic plasticizer used in the manufacturing of 
common polyvinyl chloride consumer, medical, and building products [1, 2]. DEHP is produced 
in vast quantities because it is incorporated into a myriad of commonly used products, ranging 
from flooring, roofing, and carpeting to packaging for food and beverages and personal care 
products [2]. This is of concern because DEHP is non-covalently bound to the plastic and 
frequently leaches into the products that humans consume causing daily exposure via oral 
ingestion, inhalation, and dermal contact [2]. In fact, DEHP and its metabolite mono(2-
ethylhexyl) phthalate (MEHP) are top contaminates present in human tissues including blood [3, 
4], urine [1, 3-7], amniotic fluid [8-10], umbilical cord blood [11, 12], and breast milk [4].  
From a public health standpoint, exposure to DEHP is concerning because it has been identified 
as a reproductive toxicant and endocrine disrupting chemical, often with toxicity mediated by its 
bioactive metabolite MEHP [1, 2]. Specifically, DEHP and MEHP have anti-androgenic effects 
in males indicated by tubular atrophy, testicular degeneration, and inhibition of testicular 
steroidogenesis [13, 14]. Further, DEHP and MEHP disrupt pregnancy outcomes indicated by an 
association with decreased rates of pregnancy and high rates of miscarriage in women [1] and 
reduced implantations, increased resorptions, and decreased fetal weights of offspring in 
laboratory animals [15, 16]. Interestingly, very few studies have investigated the effects of 
DEHP and MEHP on the ovary, even though the ovary is a regulator of these pregnancy 
outcomes, and MEHP is found in ovarian follicular fluid, indicating that these chemicals can 
reach the ovary [17].  
The ovary is a heterogeneous organ primarily consisting of follicles, which are the functional 
ovarian units, at varying stages of development. Follicles contain the oocyte, which is the female 
germ cell, surrounded by granulosa and theca cells, which are somatic cells. The female is born 
with a finite number of primordial follicles, the most immature follicle type, which undergo 
several irreversible transitions to become primary follicles, preantral follicles, and then antral 
follicles, the most mature follicle type also containing a fluid filled antral space [18]. This 
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process of development is known as folliculogenesis and is an essential process for normal 
reproductive and non-reproductive health. Once matured, the antral follicles are the only follicles 
capable of ovulation and are the major producers of sex steroid hormones in the female. The 
production of steroid hormones, a process known as steroidogenesis, involves the enzymatic 
conversion of cholesterol to 17β-estradiol and other necessary sex steroid hormones by the theca 
and granulosa cells [19, 20]. Steroidogenesis is another essential process for normal ovarian 
function because the steroid hormones produced by the ovary are required for reproductive and 
non-reproductive health [21-38].  
Previous studies indicate that the ovary may be a potential target of DEHP and MEHP toxicity. 
These studies suggested that DEHP at supraphysiological levels decreases serum estradiol levels, 
decreases aromatase levels, causes anovulation, and prolongs estrous cycles in vivo [39]. Further, 
studies using granulosa cell cultures suggested that MEHP decreases estradiol and aromatase 
levels [40-42]. However, the direct effects of these chemicals on the mature, antral follicle, and 
the mechanisms by which DEHP and MEHP inhibit estradiol levels are unknown. Further, aside 
from these few studies showing steroidogenic defects, the effects of DEHP and MEHP on 
ovarian folliculogenesis remain largely unknown. Thus, the overall goal of my doctoral 
dissertation work was to investigate the ovotoxic effects of DEHP and MEHP on folliculogenesis 
and steroidogenesis and to elucidate the mechanisms by which these chemicals disrupt these 
essential processes. 
To achieve this goal, I specifically tested three main hypotheses: 1) Environmentally relevant 
levels of DEHP disrupt folliculogenesis in vivo by over-activating the phosphatidylinositol 3-
kinase (PI3K) signaling pathway leading to the acceleration of primordial follicle recruitment, 2) 
DEHP directly alters regulators of the cell cycle, apoptosis, and the steroidogenic pathway in 
antral follicles in vitro to disrupt antral follicle functionality, and 3) MEHP directly mediates the 
DEHP-induced acceleration of primordial follicle recruitment in vitro, and MEHP directly 
inhibits the synthesis of sex steroid hormones in antral follicles in vitro via a different 
mechanism than DEHP. To test these hypotheses, I completed the following specific aims 
(Figure 1.1): 
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Specific Aim 1: Determine if environmentally relevant levels of DEHP over-activate PI3K 
signaling to accelerate primordial follicle recruitment in vivo.  
To complete this aim, I orally dosed adult CD-1 mice with vehicle control (tocopherol-stripped 
corn oil) or DEHP (20 μg/kg/day, 200 μg/kg/day, 20 mg/kg/day, 200 mg/kg/day, and 750 
mg/kg/day) daily for 10 and 30 days. Following dosing, I examined the effects of DEHP on 
follicular dynamics and the expression and protein levels of key PI3K signaling factors 
associated with folliculogenesis. The data indicate that DEHP exposure for 10 days decreased the 
percentage of primordial follicles and increased the percentage of primary follicles. Further, 
DEHP exposure for 30 days increased the percentage of primary follicles. In addition, DEHP 
exposure increased the ovarian mRNA levels of 3-phosphoinositide dependent protein kinase-1 
(Pdpk1), mammalian target of rapamycin complex 1 (Mtorc1), and the ovarian protein levels of 
phosphorylated protein kinase B (pAKT), which are all factors that drive PI3K signaling and 
primordial follicle recruitment. Further, DEHP exposure decreased the ovarian mRNA and 
protein levels of phosphatase and tensin homolog (PTEN), which is a factor that inhibits PI3K 
signaling and maintains primordial follicle quiescence. Collectively, these data suggest that 
DEHP exposure accelerates primordial follicle recruitment potentially via over-activation of 
ovarian PI3K signaling in vivo. These data are presented in Chapter 3.  
Specific Aim 2: Elucidate the mechanisms by which DEHP inhibits growth, induces atresia, 
and inhibits steroidogenesis is the antral follicle in vitro. 
 To complete this aim, I cultured antral follicles from adult CD-1 mice with vehicle 
control (dimethylsulfoxide, DMSO) or DEHP (1 μg/ml, 10 μg/ml, and 100 μg/ml) for 24-96 hr. 
Following each 24 hr time-point, I examined the effects of DEHP on the expression of cell cycle 
regulators, regulators of apoptosis, and steroidogenic enzymes. Further, I examined the effects of 
DEHP on the production of sex steroid hormones levels. The data indicate that DEHP inhibited 
antral follicle growth by altering the mRNA levels of cyclin D2 (Ccnd2), cyclin dependent 
kinase 4 (Cdk4), cyclin E1 (Ccne1), cyclin A2 (Ccna2), cyclin B1 (Ccnb1), and cyclin-
dependent kinase inhibitor 1A (Cdkn1a) prior to growth inhibition. Further, DEHP induced 
antral follicle atresia by increasing the mRNA levels of pro-apoptotic factors prior to atresia, 
such as BCL2-associated agonist of cell death (Bad), BCL2-associated X protein (Bax), and 
BCL2-related ovarian killer protein (Bok). In addition, DEHP decreased estradiol production by 
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decreasing the levels of the precursor sex steroid hormones progesterone, androstenedione, and 
testosterone following 48 hr of exposure; as well as by decreasing the mRNA levels of the 
steroidogenic enzymes side-chain cleavage (Cyp11a1), 17α-hydorxylase-17,20-desmolase 
(Cyp17a1), 17β-hydroxysteroid dehydrogenase (Hsd17b1), and aromatase (Cyp19a1). These 
data are presented in Chapter 4.  
Specific Aim 3: Compare and contrast the mechanisms by which DEHP and MEHP 
directly accelerate primordial follicle recruitment and inhibit steroidogenesis.  
 To complete this aim, for the folliculogenesis experiments, I cultured neonatal ovaries 
from CD-1 mice with vehicle control (DMSO), DEHP (0.2 μg/ml, 2 μg/ml, and 20 μg/ml), or 
MEHP (0.2 μg/ml, 2 μg/ml, and 20 μg/ml) from day four to day ten. Following culture, I 
examined the effects of DEHP and MEHP on follicular dynamics and PI3K signaling. To further 
complete this aim, for the steroidogenesis experiments, I cultured antral follicles from adult CD-
1 mice with vehicle control (DMSO) or MEHP (0.1 μg/ml, 1 μg/ml, and 10 μg/ml) for 24-96 hr. 
Following each 24 hr time-point, I examined the effects of MEHP on the expression of 
steroidogenic enzymes and the production of sex steroid hormones. In the neonatal ovaries, 
MEHP, but not DEHP, decreased the percentage of germ cells and increased the percentage of 
primary follicles. In addition, MEHP decreased the levels of PTEN in the whole ovary, 
decreased the percentage of positively stained PTEN primordial follicle oocytes, and increased 
the percentage of positively stained pAKT primordial follicle oocytes. Meanwhile, DEHP treated 
ovaries had comparable levels of PTEN and pAKT to vehicle control treated ovaries. In the 
antral follicles, MEHP decreased the mRNA levels of 17α-hydroxylase-17,20-desmolase 
(Cyp17a1), 17β-hydroxysteroid dehydrogenase (Hsd17b1), and aromatase (Cyp19a1) following 
96 hr, ultimately leading to a decrease in the levels of testosterone, estrone, and estradiol. These 
data are presented in Chapter 5.  
 In summary, Chapter 1 described the overview of my dissertation. Chapter 2 provides the 
background on phthalates, the ovary, ovarian toxicology, and the toxic effects of phthalates on 
ovarian function. Chapter 3 describes the work that tested the hypothesis that environmentally 
relevant levels of DEHP disrupt folliculogenesis in vivo by over-activating the 
phosphatidylinositol 3-kinase (PI3K) signaling pathway leading to the acceleration of primordial 
follicle recruitment. Chapter 4 describes the work that tested the hypothesis that DEHP directly 
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alters regulators of the cell cycle, apoptosis, and steroidogenic pathway in antral follicles in vitro 
to disrupt antral follicle functionality. Chapter 5 describes the work that tested the hypothesis 
that MEHP directly mediates the DEHP-induced acceleration of primordial follicle recruitment 
in vitro, and MEHP directly inhibits the synthesis of sex steroid hormones in antral follicles in 
vitro via a different mechanism than DEHP. Finally, Chapter 6 summarizes the findings of my 
dissertation work and outlines future research directions.  
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1.2 Figures and Legends 
 
Figure 1.1 Model of DEHP- and MEHP-induced ovarian toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model depicts the proposed mechanisms by which DEHP and MEHP disrupt ovarian 
folliculogenesis and steroidogenesis. I propose that DEHP accelerates primordial follicle 
recruitment in vivo, by over-activating PI3K signaling (Specific Aim 1). In addition, I propose 
that DEHP inhibits growth, induces atresia, and inhibits steroidogenesis in antral follicles in 
vitro, by altering the levels of regulators of the cell cycle, apoptosis, and steroidogenesis 
(Specific Aim 2). Further, I propose that MEHP mediates the effects of DEHP on 
folliculogenesis, and MEHP inhibits steroidogenesis via a different mechanism than DEHP 
(Specific aim 3). 
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CHAPTER II 
The Effects of Phthalates on the Ovary1 
2.1 Abstract 
Phthalates are commonly used as plasticizers in the manufacturing of flexible polyvinyl chloride 
products. Large production volumes of phthalates and their widespread use in common 
consumer, medical, building, and personal care products lead to ubiquitous human exposure via 
oral ingestion, inhalation, and dermal contact. Recently, several phthalates have been classified 
as reproductive toxicants and endocrine disrupting chemicals based on their ability to interfere 
with normal reproductive function and hormone signaling. Therefore, exposure to phthalates 
represents a public health concern. Currently, the effects of phthalates on male reproduction are 
better understood than the effects on female reproduction. This is of concern because women are 
often exposed to higher levels of phthalates than men through their extensive use of personal 
care and cosmetic products.  In the female, a primary regulator of reproductive and endocrine 
function is the ovary. Specifically, the ovary is responsible for folliculogenesis, the proper 
maturation of gametes for fertilization, and steroidogenesis, and the synthesis of necessary sex 
steroid hormones. Any defect in the regulation of these processes can cause complications for 
reproductive and non-reproductive health. For instance, phthalate-induced defects in 
folliculogenesis and steroidogenesis can cause infertility, premature ovarian failure, and non-
reproductive disorders. Presently, there is a paucity of knowledge on the effects of phthalates on 
normal ovarian function; however, recent work has established the ovary as a target of phthalate 
toxicity. This review summarizes what is currently known about the effects of phthalates on the 
ovary and the mechanisms by which phthalates exert ovarian toxicity, with a particular focus on 
the effects on folliculogenesis and steroidogenesis. Further, this review outlines future directions 
including the necessity of examining the effects of phthalates at doses that mimic human 
exposure.  
  
1 Reprinted, with permission, from PR. Hannon and JA. Flaws. The effects of phthalates on the ovary. Frontiers in 
Endocrinology 2015 Feb; 6:8. Epub 2015 Feb 2.  
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2.2 Phthalates  
 Phthalates are ubiquitous environmental toxicants to which humans are exposed on a 
daily basis [1]. They are a group of synthetic chemicals composed of alkyl diesters of phthalic 
acid and are named based on their varying lengths of alkyl chains (Figure 2.1). Normally, 
phthalates in their pure form are colorless, odorless, oily liquids with high lipophilic properties 
and low solubility in water. Phthalates are predominantly used as plasticizers in polyvinyl 
chloride consumer, medical, and building products to impart flexibility, as matrices and solvents 
in personal care products, and as excipients in medications and dietary supplements. As 
plasticizers, phthalates are present in commonly used items such as flooring, roofing, carpeting, 
shower curtains, packaging equipment, food and beverage packaging, automotive parts, and even 
in children’s toys. Interestingly, di(2-ethylhexyl) phthalate (DEHP) is present in common 
medical devices such as tubing, blood and intravenous bags, dialysis equipment, and in the 
manufacturing of disposable and surgical gloves [2]. As matrices and solvents, phthalates are 
commonly found in consumer and cosmetic products ranging from hairsprays and perfumes to 
pesticides and wood finishes. Further, they are frequently used as adhesives, defoaming agents, 
and lubricants [3]. As excipients, some phthalates are incorporated in the enteric coating of oral 
medications and in dietary supplements ranging from certain fish oils to probiotics [4, 5]. Thus, 
there are multiple means of phthalate exposures due to their presence in a wide range of products 
used by humans on a daily basis. 
 Daily exposure to phthalates is also attributed to their widespread production. The global 
production and use of phthalates exceeds 18 billion pounds per year, in which the majority of 
phthalates are used in polyvinyl chloride products [6]. The most commonly used phthalate is 
DEHP, which belongs to a group of phthalates known as dioctyl phthalates. Domestic production 
of dioctyl phthalates exceeds 300 million pounds annually [7]. Dibutyl phthalate (DBP) and 
diethyl phthalate (DEP) are also produced in high volumes and are among the most commonly 
used phthalates in consumer products. Production and importation of DBP was estimated to be 
between 10 to 50 million pounds in the United States in 2006 [8]. Further, production of DEP 
reached 50 million pounds in the United States in 2005 [9].  
Phthalates are non-covalently bound to plastics, meaning they frequently leach from these items 
into environmental sources such as in the atmosphere, soil and sediments, and natural water 
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bodies [10-12]. Phthalate contamination in the air can range from 1-50 ng/m3, but DEHP is often 
found at higher levels (up to 3640 ng/m3) [10]. Once in the air, phthalates typically bind to dust 
particles and are carried back to ground level [7]. Phthalates are also detectible in sediments 
(0.01-115 mg/kg), agricultural soil (0.02-264 mg/kg), and urban soil (0.01-30.1 mg/kg) [10]. 
Urban sewer wastewater is another source of phthalate accumulation in the environment. Median 
phthalate levels are 3.46 µg/l in industrial wastewater, 61.3 µg/l in residential wastewater, and 
66.0 µg/l in man-made wastewater [10]. Further, phthalates are found in surface water, including 
freshwater, saltwater, and industrial water, at levels ranging from 0.29-1.24 µg/l [10, 13-15]. 
Based on their presence in natural water bodies, fish and other aquatic animals are also exposed 
to phthalates. Although few studies have measured the levels of phthalates in fish populations, 
levels of DEHP and DBP in freshwater fish are 1.8 µg/kg each [16]. Further, levels of phthalates 
in saltwater biota range from 0.0022-28.7 µg/g, and interestingly, phthalates do not appear to 
accumulate up trophic positions [17]. Although few studies have investigated the lifespan of 
phthalates in the environment, phthalates are considered fairly stable in the environment and can 
persist for quite a long time [7, 18-20]. Phthalates in the air and soil dissolve very slowly, 
whereas phthalates in surface water dissolve quicker in water with a half-life of 2-3 weeks [7, 
18-20].            
The widespread production of phthalates, their use in commonly used products, and their 
presence in the environment leads to daily human exposure via oral ingestion, inhalation, and 
dermal contact. The most common routes of exposure are via oral ingestion from food packaging 
and use of cosmetic products, but high levels of phthalates are also present in household dust [21, 
22]. Based on large production volumes, widespread use, and environmental contamination, 
biomonitoring data suggest that 75-100% of the population is exposed to phthalates on a daily 
basis [23-25].  Thus, exposure to phthalates is ubiquitous in human populations.  
Once consumed, phthalates are rapidly metabolized in the gut, liver, and blood by esterases and 
lipases. Initially, the phthalate diester is cleaved to its respective hydrolytic monoester where 
only one alkyl chain remains on the phthalic acid backbone, and interestingly, it is often the 
monoester metabolites that induce toxicity.  Depending on the size of the remaining monoester 
metabolite, the alkyl chain can undergo further oxidative metabolism and ultimately 
glucuronidation depending on the species [21, 26]. These hydrolytic monoester and oxidative 
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monoester metabolites, in addition to the parent phthalates, are used as biomarkers to estimate 
daily human exposure levels [26]. Careful attention to the metabolite used for biomonitoring is 
essential for accurate estimations of daily exposure levels. For example, it is more accurate to 
measure oxidative monoester metabolites from high molecular weight phthalates, such as DEHP, 
than it is to measure the hydrolytic monoester metabolite [26]. In one study, the concentrations 
of the oxidative monoester metabolites of DEHP, mono(2-ethyl-5-oxohexyl) phthalate and 
mono(2-ethyl-5-hydroxyhexyl) phthalate, were found to be four-fold higher than the hydrolytic 
monoester metabolite, mono(2-ethylhexyl) phthalate (MEHP) [27]. Thus, some metabolites are 
more sensitive biomarkers than others. 
As mentioned, the vast majority of the population is exposed to phthalates on a daily basis, but 
the level of exposure to each phthalate differs. It is estimated that the average total daily 
individual ambient exposure to DEHP ranges from 0.21-2.1 mg/day for the general population 
[28-32]. Thus, the estimated range of daily human exposure to DEHP is 3-30 µg/kg/day based on 
urinary metabolite concentrations; however, measurements of DEHP in household dust can reach 
up to 700 mg/kg, potentially increasing exposure levels in certain individuals [22, 29, 33]. Koch 
and Calafat compiled data from the United States and German populations where urinary 
metabolites were used to estimate daily exposure levels for other commonly used phthalates, 
such as DEP, butyl benzyl phthalate (BBP), DBP, and diisobutyl phthalate (DIBP). The 
estimated range of daily human exposure to DEP is 2.32-12 µg/kg/day, BBP is 0.26-0.88 
µg/kg/day, DBP is 0.84-5.22 µg/kg/day, and DIBP is 0.12-1.4 µg/kg/day [26]. Based on these 
exposure levels, phthalates have been identified as top contaminants present in human tissues. As 
stated above, measureable levels of phthalates are found in human urine samples tested and in 
95% of human blood samples tested [1, 22, 23, 25, 34]. In particular to reproduction and 
development, DEHP and its metabolites are present in 90-100% of amniotic fluid samples from 
second trimester fetuses, cord blood samples from newborns, breast milk from nursing mothers, 
and even in human ovarian follicular fluid, indicating their ability to reach the ovary [1, 23, 34, 
35].  
Interestingly, certain individuals are exposed to much higher levels of phthalates than the general 
population. Not surprisingly, the levels are much higher in humans occupationally exposed to 
phthalates. For example, it was estimated that in the 1980s, over 340,000 and 239,149 workers 
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were exposed to DEHP and DEP, respectively [36]. Further, the exposure level of DEHP to these 
workers was between 143-286 µg/kg/day [37].  
The highest exposures to phthalates often result from medical therapies. Both DEP and DEHP 
are incorporated in medical equipment, and DEP and DBP can be found in the enteric coating of 
oral medications. Based on its use in medical equipment, levels of DEHP can reach 8.5 
mg/kg/day following blood transfusions, 0.36 mg/kg/day following hemodialysis, and 14 
mg/kg/day following extracorporeal membrane oxygenation procedures in neonates [38]. 
Additionally, infants in intensive neonatal care units had levels of DEHP metabolites that were 
14 times higher than infants in a low-intensive unit [39]. Based on their use in oral medications, 
urinary levels of monoethyl phthalate (MEP), the monoester metabolite of DEP, and monobutyl 
phthalate (MBP), the monoester metabolite of DBP, in women of childbearing age were over 12 
and 200 times higher, respectively, than in a reference population [40]. In another study, urinary 
measurements of MBP were 50 times higher in subjects that reported using oral medications 
containing DBP than in controls [5].  
Important for the topic of this review, women have a phthalate exposure profile that is different 
than that in men. In fact, females at all ages have increased urinary phthalate metabolite levels 
when compared to men at that same age [23]. Compared to males, females have higher levels of 
MEP, MBP, monobenzyl phthalate (MBzP), and MEHP [23]. Interestingly, women of 
reproductive age have the highest exposure levels of MBP than any other age/sex group [41]. 
These findings are likely attributed to the widespread use of phthalates, in particular MBP, in 
common cosmetic and personal care products that females use on a daily basis, including 
perfume, lotion, nail polish, and hairspray.  
Exposure to phthalates is a public health concern because several have been identified as 
reproductive and developmental toxicants and endocrine disrupting chemicals (EDCs). In 
females, chronic occupational exposure to high levels of phthalates has been associated with 
decreased rates of pregnancy and high rates of miscarriage [1, 42]. Further, high urinary 
phthalate levels are associated with pregnancy complications such as anemia, toxemia, and 
preeclampsia in women [43]. In laboratory animals, phthalates reduce implantations, increase 
resorptions, decrease fetal weights of offspring, and decrease incidence of pregnancy [44, 45]. 
The mechanisms by which phthalates disrupt these endocrine and reproductive events remain 
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unknown. Interestingly, the ovary is a critical regulator of these processes, and the effects of 
phthalates on ovarian function remain poorly understood. The next sections will provide 
background on the importance of normal ovarian function for reproductive and non-reproductive 
health and how EDCs, like phthalates, can disrupt ovarian function. 
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2.3 The Ovary 
 The ovary is the female gonad responsible for reproduction and is a primary component 
of the female endocrine system. This heterogeneous organ is comprised of a surface epithelium 
surrounding the ovary, an outer cortex region containing ovarian follicles, corpora lutea, and 
stroma, and an inner medulla region containing a vast network of blood vessels, lymphatic 
vessels, and nerves. The main functions of the ovary include maturation and ovulation of the 
female gamete (oocyte) for fertilization and secretion of sex steroid hormones necessary for 
reproductive and non-reproductive health.  
Folliculogenesis  
 One of the primary functions of the ovary is the development and maturation of follicles 
to allow for ovulation of the oocyte for subsequent fertilization. The ovarian follicle is the 
functional unit of the ovary that consists of the oocyte surrounded by two somatic cell types 
termed the granulosa cells and the theca cells. Within the ovarian unit, follicles undergo several 
irreversible developmental transitions, and this process of follicular development is known as 
ovarian folliculogenesis (Figure 2.2).  
 In mammals, the female is born with a finite number of follicles; thus, the follicular 
reserve is set at birth and represents a female’s reproductive potential and reproductive lifespan 
[46]. These follicles are first formed during the later stages of fetal life in the human and during 
the early postnatal life in the rodent. The process of follicle formation is known as germ cell nest 
breakdown. During embryonic development, primordial germ cells, which will give rise to 
oocytes, migrate from the yolk sac to the genital ridge where the undifferentiated gonad resides 
[47]. These germ cells, now termed oogonia, massively proliferate via mitosis and develop in 
clusters or nests in which squamous pre-granulosa cells surround the oogonia [48]. Once 
established in the germ cell nests, mitosis of oogonia is ceased and meiosis begins. It is here that 
the oogonia become oocytes, and the oocytes progress through meiosis until they are arrested in 
the diplotene stage of meiotic prophase I [49].  
Ovarian follicle assembly then occurs around the 6-9th month of gestation in the human and 
around post-natal day 3 in the rodent in which the most immature follicle type, the primordial 
follicle, is formed [50, 51]. For primordial follicle assembly to occur, the germ cell nests must 
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undergo programmed cell death of oocytes, primarily through regulation of the B-cell 
lymphoma/leukemia-2 (BCL-2) family members [52-56] and the actions of steroid hormone and 
intraovarian growth and transcription factors [57, 58]. The interaction of these molecular events 
leads to oocyte association with a single layer of flattened, squamous pre-granulosa cells, thus, 
the formation of the primordial follicle.       
Once the primordial follicle population is established, the follicle is destined to three fates: to 
remain quiescent for varying lengths of time to constitute the ovarian reserve, to directly undergo 
atresia, which is follicular programmed cell death via apoptosis, or to activate into the growing 
population of follicles to become primary follicles, a process termed primordial follicle 
recruitment. Primordial follicle recruitment is a tightly regulated process controlled by 
multidirectional communication between the oocyte, granulosa cells, and surrounding somatic 
cells that will give rise to the theca cells. This process is gonadotropin-independent and relies on 
paracrine and autocrine regulation by multiple intrinsic ovarian growth factors that work through 
several different signaling pathways [46, 58-61]. Primordial follicle quiescence is maintained by 
factors that suppress follicle activation, whereas primordial follicle recruitment is initiated by 
factors that activate development. These stimulatory and inhibitory factors exist in a balance to 
maintain primordial follicle survival so that downregulation of inhibitory factors and/or 
overactivation of stimulatory factors favor an environment conducive for primordial follicle 
recruitment [62]. 
Once activated, primary follicles contain a larger oocyte that has initiated growth surrounded by 
a single layer of cuboidal granulosa cells. Primary follicles then develop into preantral follicles, 
also termed secondary and tertiary follicles, that contain the oocyte surrounded by at least two 
layers of cuboidal granulosa cells and two outer theca cell layers. Follicles at this stage, because 
of the presence of both granulosa and theca cells, are gonadotropin-responsive and begin 
synthesizing sex steroid hormones. 
 Preantral follicles then develop further into antral follicles, which are the most mature follicle 
type in the ovary. Antral follicles contain the oocyte surrounded by several layers of cuboidal 
granulosa cells with a fluid filled space, termed the antral space, and two outer theca cell layers.  
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Each fertile menstrual/estrous cycle requires the presence of a pre-existing antral follicle 
population that responds to cyclic gonadotropins, and this process is termed cyclic recruitment 
[60]. Therefore, folliculogenesis must remain dynamic to allow for the continual generation of 
antral follicles to undergo cyclic recruitment for potential ovulation. As antral follicles continue 
to mature, they produce estradiol and their receptivity to the gonadotropins, follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), increases. The increase in estradiol initiates the 
LH surge causing one or multiple follicles to ovulate depending on the species. Once the oocyte 
is released, the remaining granulosa and theca cells differentiate into large and small luteal cells 
respectively, and the remaining structure is termed the corpus luteum. 
Not all follicles are destined to develop and ovulate, and in fact, approximately 99% of follicles 
undergo atresia. At birth, the human ovary contains approximately two million follicles, but by 
puberty, the number of follicles declines to roughly 400,000 due to atretic demise. Further, of the 
available follicles at puberty, only about 400 of them will ovulate throughout the reproductive 
lifespan, whereas the others undergo atresia [50]. Atresia is a coordinated process of follicle 
degeneration via hormonally controlled apoptosis [63]. Although atresia can occur at all stages of 
follicle development, early antral follicles are most susceptible to death in which apoptosis can 
occur in both somatic and germ cells. The regulation of follicular atresia involves a balance of 
pro- and anti-apoptotic factors. Specifically, gonadotropins, estrogens, insulin-like growth factor-
I, and interleukin-1β are anti-apoptotic and help prevent follicles from undergoing atresia [64-
70]. Conversely, tumor necrosis factor-α, Fas-Fas ligand, and androgens promote apoptosis and 
ultimately atresia [71-74]. The interplay of these pro- and anti-apoptotic factors primarily 
converge on the BCL-2 signaling pathway, with its own pro- and anti-apoptotic proteins, to 
regulate atresia [53-56].  
Ovarian steroidogenesis   
 Another primary function of the ovary is to produce sex steroid hormones, a process 
termed ovarian steroidogenesis. Steroidogenesis is primarily conducted by the mature antral 
follicle and the corpus luteum following ovulation. The process of steroidogenesis involves the 
enzymatic conversion of cholesterol to 17β-estradiol and other necessary sex steroid hormones to 
regulate reproductive and non-reproductive health (Figure 2.3). Prior to the peri-ovulatory 
period, the antral follicle increases the synthesis of estradiol to promote the ovulatory surge of 
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LH. As ovulation approaches, the peri-ovulatory follicle increases production of progesterone to 
promote ovulation and formation of the corpus luteum. Once the follicle has transitioned to the 
highly vascularized corpus luteum, vast amounts of progesterone as well as estradiol are 
produced.  
The steroid hormones produced by the ovary act on numerous target tissues associated with 
reproductive and non-reproductive function.  For reproductive function, steroid hormones act on 
the ovary itself as well as the brain, pituitary, oviduct, uterus, cervix, vagina, and mammary 
gland. The actions of these steroid hormones include maintenance of the reproductive tract; 
establishment of a hormonal milieu for ovulation, fertilization, implantation, and pregnancy; and 
control of menstrual/estrous cyclicity by utilizing feedback loops in the brain and pituitary. 
These steroid hormones also act in non-reproductive tissues such as the brain, cardiovascular 
system, adipose tissue, skin, bone, and liver. Therefore, proper steroidogenesis is required for 
fertility as well as for maintenance of cardiovascular, brain, and skeletal health  
[75-91].  
The generation of sex steroid hormones involves several enzymatic reactions in both the theca 
and granulosa cells. Specifically, cholesterol can either be transported into the theca cell 
cytoplasm via lipoprotein receptors or it can be synthesized de novo. Cholesterol is then 
internalized into the mitochondria via the steroidogenic acute regulatory protein (STAR) [92-94]. 
Cholesterol is then converted to pregnenolone in the mitochondria via cytochrome P450 
cholesterol side-chain cleavage (CYP11A1) [95, 96]. Pregnenolone then diffuses out of the 
mitochondria and is transported to the smooth endoplasmic reticulum where it is converted to 
progesterone or dehydroepiandrosterone (DHEA) via 3β-hydroxysteroid dehydrogenase 
(HSD3B) or 17α-hydorxylase-17,20-desmolase (CYP17A1), respectively [97]. Progesterone and 
DHEA are then converted to the androgen androstenedione again via CYP17A1 or HSD3B, 
respectively [96]. Androstenedione can then be converted to either testosterone, another 
androgen, or estrone, a weak estrogen, via 17β-hydroxysteroid dehydrogenase (HSD17B) or 
aromatase (CYP19A1), respectively [96]. Testosterone and estrone are then converted to the 
most potent estrogen, estradiol, via CYP19A1 or HSD17B, respectively [96, 97]. Estradiol can 
be inactivated and metabolized in the ovary to 2-hydroxyestradiol via CYP1A1/2 and CYP3A4 
or it can be broken down to 4-hydroxyestradiol via CYP1B1 [98, 99].         
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Interestingly, estradiol cannot be synthesized without the strict coordination of both theca cells 
and granulosa cells and the addition of pituitary derived FSH and LH. This is why ovarian 
steroidogenesis is known as the two-cell, two-gonadotropin theory [100, 101]. Theca cells in the 
early antral follicle only contain LH receptors, and upon receptor binding, LH stimulates the 
transcription of theca derived genes that encode the enzymes required for the conversion of 
cholesterol to the androgens [100, 101]. Once converted, androgens can diffuse from the theca 
cells through the basement membrane, which separates theca cells from granulosa cells, and into 
the granulosa cells. In contrast to theca cells, granulosa cells of the early antral follicle contain 
only FSH receptors, and in response to FSH binding, the transcription of granulosa derived genes 
that encode the enzymes necessary for the conversion of androgens to estrogens is stimulated 
[100, 101]. This distinct coordination is required because theca cells lack the CYP19A1 enzyme 
(which converts androgens to estrogens), and granulosa cells lack the CYP17A1 enzyme (which 
converts pregnenolone and progesterone to androgens). Luteal cells in the corpus luteum also 
utilize the two-cell approach to produce progesterone and estradiol [102, 103]. As is the case in 
the antral follicle, the small luteal cells that are derived from theca cells synthesize androgens 
from cholesterol, while the large luteal cells that are derived from granulosa cells convert 
androgens to estrogens.  
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2.4 Ovarian Toxicity of Endocrine Disrupting Chemicals 
Because of its multifaceted roles, it is important to understand how ubiquitous EDCs, like 
phthalates, affect normal ovarian function, as defects in ovarian function have implications for 
health other than fertility. Normal ovarian function is essential for reproductive, cardiovascular, 
mood, brain, and skeletal health [75-91].  Due to their widespread production, extensive use, and 
ubiquitous presence in the environment, phthalates have the potential to target the ovary at all 
stages of development and in adulthood. These toxic effects can lead to premature ovarian 
failure, anovulation, infertility, and decreased steroidogenesis [104-107]. Thus, exposure to 
phthalates can disrupt normal ovarian function by several different mechanisms, leading to 
reproductive and non-reproductive abnormalities.  
 One way that EDCs can exert ovarian toxicity is through targeting follicles at different 
stages of folliculogenesis [104-107]. Specifically, chemicals can target the primordial, primary, 
preantral, or antral populations of follicles, or they can target corpora lutea. Once a particular 
population is targeted, the chemicals can induce atresia and deplete the follicles within that stage, 
they can arrest follicles within that stage, or they can promote accelerated development from that 
stage [104-107]. Each of these potential outcomes can have detrimental effects on fertility and/or 
non-reproductive health. Specifically, EDCs that deplete or accelerate the development of 
primordial follicles will cause permanent infertility caused by premature ovarian failure, or early 
onset of menopause [104-107]. This is because the primordial follicle pool is established at birth 
and is non-renewable [46]. Premature menopause is of concern because it is associated with 
increased risks of cardiovascular disease, osteoporosis, and premature death [75-78, 108-111]. 
EDCs can also target the later stages of folliculogenesis such as the antral follicle [104, 105]. 
Chemicals can cause atresia of antral follicles or inhibit the growth of antral follicles, leading to 
estrogen deficiency and anovulatory cycles and ultimately infertility [104, 105]. Similarly, EDCs 
that affect the process of luteinization, the developmental transition of a follicle to a corpus 
luteum, or the lifespan of the corpus luteum can affect progesterone production, implantation, 
and pregnancy, leading to infertility [104, 105].  
 Chemicals can also directly interfere with ovarian steroidogenesis and this can cause 
reproductive and non-reproductive complications. Steroidogenesis can be affected either by 
depletion of the antral follicles and/or corpora lutea, or it can be affected by disrupting the 
functionality of the steroidogenic units. Specifically, the loss of antral follicles or corpora lutea 
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from the ovary will result in a decrease in the available structures that are capable of producing 
steroids [104, 105]. Further, EDCs can disrupt the functionality of antral follicles by decreasing 
ovarian mRNA, protein, and/or activity of the enzymes responsible for generating estradiol and 
its precursor sex steroid hormones [104, 105]. Additionally, EDCs can increase mRNA, protein, 
and/or activity of the enzymes responsible for metabolizing estradiol; thus, rendering it inactive 
[104, 105]. The steroidogenic enzymes in the corpora lutea can also be affected in a similar 
manner, resulting in inadequate levels of necessary progesterone and estradiol to support a 
pregnancy [104, 105]. This disruption of hormone production can also alter normal 
menstrual/estrous cyclicity. A lack of ovarian derived steroid hormones will disrupt the 
hypothalamus-pituitary-ovarian axis, leading to infertile anovulatory or oligovulatory cycles by 
inhibiting the LH surge and/or altering FSH levels that are responsible for recruiting a cohort of 
antral follicles for ovulation [46, 101, 104, 105]. Defects in ovarian steroidogenesis are linked to 
infertility and an increased risk of heart disease, osteoporosis, mood disorders, and premature 
death [75-78, 108-111].           
 Removing or minimizing toxicant exposure may alleviate the ovotoxic effects, depending 
on the duration of exposure and population of follicles targeted by the chemical [106, 107]. For 
instance, if an EDC only targets the antral follicle causing ovarian toxicity, removal of the 
chemical has the potential to restore ovarian function [106, 107]. This is because the process of 
folliculogenesis from the primordial stage to the antral stage was unaffected. Once the EDC is 
removed, primordial follicles will develop to the antral stage as they had done previously, but 
now the detrimental effect will be alleviated [106, 107]. Reversal of toxic effects is nearly 
impossible when the primordial follicle pool is targeted for an extended period of time. Because 
the follicular reserve is nonrenewable, chronic exposure to an EDC that causes death of 
primordial follicles or accelerates primordial follicle recruitment will lead to permanent ovarian 
damage [106, 107]. Although removal of toxicant exposure may be beneficial in restoring 
ovarian function, exposure to many EDCs including phthalates cannot be completely removed. 
This adds to the public health concern of the use of phthalates, as even minimizing exposure can 
be a difficult task due to their ubiquitous use in common consumer products and presence in the 
environment.    
Understanding the impact on ovarian function from exposure to phthalates is of great 
importance, particularly because the general population is constantly exposed to phthalates [23-
23 
25]. This importance is compounded in certain populations that are exposed to high levels of 
phthalates on a daily basis. These populations include patients undergoing medical care with 
phthalate containing medical devices and medications, women with careers in an industrialized 
environment, and women located near phthalate manufacturing and disposal sites [5, 36-41].  
Often, women in today’s society postpone childbirth to prioritize career development during 
prime reproductive years. This leads to a longer period of exposure to phthalates, potentially 
leading to detrimental effects on fertility, especially when the female is aging. Because of the 
prevalent use and ubiquitous exposure to phthalates and the importance of the ovary for female 
reproductive and non-reproductive health, the goal of this review is to summarize what is 
currently known about the effects of phthalates on the ovary and the mechanisms by which 
phthalates exert ovarian toxicity, with a particular focus on the effects of phthalates on 
folliculogenesis and steroidogenesis. 
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2.5 Effects of Phthalates on Folliculogenesis   
Effects of phthalates on oocyte development and primordial follicle assembly 
 Limited studies have investigated the effects of phthalates on folliculogenesis, but there is 
evidence suggesting that phthalates alter the formation and/or function of follicles at several 
stages of development. Specifically, phthalates have been shown to disrupt the earliest stages of 
folliculogenesis by altering ovarian and oocyte development. DEHP exposure in Japanese 
medaka during sexual development has been shown to inhibit oocyte development [112]. When 
given in an aqueous solution at 1-50 µg/l from hatching to 3 months of age, DEHP exposure 
decreased the percentage of completely matured oocytes in the ovaries, most likely via an anti-
estrogenic mechanism of action [112]. MEHP exposure for 24 hrs at 250-500 µM has been 
shown to decrease murine fetal oocyte viability using an in vitro oocyte culture system [113]. 
This decrease in oocyte survival is attributed to an alteration in oocyte oxidative stress as the 
mRNA levels of mitochondrial respiratory chain protein (Nd1) were decreased and Cu-Zn 
superoxide dismutase (Sod1) were increased in the oocytes following MEHP exposure [113]. A 
decrease in Nd1 mRNA may lead to an increase in reactive oxygen species (ROS), which are 
toxic to the oocyte and are also associated with an increased risk of infertility [114]. The increase 
in the antioxidant Sod1 mRNA is most likely a compensatory response in detoxifying the 
increased ROS following MEHP exposure. DEHP exposure further affects oocyte development 
by causing heritable modifications in DNA methylation in mouse oocytes [115]. When given to 
pregnant mice during the length of gestation, DEHP exposure at 40 µg/kg/day reduced the 
methylation of CpG sites in the two critical imprinting genes, insulin-like growth factor 2 
receptor (Igf2r) and paternally-expressed gene 3 (Peg3), in the primordial germ cells of the fetal 
ovary at gestational day 12.5 and the oocytes of the offspring by post-natal day 21 [115]. 
Interestingly, the decrease in oocyte DNA methylation of Igf2r and Peg3 is also evident in the 
oocytes of the F2 offspring, suggesting that the effects of DEHP on oocyte development are 
heritable [115]. Gestational exposure to a single intraperitoneal injection of DIBP resulted in 
architectural disarray of follicles in fetal rats [116]. Specifically, DIBP exposure at 0.375-1.25 
ml/kg increased the numbers of degenerated oocytes and empty follicles without oocytes, and the 
blood vessels located in the stroma of the ovary appeared prominent and congested [116]. MEHP 
has also been shown to affect ovarian development in the human. Human ovaries from 
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gestational weeks 7 to 12 were cultured with MEHP at 10-4 M for 72 hrs and had dysregulated 
lipid/cholesterol synthesis as evidenced by an increase in the mRNA levels of liver X receptor 
alpha (LXRα) and sterol regulatory element-binding protein (SREBP) members [117]. 
Interestingly, oocyte numbers were not affected by MEHP treatment, but the same study 
suggests that phthalate toxicity to the developing human ovary may be mediated by nuclear 
receptor signaling [117]. It appears that phthalates disrupt early ovarian and oocyte development 
potentially leading to oocyte death and abnormal ovarian architecture [112, 113, 116]. The 
mechanisms by which phthalates alter the earliest stages of ovarian development appear to 
include an anti-estrogenic response [112], an increase in oxidative stress [113], and heritable 
modifications to the oocyte epigenome [115].  
Phthalates have also been shown to affect germ cell nest breakdown and primordial follicle 
assembly. Newborn mouse ovaries cultured with DEHP for 72 hrs at 10-100 µM had an increase 
in oocytes contained in the germ cell nest, and there was a decrease in primordial follicle 
numbers [118]. Thus, germ cell nest breakdown and primordial follicle assembly were inhibited 
following DEHP exposure. Additionally, DEHP exposure increased apoptosis in the oocytes 
indicated by an increase in TUNEL positive oocytes and increased mRNA levels of pro-
apoptotic BCL2-associated X protein (Bax) [118]. Further, DEHP decreased the mRNA levels of 
other factors associated with oocyte survival and primordial follicle formation, such as LIM 
homeobox 8 (Lhx8), factor in the germline alpha (Figla), spermatogenesis and oogenesis helix-
loop-helix (Sohlh2), and newborn ovary homeobox (Nobox) [118]. Similar to previous reports, 
DEHP exposure affected oocyte DNA methylation by inhibiting the demethylation of CpG sites 
of Lhx8, a process required for early folliculogenesis [118]. These effects on primordial follicle 
formation can have lasting effects on folliculogenesis and fertility because primordial follicles 
serve as the female’s reproductive potential [46].   
Effects of phthalates on follicles across development    
Phthalates have also been shown to affect the rate in which primordial follicles are recruited to 
the growing population of follicles. In the adult mouse, oral exposure to DEHP for 10 and 30 
days at 20 µg/kg/day-750 mg/kg/day accelerates primordial follicle recruitment, evident by a 
decrease in primordial follicles and an increase in primary follicles [119]. The mechanism by 
which DEHP accelerates primordial follicle recruitment is likely via overactivation of the 
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phosphatidylinositol 3-kinase (PI3K) signaling pathway, a pathway that regulates primordial 
follicle survival, quiescence, and recruitment. Specifically, DEHP exposure increased the ovarian 
mRNA levels of 3-phosphoinositide dependent protein kinase-1 (Pdpk1), mammalian target of 
rapamycin complex 1 (Mtorc1), which are factors that drive primordial follicle recruitment, and 
decreased the mRNA levels of phosphatase and tensin homolog (Pten) and tuberous sclerosis 1 
(Tsc1), which are factors that maintain primordial follicle quiescence [119]. Additionally, DEHP 
exposure for 10 days increased phosphorylated protein kinase B (pAKT) protein in the whole 
ovary and in primordial and primary follicles, and decreased PTEN protein in the whole ovary, 
further suggesting that DEHP overactivates ovarian PI3K signaling to promote the acceleration 
of primordial follicle recruitment [119]. Similar effects on primordial follicle recruitment were 
observed following DEHP exposure during early postnatal life in mice. Following hypodermic 
injections during early postnatal life, DEHP at 20-40 µg/kg/day accelerated folliculogenesis by 
decreasing primordial follicles and increasing preantral and antral follicles when the ovaries were 
observed on post-natal day 15 and 21 [120]. Further, when the treated mice were allowed to 
breed, the F1 offspring had a similar decrease in primordial follicle numbers when the ovaries 
were observed in adulthood [120]. MEHP exposure in utero also accelerates folliculogenesis in 
mice. Oral exposure to MEHP via gavage from gestational days 17-19 at 100-1000 mg/kg/day 
resulted in an increase in preantral and antral follicles in the F1 generation [121]. These F1 
females exposed to MEHP in utero also exhibited premature reproductive senescence by one 
month, likely attributed to the acceleration of folliculogenesis evident by the follicle count data 
[121]. Phthalates appear to accelerate primordial follicle recruitment by decreasing primordial 
follicle numbers and increasing the numbers of more mature follicle types, and this effect is 
consistent across timing and duration of exposure and the doses of phthalates used. Because the 
primordial follicle reserve is non-renewable, the above effects on primordial follicle recruitment 
can impact a female’s reproductive lifespan.  
In addition to the effects of phthalates on immature follicle types, phthalates have also been 
shown to target and adversely affect more mature follicles. Exposure to DEHP alone and in 
combination with benzo[a]pyrene (B[a]P) via oral gavage decreased the population of primary 
and secondary follicles, potentially via induced follicular atresia in adult rats [122]. Specifically, 
DEHP alone (600 mg/kg/day) and in combination with B[a]P (10 mg/kg/day) induced granulosa 
cell apoptosis, resulting in an increase in the number of atretic follicles across developmental 
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stages [122]. Likewise, in utero and lactational exposure to DEHP from midgestation to weaning 
at 405 mg/kg/day increased the number of atretic preantral follicles in the rat offspring during 
adulthood [123]. A similar effect of increased atresia in growing follicles was seen in adult 
marine medaka. DEHP in an aqueous solution at 0.1-0.5 mg/l increased the numbers of atretic 
late-stage follicles resulting in reproductive dysfunction following exposure from hatching to 
adulthood [124]. A reduction in the growing population of follicles was also observed in DEHP 
exposed neonatal ovaries after transplantation into the kidney capsules of immunodeficient mice. 
Specifically, newborn mouse ovaries were cultured with DEHP for 72 hrs at 10-100 µM and 
were then transplanted into adult mice to observe if folliculogenesis was impaired. Contrary to 
control treated transplanted ovaries, DEHP treated transplanted ovaries had few, if any, growing 
follicles following 21 days post-transplantation [118]. Further, preantral follicles from rats 
cultured with MEHP in vitro for 10 days at 10-80 µg/ml had a lower survival rate and decreased 
rate of development to the antral stage [125]. Likewise, secondary follicles from rats cultured 
with MEHP at 100 µg/ml had suppression of follicular development accompanied by a decrease 
in follicular viability and an increase in granulosa cell apoptosis [126]. Prior to development to 
the antral follicle stage, phthalates appear to target primary and preantral to induce atresia at a 
wide range of doses. This effect on atresia is likely attributed to phthalate-induced apoptosis of 
granulosa cells [122, 126]. 
Phthalates also target mature antral follicles by adversely inhibiting their growth and maturation. 
Much of the work investigating the effects of phthalates on antral follicle growth utilizes the 
novel method of the whole antral follicle culture system [127, 128].  Using this method, DBP 
exposure for 168 hrs at 1000 µg/ml has been shown to inhibit antral follicle growth [129]. This 
inhibition of antral follicle growth is likely attributed to defects in the cell cycle, which is 
necessary for appropriate granulosa cell proliferation and follicle growth. Specifically, DBP 
exposure at 1-1000 µg/ml decreased mRNA levels of cyclin D2 (Ccnd2), cyclin E1 (Ccne1), 
cyclin A2 (Ccna2), and cyclin B1 (Ccnb1), and increased the mRNA levels of cyclin-dependent 
kinase inhibitor 1A (Cdkn1a) at a time-point prior to growth inhibition [129]. DBP treated 
follicles had greater numbers of cells in the G1 phase, fewer numbers of cells in the S phase, and 
a trend for fewer numbers of cells in the G2 phase, further indicating cell cycle arrest following 
24 hrs of culture [129]. These defects in antral follicle growth potentially lead to the observed 
increase in atresia in DBP treated follicles [129]. Both DEHP at 1-100 µg/ml and MEHP at 0.1-
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100 µg/ml also inhibit antral follicle growth in vitro. Specifically, both chemicals inhibit antral 
follicle growth following 72 hrs of culture, and this effect persists for the duration of the 96 hr 
culture [130-132]. Similar to DBP, DEHP at 100 µg/ml disrupts the cell cycle by decreasing the 
mRNA levels of Ccnd2 and cyclin-dependent kinase 4 (Cdk4), and MEHP at 10-100 µg/ml 
disrupts the cell cycle by decreasing the mRNA levels of Ccnd2, Ccne1 and Cdk4 [131, 132]. 
Further, MEHP exposure at 1-100 µg/ml increased the mRNA levels of pro-apoptotic Bax and 
apoptosis-inducing factor, mitochondrion-associated, 1 (Aifm1) and decreased the mRNA levels 
of anti-apoptotic Bcl2 and Bcl2-like 10 (Bcl2l10), leading to antral follicle atresia [131, 133]. 
Interestingly, DEHP and MEHP likely inhibit antral follicle growth and induce atresia via a 
mechanism involving oxidative stress. Specifically, DEHP at 10 µg/ml and MEHP at 1-100 
µg/ml increased ROS levels in the treated follicles [130, 131]. This is accompanied by reduced 
expression and enzyme activity of SOD1 following DEHP exposure, and reduced expression and 
enzyme activities of SOD1 and glutathione peroxidase (GPX) following MEHP exposure [130, 
131]. Supplementing the DEHP and MEHP treated follicles with estradiol (1-10 nM) or the anti-
oxidant N-acetyl cysteine (NAC; 0.25-1 mM) only partially protects the follicles from phthalate-
induced growth inhibition [130-132], but estradiol supplementation rescues the antral follicles 
from MEHP-induced atresia [133]. In additional studies, exposure to DEHP via oral gavage at 2 
g/kg/day reduced preovulatory follicle size in rats, due to a reduced granulosa cell size and area 
[134]. Phthalates appear to directly target the antral follicle to inhibit growth via cell cycle 
inhibition [129, 131, 132], induction of atresia [129, 131, 133], and increased oxidative stress 
[130, 131]. Overall, the phthalate-induced inhibition of antral follicle growth can potentially 
impair ovulation and steroidogenesis [46, 101].   
Effects of phthalates on ovulation and the corpus luteum      
The process of oocyte maturation during the peri-ovulatory period is also affected by phthalate 
exposure. DEHP exposure in an aqueous solution at 0.02-40 µg/l in zebrafish inhibited oocyte 
germinal vesicle breakdown, which is a process required for the resumption of meiosis prior to 
ovulation [135]. This effect was accompanied by an increase in the levels of ovarian bone 
morphogenetic protein 15 (BMP15) and decreases in the levels of LH receptor (LHR) and 
membrane progesterone receptors (mPRs), which are factors that drive oocyte maturation [135]. 
Similar effects were seen using in vitro maturation assays with bovine oocytes. MEHP exposure 
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at 5-100 µM to denuded oocytes and cumulus-oocyte complexes for 22-24 hrs reduced the 
number of oocytes that resumed meiosis, indicated by an increase in the number of oocytes still 
in the germinal vesicle stage, and reduced the number of oocytes that progressed to metaphase II 
[136, 137]. Bovine oocytes exposed to MEHP at 50 µM during maturation also had a decrease in 
the mRNA levels of CCNA2, acid ceramidase 1 (ASAH1; an anti-apoptotic factor), and POU 
domain, class 5, transcription factor 1 (POU5F1; a factor responsible for pluripotency), which 
potentially led to the observed increased in apoptotic oocytes during culture [137]. These defects 
in oocyte maturation resulted in increased instances of poor quality early embryos [137]. Similar 
to the bovine model, DEHP exposure at 0.12-1200 µM inhibited oocyte maturation in the horse 
following an in vitro maturation assay [138]. Further, ROS levels and apoptosis were increased 
in the cumulus granulosa cells [138]. Additionally, BBP exposure at 100 µM to FSH-matured 
(10 ng/ml) porcine cumulus oocyte complexes inhibited cumulus cell expansion, a process 
required for normal ovulation, transport through the oviduct, and fertilization [139]. In the 
mouse, MEHP exposure at 200-400 µM in a maturation assay increased the number of oocytes in 
the germinal vesicle stage and decreased the number of oocytes that resumed meiosis in 
metaphase II [140]. A similar effect was seen with in utero and lactational exposure to DEHP in 
adult female offspring. Specifically, DEHP exposure through gestation and weaning at 0.05-5 
mg/kg/day decreased the numbers of oocytes that reached meiosis II when the offspring were 
superovulated as adults [141]. Further, mouse oocytes that were matured in vitro had increased 
metaphase II spindle abnormalities following in vivo exposure to DEHP at 20-40 µg/kg/day, 
indicating that phthalates have the potential to alter post-meiotic resumption maturation 
processes [120]. Phthalates appear to inhibit germinal vesicle breakdown and resumption of 
meiosis in multiple different models, and these effects on oocyte maturation may be detrimental 
to ovulation and normal embryonic development.    
Along with defects in oocyte maturation, phthalates disrupt the ovulatory process. Zebrafish 
exposed to DEHP in an aqueous solution at 0.02-40 µg/l had a significant reduction in ovulations 
likely attributed to a decrease in the mRNA levels of prostaglandin-endoperoxide synthase 2 
(Ptgs2), which is an enzyme required for one of the final triggers of ovulation following the LH 
surge [135]. Further, the injection of DEHP inhibits ovulation in rats following equine chorionic 
gonadotropin (eCG)-induced ovulation (15-30 IU). Specifically, DEHP exposure at 500 
mg/kg/day decreased the total number of rats that ovulated in response to eCG treatment, and 
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DEHP exposure reduced the total number of ovulated oocytes following eCG treatment [142]. 
Likewise, oral exposure to DEHP via gavage during metestrus at 2 g/kg/day delayed or 
suppressed ovulation by the first proestrus/estrus in rats [134]. In fact, 7 out of 10 rats did not 
ovulate by vaginal estrus in response to DEHP treatment [134]. These studies suggest that DEHP 
exposure is capable of inhibiting ovulation by decreasing the transcription of LH surge-response 
genes, even when the ovulatory process is chemically induced. 
Phthalates have also been shown to disrupt the luteal transition and/or target corpora lutea.  
Perinatal exposure to diisononyl phthalate (DINP) at 20,000 ppm in the rat decreased the number 
of corpora lutea present in adulthood [143]. Adolescent rats exposed to DEHP via oral gavage 
for 28 days at 150-500 mg/kg/day also had a decrease in corpora lutea numbers [144]. A similar 
effect of decreased corpora lutea numbers is seen when DEHP alone (300-600 mg/kg/day) and in 
combination with B[a]P (10mg/kg/day) is administered to adult rats [122]. Because mechanistic 
studies were not conducted, it is unknown if the decreases in corpora lutea numbers are due to an 
inhibition of ovulation, an inhibition in the luteal transition, and/or a direct destruction of corpora 
lutea caused by phthalate exposure. However, previous studies have shown that phthalates inhibit 
ovulation [134, 135, 142]. 
A few studies suggest that phthalates may alter the functionality of corpora lutea. Marmosets 
exposed to DEHP via oral gavage from weaning to sexual maturity at 500-2500 mg/kg/day had 
abnormally large corpora lutea present in the ovary, which is a finding often seen in older female 
marmosets [145]. This increase in corpora lutea size likely causes the observed increase in 
ovarian weights following DEHP exposure [145]. Conversely, adult sheep treated with DEHP 
intramuscularly at 25-50 mg/kg/day had smaller corpora lutea and a decreased luteal phase of the 
estrous cycle [146]. These data suggest that phthalates have the potential to disrupt post-
ovulatory ovarian processes, but further work must be done to elucidate the differences observed 
in the two studies. 
Epidemiological links between phthalate exposure and alterations in folliculogenesis 
 Very few studies have investigated the link between phthalate exposure in humans and 
alterations in folliculogenesis. One study examined the association of phthalate exposure and 
prevalence of polycystic ovary syndrome (PCOS), which is a gynecological disorder often 
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associated with infertility and the presence of large, cystic follicles incapable of ovulating. 
Interestingly, lower urinary levels of MEHP, MEP, MBP and MBzP were associated with an 
increased likelihood of PCOS when compared to control patients and patients with higher levels 
of these phthalate metabolites [147]. Similarly, in the Western Australian Pregnancy Cohort 
Study, maternal serum levels of MEP and the sum of all phthalate metabolites were negatively 
associated with PCOS in the daughters [148]. However, this study did not investigate the 
prevalence of PCOS in the daughters whose mothers had low levels of phthalate metabolites. In 
the same study, maternal levels of MEP had a negative association with anti-Müllerian hormone 
(AMH), which is a hormone secreted by granulosa cells of maturing follicles to restrict 
primordial follicle activation [148]. Based on the paucity of available information, further 
epidemiology studies are warranted in investigating the effects of phthalate exposure on 
folliculogenesis in the human.  
Ovarian folliculogenesis is an essential process for normal reproductive and non-reproductive 
health, and increasing evidence suggests that phthalates have the ability to adversely affect this 
process in numerous aspects. Specifically, phthalates have been shown to disrupt ovarian/oocyte 
development, accelerate primordial follicle recruitment, target growing follicles, inhibit growth 
of antral follicles, disrupt oocyte maturation and ovulation, and alter post-ovulatory processes 
(Figure 2.4). The mechanisms by which phthalates exert these toxic effects on folliculogenesis 
are unknown, but a few studies have begun to elucidate these mechanisms and have shown that 
phthalates can modulate genes associated with folliculogenesis (Table 2.1). It is clear that the 
majority of work investigating the effects of phthalates on folliculogenesis focus solely on DEHP 
and its metabolite MEHP. Future work should elucidate the mechanisms by which DEHP and 
MEHP disrupt folliculogenesis and should incorporate exposures to other commonly used 
phthalates. Further, the doses used in the reviewed animal studies rarely encompass the range of 
estimated human exposure. It would be advantageous to conduct experiments with levels of 
phthalates that fall within the range of human exposure, especially considering that phthalates 
exhibit non-monotonic dose responses [149, 150].  Additionally, experiments should be 
conducted to observe if these effects on folliculogenesis persist throughout the reproductive 
lifespan and if these effects directly cause infertility.  
 
32 
2.6 Effects of Phthalates on Steroidogenesis   
Effects of phthalate exposure on steroidogenesis in vivo 
 Gestational exposure to phthalates has been shown to alter steroidogenesis in female 
offspring. Oral exposure to MEHP via gavage from gestational days 17-19 at 100-1000 
mg/kg/day increased the levels of serum FSH and estradiol in female mouse offspring once they 
reached adulthood [121]. MEHP exposure in utero also decreased the mRNA levels of Star and 
Cyp19a1 in the ovaries of the adult offspring [121]. Estrous cyclicity, a process controlled by 
ovarian derived hormones, was also altered in these offspring. MEHP exposed females exhibited 
a delay in the onset of cyclicity, and MEHP exposure increased the time spent in the estrus stage 
[121].  Oral exposure to DIBP via gavage from gestational days 7-21 at 600 mg/kg/day increased 
anogenital distance in female rat offspring, a steroid hormone regulated process, and increased 
the mRNA levels of Cyp19a1 in the ovaries when the offspring were prepubertal [151]. A similar 
effect of increased anogenital distance was observed in female offspring following gestational 
BBP exposure via oral gavage to rats at 500 mg/kg/day [152]. Maternal exposure to DEHP in the 
diet at 0.05-5 mg/kg/day during the entire length of gestation through weaning decreased the 
mRNA levels of key steroidogenic enzymes and receptors in the ovaries of adult mouse offspring 
[141]. Specifically, ovaries from the adult offspring had decreased levels of Cyp19a1, Cyp17a1, 
progesterone receptor (Pgr), FSH receptor (Fshr), and LH receptor (Lhr) [141]. It is apparent 
that gestational exposure to phthalates results in defects in ovarian steroidogenesis across 
multiple developmental time-points by decreasing key steroidogenic enzyme levels. 
 Prepubertal exposure to phthalates has also been shown to disrupt ovarian 
steroidogenesis. DEHP exposure via inhalation from post-natal day 22-41 at 25 mg/m3 increased 
serum levels of cholesterol, LH, and estradiol in female rats following the duration of exposure 
[153]. When the exposure window was expanded from post-natal day 22-84, DEHP exposure 
increased the mRNA levels of ovarian Cyp19a1, advanced the age of vaginal opening and first 
estrous cycle, and increased the number of irregular estrous cycles [153]. The increase in 
Cyp19a1 likely attributes to the increase in estradiol levels. Oral exposure to DEHP via gavage 
for 10 days at 500 mg/kg/day decreased the serum levels of progesterone and estradiol, and there 
was a trend of increased serum LH levels in prepubertal rats [154]. Further, granulosa cells from 
DEHP exposed prepubertal rats exhibited a decrease in ex vivo progesterone production even 
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following FSH and LH stimulation, which was likely attributed to a decrease in the required 
transport of endogenous cholesterol into the mitochondria to initiate steroidogenesis [154]. The 
discrepancy in the levels of steroid hormones following phthalate exposure is likely attributed to 
the route of exposure. When rats were exposed via inhalation, steroid hormone levels were 
increased [153]. On the contrary, when rats were exposed via oral ingestion, steroid hormone 
levels were decreased [154]. Further, the timing of exposure may explain why prepubertal-
exposed animals had increased Cyp19a1 levels [153], but in utero-exposed animals had 
decreased Cyp19a1 levels [121, 141]. 
 Additional in vivo studies indicate that phthalate exposure during adulthood targets the 
ovary and disrupts steroidogenesis. Exposure to DEHP via oral gavage for 8 days at 2 g/kg/day 
decreased serum estradiol levels in adult rats [134]. This suppression of estradiol led to 
secondary rises in FSH levels and was unable to induce the LH surge needed for ovulation [134]. 
Thus, DEHP exposure caused anovulation in the study [134]. Further, DEHP exposure prolonged 
the duration of the estrous cycle in the adult rats [134]. A similar study showed that DEHP 
exposure via oral gavage at 1000-3000 mg/kg/day also decreased serum estradiol levels in adult 
rats [155]. In addition, serum testosterone, progesterone, LH, and FSH were also decreased 
following DEHP exposure [155]. Similarly, DEHP exposure via oral gavage for 16 weeks at 
500-2000 mg/kg/day prolonged the duration of estrous cycles, caused apoptosis and cell cycle 
arrest in granulosa cells, and decreased serum progesterone levels in adult mice [156]. A similar 
effect on estrous cyclicity was seen where oral exposure to DEHP for 10 and 30 days at 20 µg 
/kg/day-750 mg/kg/day increased the amount of time adult mice spent in the estrous stage [119]. 
Further, chronic DBP exposure from weaning, through puberty, mating, and gestation at 500-
1000 mg/kg/day increased gestational ex vivo ovarian estradiol production and decreased 
gestational ex vivo ovarian progesterone production in adult rats [157]. Conversely, DEHP 
exposure via intramuscular injections at 25-50 mg/kg/day increased plasma concentrations of 
progesterone in the adult ewe [146]. DEHP exposure also decreased the duration of the ewe’s 
estrous cycle and increased the number of irregular estrous cycles [146]. The effects on 
progesterone production and estrous cyclicity are likely attributed to DEHP toxicity on the 
copora lutea [146]. Estradiol and progesterone mediated processes, such as uterine 
decidualization, are also affected by exposure to phthalates in the adult rat. BBP, DBP, and MBP 
exposure via gastric intubation at 750-1500 mg/kg/day suppressed uterine decidualization in the 
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adult rat, which is a required process for pregnancy and is controlled by ovarian derived steroid 
hormones [158-160]. Together, these studies provide evidence that phthalate exposure during 
adulthood alters ovarian steroidogenesis.   
Effects of phthalate exposure on steroidogenesis in vitro  
Several in vitro studies using multiple culture models confirm and expand upon the ability of 
phthalates to disrupt ovarian steroidogenesis. Importantly, some of these studies also provide 
essential insight into the mechanisms by which phthalates disrupt steroidogenesis. Isolated 
ovarian cell cultures have shown that phthalates directly target specific cell types in the ovary 
and disrupt steroidogenesis in animal models. Specifically, MEHP exposure for 48 hrs at 50-200 
µM suppressed estradiol production in rat granulosa cells [161-163]. The decrease estradiol 
production from the granulosa cells was observed even with the supplementation of testosterone 
(a precursor for estradiol at 500 nM), FSH (an inducer and activator of aromatase for the 
conversion of testosterone to estradiol at 10 ng/ml), and 8-bromo cyclic adenosine 
monophosphate (a stable cAMP analogue, which is a secondary messenger for FSH signaling in 
granulosa cells at 1 mM). Thus, MEHP exposure disrupts estradiol production independent of 
FSH-cAMP signaling [161]. The mechanism by which MEHP suppresses estradiol in the culture 
system is via decreased mRNA levels, protein levels, and availability of aromatase [161, 162]. 
Further, it is likely that MEHP acts through peroxisome proliferator-activated receptors (PPARs) 
to decrease aromatase transcription [163]. PPARs are involved in granulosa cell differentiation, 
lipid metabolism, and even in the regulation of aromatase transcription and activity, and MEHP 
appears to activate PPARα and PPARγ in the granulosa cells to inhibit aromatase transcription 
[163]. Further, MEHP exposure for 24 hrs at 100 µM decreased progesterone production and 
FSH-induced cAMP accumulation in rat granulosa cells [164]. In contrast, MEHP exposure for 
48 hrs at 100-250 µM in a different study increased basal steroidogenesis in rat granulosa cells, 
evident by increases in progesterone and protein levels of STAR [165]. Perhaps the discrepancy 
in the MEHP-induced defects in steroidogenesis can be attributed to the dosage and use of 
different rat strains and the different susceptibilities to phthalate toxicity across strains. MEHP 
exposure inhibited steroidogenesis in Fisher 344 rat granulosa cells [161-164], but it stimulated 
steroidogenesis in Sprague-Dawley rat granulosa cells [165]. This stimulation of steroidogenesis, 
evident by an increase in progesterone production, was also observed in KK-1 granulosa tumor 
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cells exposed to MEHP for 24 hrs at 25-100 µM [166]. Using another cellular model, DEHP 
exposure for 44 hrs at 1 µM increased the production of progesterone in FSH matured porcine 
cumulus oocyte complexes [139]. This effect can potentially disrupt the final maturation 
processes of the oocyte following ovulation. In isolated bovine granulosa cells and isolated luteal 
cells, DEHP and MEHP exposure for 72 hrs at 0.1-10 ng/ml increased the production of oxytocin 
[167]. Ovarian derived oxytocin plays a role in the regulation of the estrous cycle. These studies 
show that phthalates have a direct effect on disrupting steroidogenesis in specific ovarian cell 
types in multiple animal models. The mechanism by which phthalates inhibit steroidogenesis in 
granulosa cells appears to be via suppression of PPAR-mediated aromatase transcription [161-
163]. The mechanism by which phthalates stimulate steroidogenesis in granulosa cells appears to 
be via increased steroidogenic enzyme levels [165]. Future studies should aim to understand the 
differences in steroidogenesis in the different granulosa cell models.  
Phthalates have also been shown to disrupt steroidogenesis in isolated human ovarian cell 
cultures. Similar to the previously mentioned study with rat granulosa cells [161-163], MEHP 
exposure at 0-500 µM/l decreased the production of estradiol in human granulosa-lutein cells 
isolated from women undergoing in vitro fertilization [168]. Likewise, this inhibition of estradiol 
production is independent of FSH-cAMP signaling; thus, it is attributed to a decrease in the 
mRNA levels and activity of aromatase [168]. In human luteal cells isolated from corpora lutea, 
DEHP, DBP, and BBP exposure for 24 hrs at 10-6-10-9M decreased basal and human chorionic 
gonadotropin-stimulated progesterone production [169]. In conjunction, DEHP, DBP, and BBP 
exposure decreased prostaglandin E2 (PGE2) secretion, and DEHP decreased prostaglandin F2α 
(PGF2α) secretion from the luteal cells [169]. Further, all three chemicals inhibited luteal cell 
release of vascular endothelial growth factor (VEGF) [169]. Prostaglandins and VEGF are 
regulators of corpora lutea survival. Specifically, PGE2 and VEGF are luteotrophic factors and 
PGF2α is a luteolytic factor. Another study has shown phthalate-induced defects in immortalized 
human granulosa cell lines. In detail, BBP exposure at 1 µM in HO23 cells increased the mRNA 
and protein levels of arylhydrocarbon receptor (AHR), arylhydrocarbon receptor nuclear 
translocator (ARNT), and cytochrome-P450 1B1 (CYP1B1), which are involved in estradiol 
metabolism, resulting in reduced cell viability and potential decreases in estradiol, though this 
was not directly tested [170]. Overall, phthalates appear to directly disrupt steroidogenesis by 
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decreasing steroid hormone and steroidogenic enzyme levels in human ovarian cells in a manner 
similar to animal studies in vitro.  
Expanding on the use of individual cell types, other culture systems utilizing the entire antral 
follicle and whole sections of ovaries have been used to investigate the effects of phthalates on 
steroidogenesis. This is important because steroidogenesis is a multi-cellular process involving 
both granulosa cells and theca cells. MEHP exposure for 48 hrs at 10-100 µg/ml increased the 
levels of progesterone and decreased the levels of androstenedione, testosterone, and estradiol in 
isolated rat secondary follicles [126]. Interestingly, even with the decreases in the three sex 
steroid hormones, the increase in progesterone promoted an increase in the combined level of all 
steroid hormones in response to MEHP exposure [126]. This suggests that MEHP potentially 
stimulates steroidogenesis in the secondary follicle, but it inhibits the conversion of progesterone 
to androstenedione [126]. Further studies using mouse preantral follicles show that MEHP 
exposure at 10-200 µM increased the levels of progesterone, testosterone, and estrone [127]. The 
discrepancies between testosterone production in these two studies can possibly be attributed to 
species differences and differences in culture methods. Using antral follicles, the most 
steroidogenically-active follicle type, isolated from mice, DEHP (10-100 µg/ml) and MEHP (1-
100 µg/ml) exposure for 96 hrs decreased estradiol production via inhibition of Cyp19a1 
transcription [132]. This effect on steroidogenesis coincides with the DEHP- and MEHP-induced 
inhibition of antral follicle growth, cell cycle arrest evident by alterations in Ccnd2, Ccne1, and 
Cdk4 mRNA levels, atresia evident by alterations in Bax, Aifm1, Bcl2, and Bcl2l10 mRNA 
levels, and induction of oxidative stress evident by increases in ROS and altered SOD1 and GPX 
protein and activity [130-132]. However, it is unknown if the inhibition of steroidogenesis causes 
these other toxic events or is a secondary response to defects in cell cycle progression and/or 
oxidative stress. Interestingly, supplementing the media with estradiol (1-10 nM) and NAC 
(0.25-1 mM), an antioxidant, only partially protected the antral follicle from DEHP- and MEHP-
induced growth inhibition and Cyp19a1 transcription [130-132], but estradiol completely rescued 
antral follicles from MEHP-induced atresia [133]. This likely suggests that the effects of MEHP 
on estradiol production precede and promote the incidence of atresia [133]. In another study, 
DBP exposure for 96 hrs at 1000 µg/ml decreased estradiol levels, and exposure for 168 hrs 
promoted atresia in cultured mouse antral follicles [129]. Similar to DEHP and MEHP, this 
effect on steroidogenesis coincided with DBP-induced (1-1000 µg/ml) inhibition of antral 
37 
follicle growth, cell cycle arrest evident by an increase in the number of follicular cells in the G1 
stage and alterations in the mRNA levels of Ccnd2, Ccne1, Ccna2, Ccnb1, and Cdkn1a, and 
atresia evident by alterations in the mRNA levels of BH3 interacting-domain death agonist (Bid) 
and Bcl2 [129]. These studies suggest that the entire follicle unit is a target for phthalate-induced 
disruption of steroidogenesis. Studies using secondary and preantral follicles have shown an 
increase in steroid hormone levels following phthalate exposure [126, 127]. Meanwhile, studies 
using more mature antral follicles have shown a decrease in steroid hormone levels following 
phthalate exposure, and the mechanisms by which phthalates inhibit steroidogenesis may involve 
an inhibition of antral follicle growth [129, 132], an induction of atresia [130-133], an increase in 
oxidative stress [130, 131], and decreases in steroidogenic enzyme levels [132].  
Similar to the follicle culture, minced ovary cultures, containing all follicular cell types, have 
been used to investigate the effects of phthalates on steroidogenesis. DEHP exposure in vivo 
altered the steroidogenic profile of minced rat ovaries cultured for 1 hr depending on the stage of 
the estrous cycle. Specifically, DEHP exposure at 1500 mg/kg/day increased the minced ovary 
production of testosterone and estradiol when the rats were euthanized in diestrus [171, 172]. 
Conversely, when the rats were euthanized in estrus, cultured minced ovaries produced less 
estradiol [171, 172].        
Epidemiological links between phthalate exposure and alterations in steroidogenesis  
 Exposure to phthalates has been shown to disrupt ovarian steroidogenesis and 
steroidogenic controlled processes. Though limited, there is epidemiologic evidence that 
phthalate exposure is associated with steroidogenic defects. Specifically in the Western 
Australian Pregnancy Cohort Study, serum from pregnant women during gestational week 18 
was subjected to measurements of phthalate metabolites and hormones and found that several 
phthalate metabolites have a negative association with maternal sex hormone binding globulin, 
and MEP had a negative association with AMH in the adolescent daughter [148]. Further, the 
sum of DEHP metabolites was associated with a trend for an earlier age at menarche in the 
adolescent female offspring, which is a process heavily controlled by ovarian steroid production 
[148]. In another study, urinary levels of MEHP and the oxidative monoester metabolite mono(2-
ethyl-5-hydroxyhexyl) phthalate in mothers were negatively associated with free testosterone 
levels and the free testosterone to estradiol levels ratio in the cord serum from female human 
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infants [173]. Similarly, the urinary levels of several phthalate metabolites were associated with 
decreased serum total testosterone levels in women aged 6-20 and 40-60 years from the National 
Health and Nutrition Examination Survey [174]. Further, urinary levels of DEHP metabolites 
and MBP were associated with decreased testosterone levels in pregnant women in the Study for 
Future Families [175]. Conversely, in utero exposure to MEP and MBzP was associated with 
increased testosterone levels in girls at ages 8-13 years from the Mexico City birth cohort [176]. 
Urinary levels of MEHP and MBzP in eight year old girls from Taiwan were also positively 
associated with increased serum progesterone levels, and urinary levels of MBzP and MBP were 
positively associated with increased serum FSH levels [177].  
Proper regulation of ovarian steroidogenesis is vital for reproductive and non-reproductive 
health, and numerous studies indicate that phthalates have the ability to dysregulate 
steroidogenesis in multiple aspects (Figure 2.5). Specifically, phthalates have been shown to 
intervene in the production and secretion of multiple sex steroid hormones in both in vivo and in 
vitro systems to often lead to a decrease in estradiol levels. Further, phthalates have been shown 
to directly target several steroidogenic cell types in the ovary to elicit an adverse effect on steroid 
hormone production. These effects on steroidogenesis are likely attributed to alterations in the 
transcription of genes that synthesize and metabolize estradiol (Table 2.2). Importantly, the 
effects observed in animal studies moderately correlate to the effects observed in human ovarian 
cell types [161, 162, 164, 168, 169]. As is the case with studies investigating the effects of 
phthalates on folliculogenesis, future work investigating the effects of phthalates on 
steroidogenesis should incorporate exposures to other commonly used phthalates to expand upon 
what is known regarding DEHP and MEHP, which are the two most extensively studied 
phthalates. Further, the doses used in these studies should fall within the range of estimated 
human exposure. Most often, the doses used in the reviewed studies exceed human exposure 
levels. Because phthalates exhibit a non-monotonic dose response, the effects of phthalates on 
steroidogenesis at lower levels may be more toxic and/or have different mechanisms than at 
higher levels [149, 150]. Additionally, future work should elucidate the mechanisms by which 
phthalates disrupt steroidogenesis, and investigate whether the phthalate-induced disruption in 
steroidogenesis leads to infertility and non-reproductive complications.   
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2.7 Summary and Conclusions 
 Phthalates are a group of endocrine disrupting chemicals that target the ovary to 
adversely affect the two essential processes of folliculogenesis and steroidogenesis. This is 
concerning for public health because phthalates are used extensively in a wide variety of 
commonly used items, resulting in ubiquitous human exposure. Phthalates have been shown to 
alter ovarian and oocyte development, target specific follicle types, alter progression of follicular 
development, and disrupt the functionality of follicles and corpora lutea. Specifically, phthalates 
have been shown to inhibit germ cell nest breakdown and primordial follicle assembly [118], 
accelerate primordial follicle recruitment [119-121], inhibit antral follicle growth [129-132] and 
final oocyte maturation [120, 135-141] to potentially inhibit ovulation [134, 142], and induce 
atresia in follicles across several stages of development [122-124, 129-131, 133]. Further, 
increasing evidence suggests that phthalates disrupt the production, secretion, and action of 
several essential sex steroid hormones via altered mRNA, protein, and activity of multiple 
steroidogenic enzymes. These effects most commonly result in decreased estradiol levels [126, 
129, 132, 134, 154, 155, 161-163, 168, 171, 172]; however, some studies suggest that phthalates 
stimulate steroidogenesis [121, 126, 139, 146, 165, 171, 172]. Regardless, these effects on 
folliculogenesis and steroidogenesis can have lasting effects on reproductive and non-
reproductive health, as both of these processes are essential for fertility, maintenance of 
appropriately timed reproductive senescence, and the regulation of skeletal, cardiovascular, and 
brain health.  
 Further study is warranted in investigating the effects of phthalates on ovarian function. 
In particular, researchers should expand upon the dose ranges used in their studies to incorporate 
doses that mimic human exposure. The majority of the cited work focuses primarily on doses 
that exceed the range of estimated human exposure. Although these findings are important, 
observing the effects at levels that mimic human exposure would increase the translational nature 
of studies. Further, a unique characteristic of endocrine disrupting chemicals is that low doses 
often elicit different or more profound effects than high doses [149, 150]. To expand upon the 
use of doses that mimic human exposure, future studies should also consider realistic routes and 
lengths of exposure. Humans are predominantly exposed to phthalates via oral ingestion, not 
gavage, and are exposed throughout the duration of the day, not a single bolus. Thus, studies 
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should utilize oral dosing or exposure in the diet over multiple time-points in the day. Humans 
are also chronically exposed to phthalates from gestation through adulthood. Therefore, studies 
should investigate the effects of phthalate exposure, starting in utero and continuing in 
adulthood, on ovarian function across all stages of development. Additionally, humans are 
exposed to multiple phthalates and other environmental toxicants daily. The majority of the cited 
work understandably focuses on single phthalate exposures, but future studies should incorporate 
exposures to phthalate mixtures as well as a mixture of phthalates and other ubiquitous toxicants. 
The above suggestions would aid in translating the findings from animal studies to potential 
effects in humans. These future studies should also focus on the mechanisms of phthalate-
induced ovotoxicity. Some studies suggest that phthalates exert toxicity via an estrogenic, anti-
estrogenic, oxidative stress response, or PPAR activation depending on the model system, dose, 
and exposure window. However, further work must be done to elucidate the mechanisms by 
which phthalates disrupt folliculogenesis and steroidogenesis. This will aid in the treatment 
and/or prevention of phthalate-induced reproductive diseases. 
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2.8 Tables, Figures, and Legends  
Figure 2.1 Chemical structures of common phthalates and their monoester metabolites that 
are mentioned in this introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical structures of parent phthalates are present on the left. Their respective monoester 
metabolites are present on the right.  
  
42 
Figure 2.2 Ovarian folliculogenesis 
 
 
 
 
 
 
The female is born with a finite number of primordial follicles that can mature through the 
primary, preantral, and antral stages of development. The follicle contains the gamete (oocyte) 
surrounded by granulosa cells (shown in red) and theca cells (shown in green), which are somatic 
cells. Following ovulation, the antral follicle differentiates into the corpus luteum, and the 
granulosa and theca cells become large and small luteal cells, respectively. 
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Figure 2.3 Ovarian steroidogenesis  
 
 
 
 
 
 
 
 
 
 
 
Steroidogenesis is primarily conducted by the mature antral follicle and the corpus luteum 
following ovulation. This process requires both the theca cells and granulosa cells, and involves 
the enzymatic conversion of cholesterol to 17β-estradiol and other necessary sex steroid 
hormones. The hormones produced by the ovary are listed in the white text boxes while the 
steroidogenic enzymes are listed in blue adjacent to the arrows between hormones.  
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Figure 2.4 Phthalates disrupt folliculogenesis 
 
 
 
 
 
 
 
 
 
This figure is a summation of the major findings on the effects of phthalates on folliculogenesis. 
Text boxes above a particular follicle type outline the major effects of phthalates at that stage of 
development, while text boxes below transition arrows outline the major effects of phthalates on 
that developmental transition. 
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Table 2.1 Genes associated with folliculogenesis that are altered by phthalate exposure 
 
 
 
 
 
 
This table is a summation of the major effects of phthalates on genes involved with 
folliculogenesis.  
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Figure 2.5 Phthalates alter steroidogenesis 
 
 
 
 
 
 
 
 
 
 
 
This figure is a summation of the major findings on the effects of phthalates on steroidogenesis. 
Black text boxes connected to hormones outline the major effects of phthalates on the levels of 
that hormone. Blue text boxes connected to steroidogenic enzymes outline the major effects of 
phthalates on the mRNA and/or protein levels of that enzyme.  
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Table 2.2 Genes associated with steroidogenesis that are altered by phthalate exposure 
 
 
 
 
This table is a summation of the major effects of phthalates on genes involved with 
steroidogenesis.  
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CHAPTER III 
Daily Exposure to Di(2-ethylhexyl) Phthalate Alters Estrous Cyclicity and Accelerates 
Primordial Follicle Recruitment Potentially Via Dysregulation of the Phosphatidylinositol 
3-Kinase Signaling Pathway in Adult Mice2 
3.1 Abstract 
Humans are exposed daily to di(2-ethylhexyl) phthalate (DEHP), a plasticizer found in many 
consumer, medical, and building products containing polyvinyl chloride. Large doses of DEHP 
disrupt normal ovarian function; however, the effects of DEHP at environmentally relevant 
levels, the effects of DEHP on folliculogenesis, and the mechanisms by which DEHP disrupts 
ovarian function are unclear. The present study tested the hypothesis that relatively low levels of 
DEHP disrupt estrous cyclicity as well as accelerate primordial follicle recruitment by 
dysregulating phosphatidylinositol 3-kinase (PI3K) signaling. Adult CD-1 mice were orally 
dosed with DEHP (20 µg/kg/day-750 mg/kg/day) daily for 10 and 30 days. Following dosing, 
the effects on estrous cyclicity were examined and follicle numbers were histologically 
quantified. Further, the ovarian mRNA and protein levels of PI3K signaling factors that are 
associated with early folliculogenesis were quantified. The data indicate that 10 and 30 day 
exposure to DEHP prolonged the duration of estrus and accelerated primordial follicle 
recruitment. Specifically, DEHP exposure decreased the percentage of primordial follicles and 
increased the percentage of primary follicles counted following 10 day exposure and increased 
the percentage of primary follicles counted following 30 day exposure. DEHP exposure, at doses 
that accelerate folliculogenesis, increased the levels of 3-phosphoinositide dependent protein 
kinase-1, mammalian target of rapamycin complex 1, and protein kinase B and decreased the 
levels of phosphatase and tensin homolog, potentially driving PI3K signaling. Collectively, 
relatively low levels of DEHP disrupt estrous cyclicity and accelerate primordial follicle 
recruitment potentially via a mechanism involving dysregulation of PI3K signaling.  
 
2 Reprinted, with permission, from PR. Hannon et al. Daily Exposure to Di(2-ethylhexyl) Phthalate Alters Estrous 
Cyclicity and Accelerates Primordial Follicle Recruitment Potentially Via Dysregulation of the Phosphatidylinositol 
3-Kinase Signaling Pathway in Adult Mice. Biology of Reproduction 2014 Jun; 90(6):136. Epub 2014 May 7.  
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3.2 Introduction 
Phthalate esters are synthetic plasticizers added to plastics to impart flexibility. The most 
widely used phthalate ester is di(2-ethylhexyl) phthalate (DEHP), which is used in the 
manufacturing of common consumer, medical, and building products containing polyvinyl 
chloride. Products that contain DEHP include flooring, roofing, carpeting, food and beverage 
packaging, automobile upholstery, shower curtains, packaging equipment, medical bags and 
tubing, and personal care products. Although production volumes of DEHP alone are not 
quantified, DEHP belongs to a group of phthalates known as dioctyl phthalates. Domestic 
production of these phthalates reaches up to 300 million pounds per year [1]. DEHP is non-
covalently bound to plastics, and therefore, leaching can occur after repeated use, heating, and/or 
cleaning of the products, allowing the toxicant to be ingested on a daily basis via oral ingestion, 
inhalation, and dermal contact [2]. In fact, the Agency for Toxic Substances and Disease 
Registry estimates that the range of daily human exposure to DEHP is 3-30 μg/kg/day, but 
measurements of DEHP in household dust can reach as high as 700 mg/kg [1, 3].  
Exposure to DEHP represents a public health concern, partially because it has been 
identified as a top contaminant present in human tissues. DEHP and its metabolites are present in 
over 95% of human blood samples and nearly 100% of human urine samples tested [2-6]. In 
particular to reproduction, DEHP and its metabolites are present in 90-100% of amniotic fluid 
samples from second trimester fetuses, cord blood samples from newborns, breast milk from 
nursing mothers, and even in human ovarian follicular fluid, indicating its ability to reach the 
ovary [2, 4, 5, 7].  
Continuous, daily exposure to DEHP, along with its prevalence in human tissues, is of 
major concern because DEHP has been designated as an endocrine disrupting chemical and 
reproductive toxicant for its ability to interfere with reproductive and hormone-regulated 
processes [8-10]. In males, DEHP exhibits anti-androgenic effects by inducing tubular atrophy 
and testicular degeneration and by inhibiting testicular steroidogenesis [11, 12]. To date, the 
majority of studies examining the effects of DEHP focus on male reproduction and development; 
however, in females, chronic occupational exposure to phthalates has been associated with 
decreased rates of pregnancy and high rates of miscarriage in women [2]. In laboratory animals, 
DEHP reduces implantations, increases resorptions, and decreases fetal weights of offspring [9, 
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13]. Surprisingly, much less is known about the effects of DEHP on the adult ovary, but recent 
work suggests that the ovary may be a target of DEHP toxicity. Specifically, DEHP exposure has 
been shown to decrease serum and antral follicle-produced 17β-estradiol levels, decrease 
aromatase levels, cause anovulation, and disrupt estrous cyclicity [14-19]. Some of the doses of 
DEHP used in these previous studies, however, are not environmentally relevant; thus, the 
effects of DEHP at environmentally relevant levels on ovarian function remain unclear. Further, 
the mechanisms by which DEHP disrupts ovarian function remain unclear; however, DEHP is 
hypothesized to cause toxicity independent of steroid receptor signaling as both DEHP and its 
metabolite, mono(2-ethylhexyl) phthalate (MEHP), have weak to no binding to the androgen and 
estrogen receptor [20-25].  
Understanding the effects of DEHP on ovarian function is vital because the ovary is an 
integral regulator of reproductive and non-reproductive health, and one of the most essential 
ovarian processes is folliculogenesis. The ovary is a heterogeneous endocrine organ containing 
ovarian follicles, which are the functional units of the ovary. In mammals, the female is born 
with a finite number of ovarian follicles; thus, the follicular reserve is set at birth and represents a 
female’s reproductive potential and reproductive lifespan [26]. Within the ovarian unit, follicles 
undergo several irreversible developmental transitions, starting from the primordial stage, in 
which the follicles are immature, dormant, and constitute the ovarian reserve, to the antral stage, 
in which the follicles are mature and capable of ovulation [26, 27]. This process of follicular 
development is known as ovarian folliculogenesis. Because the ovarian reserve is established at 
birth and folliculogenesis is an irreversible process, aberrant regulation of folliculogenesis can 
have adverse reproductive implications. In particular, the accelerated depletion of primordial 
follicles, either through apoptosis or irregular activation of development, can result in infertility 
and/or premature ovarian failure, or early onset of menopause. Although DEHP has been shown 
to disrupt normal ovarian function, its effects on folliculogenesis remain unclear.  
 
Because ovarian folliculogenesis is essential for reproductive and non-reproductive 
health, and increasing evidence indicates that the ovary is a potential target of DEHP toxicity, the 
present study was designed to investigate the effects of in vivo DEHP exposure on normal 
ovarian function, as well as the role and mechanisms by which DEHP disrupts folliculogenesis. 
Specifically, the present study was designed to test the hypothesis that relatively low levels of 
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DEHP disrupt folliculogenesis by dysregulating the phosphatidylinositol 3-kinase (PI3K) 
signaling pathway, potentially leading to the acceleration of primordial follicle recruitment. We 
decided to investigate the effects of DEHP on the PI3K signaling pathway because PI3K 
signaling has recently been shown to be a critical regulator of early folliculogenesis, specifically 
in primordial follicle survival, quiescence, and recruitment [28-33]. In further detail, increased 
PI3K signaling is associated with the promotion of primordial follicle recruitment. To test our 
hypothesis, we orally dosed adult mice with DEHP daily for 10 and 30 days. Following dosing, 
we investigated reproductive endpoints and histologically examined the effect of DEHP on 
follicular dynamics. To provide insight into the mechanism of DEHP-induced defects in 
folliculogenesis, we measured the levels of key PI3K signaling factors that are associated with 
early folliculogenesis. Specifically, we examined the effects of DEHP on 3-phosphoinositide 
dependent protein kinase-1 (PDPK1), mammalian target of rapamycin complex 1 (mTORC1), 
mast/stem cell growth factor receptor (KIT), protein kinase B (AKT), and ribosomal protein s6 
(rpS6), which are all factors that drive PI3K signaling. Additionally, we examined the effects of 
DEHP on forkhead box O3A (FOXO3A), phosphatase and tensin homolog (PTEN), and 
tuberous sclerosis 1 (TSC1), which negatively regulate PI3K signaling. 
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3.3 Materials and Methods 
Chemicals  
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Five stock 
solutions of DEHP were prepared using tocopherol-stripped corn oil (MP Biomedicals, Solon, 
OH) as the vehicle. The doses used for these experiments were 20 µg/kg/day, 200 µg/kg/day, 20 
mg/kg/day, 200 mg/kg/day, and 750 mg/kg/day. To achieve these doses, the stock concentrations 
were 0.0125, 0.125, 12.5, 125, and 468.8 mg/ml for each respective dose. 
The doses were chosen because they are much more environmentally relevant than doses 
used in previous DEHP ovotoxicity studies (2 g/kg/day) [15, 17, 34]. In particular, the Agency 
for Toxic Substances and Disease Registry estimates that the range of daily human exposure to 
DEHP is 3-30 µg/kg/day [1]. Additionally, they note that the no-observed-adverse-effect level 
(NOAEL) for DEHP is 5.8 mg/kg/day and the lowest-observed-adverse-effect level (LOAEL) is 
140 mg/kg/day; however, potential reproductive effects of DEHP occur at lower levels ranging 
from 1-30 µg/kg/day [1, 2]. Further, the Environmental Protection Agency (EPA) reference dose 
for DEHP is 20 µg/kg/day, but it is possible that certain populations can be exposed to much 
higher levels than this EPA reference dose [3]. 
Animals 
Cycling, adult CD-1 female mice at 39 days of age were obtained from Charles River 
Laboratories (Wilmington, MA) and were allowed to acclimate to the facility prior to dosing. 
The mice were housed at the University of Illinois at Urbana-Champaign, Veterinary Medicine 
Animal Facility. The mice were provided food and water ad libitum. Housing in a controlled 
animal room environment was established by the maintenance of temperature at 22 ± 1 °C and 
12-hour light–dark cycles. The Institutional Animal Use and Care Committee at the University of 
Illinois at Urbana-Champaign approved all procedures involving animal care, euthanasia, and 
tissue collection. 
In vivo dosing regimen  
The mice were orally dosed with vehicle or DEHP daily for 10 and 30 days. For the 10 
day dosing study, the mice received vehicle or DEHP at 20 µg/kg/day, 200 µg/kg/day, 20 
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mg/kg/day, 200 mg/kg/day, and 750 mg/kg/day (n=8/group). For the 30 day dosing study, the 
mice received vehicle or DEHP at 20 µg/kg/day, 200 µg/kg/day, 20 mg/kg/day, and 200 
mg/kg/day (n=8/group). Dosing volumes were determined daily by corresponding mouse weight, 
and the dose was given orally by inserting a pipet tip beyond the incisors towards the cheek 
pouch. Estrous cyclicity was monitored daily, and the mice were sacrificed in estrus following 
the 10 and 30 day dosing period.  
Body and organ weight analysis  
The mice were weighed daily to both calculate a dosing volume and monitor the effect of 
DEHP on body weight. Following 10 and 30 days of dosing, the mice were weighed and 
euthanized in estrus (n=8/group). Organs were aseptically removed, cleaned of interstitial tissue, 
and weighed. Percent body weight change was calculated by dividing the weight at the time of 
euthanasia by the weight at the start of dosing and multiplying that value by 100. Organ weights 
were recorded as whole organ weights or relative organ weights. Relative organ weights were 
calculated by dividing the weight of the organ by the body weight at the time of euthanasia and 
multiplying that value by 100.   
Estrous cyclicity analysis 
During dosing, the mice were subjected to daily vaginal smears to monitor estrous 
cyclicity (n=8/group). Stage of estrus was determined by vaginal cytology using a light 
microscope and was recorded based on previously defined and well-documented criteria [35-37]. 
Percentage of days in estrus was calculated by dividing the number of days in estrus by the 
number of days in the study and multiplying that value by 100. Percentage of days in 
metestrus/diestrus was calculated by dividing the number of days in either metestrus or diestrus 
by the number of days in the study and multiplying that value by 100. 
 
Histological evaluation of follicle numbers 
Following dosing, mice were euthanized in estrus and some ovaries were aseptically 
collected and fixed in Dietrich’s fixative for at least 24 hrs for histological evaluation of follicle 
numbers (n=3-8 ovaries/group). The ovaries were then transferred to 70% ethanol, embedded in 
paraffin wax, and serial sectioned (8 µM) using a microtome. The serial sections were mounted 
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on a glass slide and stained with hematoxylin and eosin. The numbers of oocyte containing 
follicles were counted in every tenth serial section using a light microscope, and the percentage 
of each follicle type was calculated by dividing the number of follicles of each specific type by 
the total number of follicles counted in every tenth serial section and multiplying that value by 
100. Stage of follicular development was assessed using previously defined criteria [38, 39]. 
Briefly, primordial follicles contained the oocyte surrounded by a single layer of squamous 
granulosa cells, primary follicles contained the oocyte surrounded by a single layer of cuboidal 
granulosa cells, preantral follicles contained the oocyte surrounded by at least two layers of 
cuboidal granulosa cells and theca cell layers, and antral follicles contained the oocyte 
surrounded by multiple layers of cuboidal granulosa cells with a fluid filled antral space and 
theca cell layers. All primordial and primary follicles with oocytes, regardless of nuclear material 
in the oocytes, were counted; whereas, only preantral and antral follicles with visible nuclear 
material in the oocyte were counted to avoid the risk of double counting follicles large enough to 
span serial sections. 
 
Gene expression analysis 
Following dosing, mice were sacrificed in estrus and some ovaries were aseptically 
collected, snap frozen in liquid nitrogen, and stored at -80°C for quantitative real-time 
polymerase chain reaction (qPCR) analysis (n=3-5 ovaries/group). Total RNA was extracted 
from the ovaries using the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) according to the 
manufacturer’s protocol. Total RNA (1000 ng) was then reverse transcribed to complementary 
DNA (cDNA) using the iScript RT kit (Bio-Rad Laboratories, Inc., Hercules, CA) according to 
the manufacturer’s protocol. Each cDNA sample was diluted 1:4 with nuclease-free water prior 
to analysis. Analysis of qPCR was conducted using the CFX96 Real-Time PCR Detection 
System (Bio-Rad Laboratories, Inc., Hercules, CA) and accompanying CFX Manager Software 
according to the manufacturer’s protocol. The machine quantifies the amount of PCR product 
generated by measuring SsoFastEvaGreen dye (Bio-Rad Laboratories, Inc., Hercules, CA) that 
fluoresces when bound to double-stranded DNA. A standard curve was generated from six serial 
dilutions of three samples spanning different treatment groups to calculate the amplification 
efficiencies of each primer. Specific qPCR primers (Integrated DNA Technologies, Inc., 
Coralville, IA) for the genes of interest as well as the reference gene, beta-actin (Actb), which did 
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not differ across treatment groups, can be found in Table 3.1. All qPCR reactions were done in 
triplicate using 2 µl cDNA, forward and reverse primers (5 pmol) for Mtorc1, Pdpk1, Pten, Kit, 
Rps6, Tsc1, Foxl2, or Actb, in addition to a SsoFastEvaGreen Supermix qPCR kit for a final 
reaction volume of 10 µl. The qPCR program consisted of an enzyme activation step (95°C for 1 
min), an amplification and quantification program (40 cycles of 95°C for 10 sec, 60°C for 10 sec, 
single fluorescence reading), a step of 72°C for 5 min, a melt curve (65°C −95°C heating 0.5°C 
per sec with continuous fluorescence readings), and a final step at 72°C for 5 min as per the 
manufacturer’s protocol. Expression data were generated using the mathematical model for 
relative quantification of real-time PCR data developed by Pfaffl [40]. The genes tested were 
chosen because they are associated with the regulation of early folliculogenesis, in particular 
primordial follicle recruitment [28, 29, 31, 41-43]. Additionally, each gene tested, except Foxl2, 
is involved in PI3K signaling [28-33, 44]. 
Immunohistochemistry  
Following 10 days of dosing, mice were sacrificed in estrus and some ovaries were 
aseptically collected, fixed in 4% paraformaldehyde overnight, and transferred to 70% ethanol 
for immunohistochemical analysis (n=3/group). The ovaries were then embedded in paraffin 
wax, serial sectioned (5 µM), and five representative sections that span the entire length of the 
ovary were mounted on a glass slide. Following deparaffinization, the tissues were subjected to 
heat-induced antigen retrieval (10 mM sodium citrate buffer at pH 6.0) for 60 min followed by 
endogenous peroxide quenching in 3% hydrogen peroxide for 20 min. The tissues were then 
blocked in 5% goat serum and avidin for 30 min. In some experiments, the tissues were 
incubated with a rabbit anti-mouse phosphorylated-AKT (Ser473) (the active form of the 
protein) antibody (1:50) (Cell Signaling Technology, Inc., Boston, MA) with biotin for 60 min, 
while in other experiments, the tissues were incubated with a rabbit anti-mouse PTEN antibody 
(1:200) (Cell Signaling Technology, Inc., Boston, MA) with biotin for 60 min. The tissues were 
then incubated with a secondary biotinylated goat anti-rabbit antibody (Vector Laboratories, Inc., 
Burlingame, CA) for 20 min, followed by an incubation with an avidin biotin complex solution 
(Vector Laboratories, Inc., Burlingame, CA) for 20 min. ImmPACT NovaRED peroxidase 
substrate solution (Vector Laboratories, Inc., Burlingame, CA)  was then applied until color 
optimally developed. Each sample was exposed to the chromogen for equal amounts of time. The 
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slides were then rinsed, counter-stained with a 1:10 dilution of hematoxylin, and coverslipped. A 
negative control was used in each experiment and was subjected to the same methods listed 
above, except instead of primary antibody, the negative control tissues were incubated with a 
negative control rabbit immunoglobulin fraction (Dako, Carpinteria, CA) at the same 
concentration of each primary antibody. Negative controls were confirmed to have no positive 
staining after exposure to the chromogen for equal amounts of time as the samples. Both pAKT 
and PTEN were chosen because they are integral regulators of the PI3K signaling pathway and 
have been associated with the regulation of primordial follicle recruitment [31, 43-46]. 
Specifically, pAKT drives PI3K signaling and ultimately promotes primordial follicle 
recruitment [31, 43-46]. Additionally, PTEN inhibits PI3K signaling and ultimately maintains 
primordial follicle quiescence [31, 43-46].  
Analysis of the levels of protein staining  
Following immunohistochemistry, the levels of pAKT and PTEN staining in the ovaries 
were quantified using published methods [47-49]. Briefly, images of whole ovaries and 
primordial and primary follicles were digitally captured using a Leica DFC 290 camera and 
analyzed using the ImageJ software (http://rsb.info.nih.gov/nih-image/). For whole ovarian 
analysis, 5 representative sections from each ovary were assessed from 3 separate animals per 
treatment group. For follicular analysis, 2-3 follicles of each type from the 5 representative 
ovarian sections were assessed from 3 separate animals per treatment group. Digital images were 
converted to 8-bit grayscale images and then converted to pseudocolored images. Colors were 
based on relative stain intensity, as defined digitally. Areas with no staining appeared black and 
blue, while areas with the most intense staining appeared deep yellow to orange. The pAKT and 
PTEN labeling index was defined as the percentage of positively stained area per whole ovary, 
primordial follicles, and primary follicles. The pixels of positively stained areas were divided by 
the total amount of pixels in the whole ovary, primordial follicles, and primary follicles, and that 
value was multiplied by 100.  
Statistical analysis 
All data were analyzed using SPSS statistical software (SPSS, Inc., Chicago, IL). Data 
were expressed as means ± standard error of the means (SEM). Multiple comparisons between 
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normally distributed experimental groups were made using one-way analysis of variance 
(ANOVA) followed by Tukey post-hoc comparison. Multiple comparisons between non-
normally distributed experimental groups were made using Mann-Whitney and Kruskal Wallis 
tests when appropriate. Statistical significance was assigned at p ≤ 0.05. 
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3.4 Results 
Effect of DEHP exposure on body and organ weights 
To observe if DEHP is overtly toxic to the body and/or specific organs, we recorded body 
and organ weight changes in response to DEHP treatment. Importantly, DEHP exposure for 10 
and 30 days had no effect on mortality of the mice and had no statistically significant effect on 
percent body weight change when compared to the vehicle control group (Table 3.2). However, 
DEHP exposure for 10 days significantly increased the whole and relative weight of the liver at 
the 750 mg/kg/day dose when compared to the vehicle control group (n=8/group, p ≤ 0.05). 
Additionally, DEHP exposure for 10 days significantly increased the whole and relative weight 
of the spleen at the 200 µg/kg/day and 20 mg/kg/day doses, respectively, when compared to the 
vehicle control group (n=8/group, p ≤ 0.05). In the 30 day dosing study, DEHP significantly 
increased the whole and relative weight of the uterus at the 20 µg/kg/day dose when compared to 
the vehicle control group (n=8/group, p ≤ 0.05). Again, these changes in organ weights had no 
effect on body weight change and mortality. Thus, the doses chosen for these studies were not 
overtly toxic to the body. 
Effect of DEHP exposure on estrous cyclicity 
DEHP exposure at high doses (2 g/kg/day) in adult rats previously has been shown to 
prolong estrous cycles, and DEHP treated antral follicles exhibit inhibition of estradiol 
production in vitro [15, 19]; thus, we decided to investigate if DEHP treatment altered estrous 
cyclicity in our dosing studies. In the 10 day dosing study, DEHP exposure significantly 
increased the percentage of days the mice were in estrus at the 20 µg/kg/day, and the 20, 200, 
and 750 mg/kg/day doses when compared to the vehicle control group (Fig. 3.1A, n=8/group, p ≤ 
0.05). Similarly, DEHP exposure for 30 days significantly increased the percentage of days the 
mice were in estrus at the 200 mg/kg/day dose when compared to the vehicle control group (Fig. 
3.1B, n=8/group, p ≤ 0.05). In both studies, DEHP exposure had no effect on the percentage of 
days the mice were in metestrus and diestrus when compared to the vehicle control group (Fig. 
3.1A and 3.1B).  
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Effect of DEHP exposure on folliculogenesis  
Because the ovary is a potential target of DEHP toxicity and ovarian folliculogenesis is 
essential for fertility and the maintenance of appropriately timed reproductive senescence, we 
histologically evaluated the effects of DEHP on follicular dynamics. In the 10 day dosing study, 
DEHP exposure significantly decreased the percentage of primordial follicles counted at the 20 
and 200 mg/kg/day doses when compared to the vehicle control group (Fig. 3.2A, n=3-4/group, 
p ≤ 0.05). Likewise, DEHP exposure significantly increased the percentage of primary follicles 
counted at all selected doses of DEHP when compared to the vehicle control group (n=3-
4/group, p ≤ 0.05). In accordance, DEHP exposure for 30 days significantly increased the 
percentage of primary follicles counted at the 200 µg/kg/day and 20 mg/kg/day doses when 
compared to the vehicle control group (Fig. 3.2B, n=8/group, p ≤ 0.05). These data suggest that 
DEHP exposure may affect early folliculogenesis, in that it may accelerate primordial follicle 
recruitment to the primary stage of development. 
Effect of DEHP exposure on the mRNA levels of factors within the PI3K signaling pathway 
Early folliculogenesis, specifically primordial follicle recruitment, relies on paracrine and 
autocrine regulation by intrinsic ovarian growth factors, and recent work has established the 
PI3K signaling pathway as an integral regulator of this process [26-33]. Thus, we measured the 
ovarian mRNA levels of several PI3K signaling factors that are associated with primordial 
follicle recruitment. In the 10 day dosing study, DEHP exposure significantly increased the 
mRNA levels of Mtorc1, a stimulator of the PI3K signaling pathway, at the 20 and 200 
µg/kg/day doses, and at the 200 and 750 mg/kg/day doses when compared to the vehicle control 
group (Fig. 3.3A, n=4-5/group, p ≤ 0.05). Additionally, 10 day exposure to DEHP significantly 
increased the mRNA levels of Pdpk1, another stimulatory PI3K signaling factor, at the 200 and 
750 mg/kg/day doses when compared to the vehicle control group (Fig. 3.3B, n=4-5/group, p ≤ 
0.05). In the same study, DEHP exposure significantly decreased the mRNA levels of Pten, an 
inhibitory PI3K signaling factor, at the 200 µg/kg/day and 20 mg/kg/day doses when compared 
to the vehicle control group (Fig. 3.3C, n=4-5/group, p ≤ 0.05). However, 10 day exposure to 
DEHP had no effect on the mRNA levels of Kit, Rps6, Tsc1, or Foxl2 when compared to the 
vehicle control group.  
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In the 30 day dosing study, DEHP exposure significantly increased the mRNA levels of 
Kit, a stimulatory PI3K signaling factor, at the 20 µg/kg/day dose, but decreased its expression at 
the 200 mg/kg/day dose when compared to the vehicle control group (Fig. 3.4A, n=3-4/group, p 
≤ 0.05). Similar to the 10 day dosing study, DEHP exposure for 30 days significantly decreased 
the mRNA levels of Pten at the 20 and 200 mg/kg/day doses when compared to the vehicle 
control group (Fig. 3.4B, n=3-4/group, p ≤ 0.05). DEHP exposure for 30 days also significantly 
decreased the mRNA levels of Rps6, a stimulatory PI3K signaling factor, at the 200 mg/kg/day 
dose when compared to the vehicle control group (Fig. 3.4C, n=3-4/group, p ≤ 0.05). 
Additionally, DEHP exposure significantly decreased the mRNA levels of Tsc1, another 
inhibitory PI3K signaling factor, at the 200 mg/kg/day dose when compared to the vehicle 
control group (Fig. 3.4D, n=3-4/group, p ≤ 0.05). Interestingly, DEHP exposure for 30 days 
altered factors outside of the PI3K signaling pathway that are also associated with primordial 
follicle recruitment. Specifically, DEHP significantly decreased the mRNA levels of Foxl2, an 
inhibitor of recruitment, at the 20 mg/kg/day dose when compared to the vehicle control group 
(vehicle: 1.1±0.3; 20 mg/kg/day: 0.5±0.1; n=4/group, p ≤ 0.05). However, DEHP exposure for 
30 days had no effect on the mRNA levels of Pdpk1 and Mtorc1 when compared to the vehicle 
control group. 
Effect of DEHP exposure on protein levels of PI3K signaling factors 
DEHP exposure in the 10 and 30 day dosing studies selectively altered the mRNA levels 
of PI3K signaling factors that are associated with early folliculogenesis; however, some doses 
that exhibited phenotypic changes in folliculogenesis had unaltered mRNA expression. 
Additionally, certain factors within the PI3K signaling pathway are translationally and post-
translationally regulated, thus the mRNA levels may not be indicative of the ovarian phenotypic 
changes observed in our dosing studies. Therefore, we measured protein levels of two key PI3K 
signaling factors that regulate primordial follicle recruitment in the 10 day dosing study. 
Representative images of pAKT, a stimulatory PI3K signaling factor involved in the promotion 
of primordial follicle recruitment, and PTEN, an inhibitory PI3K signaling factor involved in 
maintaining primordial follicle quiescence, staining in the ovary are found in Figure 3.5. 
Qualitatively, it appears that DEHP exposure increased the staining of pAKT (Fig. 3.5A-3.5D) 
and decreased the staining of PTEN (Fig. 3.5I-3.5L) in the whole ovary and in immature follicle 
77 
types (Fig. 3.5E-3.5H). When quantified, DEHP exposure significantly increased pAKT and 
significantly decreased PTEN staining in the whole ovary at all selected doses of DEHP when 
compared to the vehicle control group (Fig. 3.6A and 3.6B, n=3/group, p ≤ 0.05). To confirm 
that these effects were evident in the follicles of interest, we measured protein staining within the 
primordial and primary follicles themselves. DEHP exposure significantly increased pAKT 
staining in primordial follicles at all selected doses of DEHP and in primary follicles at the 20 
and 200 µg/kg/day doses, and the 20 mg/kg/day dose when compared to the vehicle control 
group (Fig. 3.6C and 3.6D, n=3/group, p ≤ 0.05). 
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3.5 Discussion  
We have shown that 10 and 30 day oral exposure to DEHP disrupts normal reproductive 
and ovarian function. Specifically, we provide evidence that relatively low levels of DEHP, 
including a dose within the estimated range of daily human exposure, alter estrous cyclicity and 
accelerate primordial follicle recruitment. Further, we are the first, to our knowledge, to provide 
mechanistic evidence by which adult exposure to DEHP accelerates early folliculogenesis. Our 
data show that DEHP exposure may interfere with normal PI3K signaling by altering the 
expression of key genes and/or the levels of key proteins.  
An important note is that the selected doses of DEHP had no effect on mortality and very 
minor effects on organ weights. Thus, the adverse reproductive outcomes in response to DEHP 
exposure are most likely not due to overt toxicity. Additionally, the doses used in these studies 
are more environmentally relevant than doses used in several previous studies found within the 
literature [15, 17, 34]. Therefore, these findings provide some insight into the effects of DEHP 
on ovarian function at human exposure levels, though we acknowledge that investigating the 
effects at even lower levels would be beneficial.  
Our data provide evidence that relatively low levels of DEHP disrupt estrous cyclicity, 
which may cause complications in reproductive function. DEHP exposure for 10 days increased 
the percentage of days that the mice were in estrus at the 20 µg/kg/day, and the 20, 200, and 750 
mg/kg/day doses when compared to the vehicle control group. Likewise, but to a lesser degree, 
DEHP exposure for 30 days increased the percentage of days the mice were estrus at the 200 
mg/kg/day dose when compared to the vehicle control group. These results correlate to previous 
reports suggesting that higher doses of DEHP (2 g/kg/day) disrupt estrous cyclicity, but also 
expand upon those findings, in that the lower levels of DEHP used in this study also exhibit 
effects on estrous cyclicity [15]. Interestingly, the effects of DEHP on estrous cyclicity exhibit a 
non-monotonic dose response and appear to be greater following 10 days of exposure than what 
is observed following 30 days of exposure. A non-monotonic dose response is typical among 
common endocrine disrupting chemicals, which suggests that different effects and mechanisms 
may exist at different doses. Further, we hypothesize that the ovary and/or the hypothalamus-
pituitary-ovarian axis is able to compensate for the toxicity of DEHP between days 10 and 30. 
Additionally, it is possible that the biotransformation of DEHP is altered following a longer 
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period of dosing so that altered metabolism of the chemical helps protect the ovary from toxicity, 
but further work investigating this matter would need to be conducted to verify this statement.  
Although DEHP has been shown to disrupt reproductive function in males and, to lesser 
extent, in females, the effect of DEHP on ovarian folliculogenesis, especially in the adult, is 
relatively unknown. For normal fertility and the appropriate timing of reproductive senescence, 
primordial follicles must undergo a strict and coordinated process known as primordial follicle 
recruitment. Under normal conditions, the primordial follicle is essentially destined for three 
fates: to survive in dormancy for varying lengths of time throughout reproductive life, to be 
recruited into the growing population of follicles, or to undergo death in the dormant state [50-
52]. Our data show that 10 and 30 day exposure to DEHP accelerates this essential stage of early 
folliculogenesis. Specifically, 10 day exposure to DEHP decreased the percentage of primordial 
follicles counted at the 20 and 200 mg/kg/day doses and increased the percentage of primary 
follicles counted at all selected doses (20 µg/kg/day-750 mg/kg/day) when compared to the 
vehicle control group. A similar effect is observed following a longer period of dosing where 30 
day exposure to DEHP increased the percentage of primary follicles counted at the 200 
µg/kg/day and 20 mg/kg/day doses when compared to the vehicle control group. Thus, DEHP 
exposure at these two timepoints accelerates primordial follicle recruitment to the primary stage 
of development in the adult murine model. These results are consistent with those from other 
studies using different methods. Specifically, DEHP in vitro and in vivo alters early 
folliculogenesis and primordial follicle assembly in mice; however the exposure periods were 
limited to the neonate [53, 54]. Additionally, in utero exposure to high levels of MEHP, the 
metabolite of DEHP, accelerates early folliculogenesis in the F1 generation of mice [55]. Our 
data add to these existing studies by showing that adult exposure to relatively low levels of 
DEHP accelerates early folliculogenesis in the mouse.   
Interestingly, in our study, the effects on early folliculogenesis appear to be more 
profound following 10 days of exposure than what is observed following 30 days of exposure. 
We attribute this observation to the ovary being able to compensate for the toxicity of DEHP 
between days 10 and 30 by potentially altering the biotransformation of DEHP. Although the 
defects in follicle numbers appear to be undergoing compensation, it is possible that the oocytes 
in follicles that undergo accelerated folliculogenesis may not be of fertilizable quality. In fact, 
previous work has determined that accelerated early folliculogenesis results in poor quality 
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oocytes and compromised fertility [56]. Further, it is possible that our follicle count data 
represent a single “snap-shot” following 10 and 30 days of DEHP exposure and that changes in 
follicle numbers may be observed at later time points. Additionally, it is possible that the excess 
primary follicles may undergo atresia which may be why we do not see changes in the later 
stages of folliculogenesis. In accordance with the estrous cyclicity results, we also observe a non-
monotonic dose response for the effects of DEHP on early folliculogenesis. Future studies should 
examine the mechanisms underlying compensation and the non-monotonic dose response. 
Further, these studies should determine if accelerated primordial follicle recruitment has long 
term implications for fertility.  
Primordial follicle recruitment is a gonadotropin-independent process that relies on 
paracrine and autocrine regulation by intrinsic ovarian growth factors [26, 27]. These factors 
either suppress activation and thus, maintain primordial follicle dormancy, or they activate 
primordial follicles and thus, promote recruitment. A balance exists between these inhibitory and 
stimulatory factors to maintain primordial follicle survival so that downregulation of inhibitory 
factors and/or overactivation of stimulatory factors favor an environment conducive for 
primordial follicle recruitment [43]. Although the exact mechanism by which follicles are 
recruited to the growing pool is unknown, recent work has established the existence of several 
key intrinsic ovarian factors that belong to multiple signaling pathways [41, 42, 50, 57]. 
Interestingly, several of these factors are involved in the PI3K signaling pathway, which 
indicates this pathway as a critical regulator of primordial follicle survival, quiescence, and 
recruitment to the primary stage of development [28-33].  
The PI3K signaling pathway is involved in cell proliferation, survival, migration, 
metabolism, and most recently in early ovarian folliculogenesis [43, 45, 46]. Components of this 
signaling pathway that are also associated with primordial follicle recruitment and have been 
tested in these studies include PDPK1, mTORC1, KIT, pAKT, and rpS6, which are all factors 
that drive PI3K signaling. Additional components of this pathway that are associated with 
primordial follicle recruitment and have been tested in these studies include FOXO3A, PTEN, 
and TSC1, which negatively regulate PI3K signaling. Conditional deletion of Foxo3a, Pten, and 
Tsc1 from mouse oocytes results in global activation of all primordial follicles, leading to 
premature ovarian failure [31, 44, 58-61]. Thus, these inhibitors of PI3K signaling maintain 
primordial follicle dormancy. Acceleration of primordial follicle recruitment occurs because of 
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over-activation of the PI3K signaling pathway brought about by the unrestricted regulation of 
stimulatory PI3K factors, such as pAKT, mTORC1, and PDK1 [44, 59, 62, 63]. Therefore, 
proper regulation of PI3K signaling is needed for appropriate primordial follicle survival, 
quiescence, and recruitment; and dysregulation of this pathway may lead to the acceleration of 
primordial follicle recruitment and ultimately premature ovarian failure and infertility. 
Our data provide evidence that 10 and 30 day DEHP exposure dysregulates the ovarian 
mRNA and protein levels of key PI3K signaling factors that are associated with primordial 
follicle recruitment. These findings are critical because PI3K signaling is an integral regulator of 
primordial follicle recruitment and because they provide mechanistic evidence by which DEHP 
disrupts folliculogenesis in an adult model. Specifically, in the 10 day dosing study, DEHP 
selectively increased the mRNA levels of the stimulatory PI3K signaling factors Mtorc1 and 
Pdk1 at doses that correspond to the acceleration of early folliculogenesis when compared to the 
vehicle control group. Additionally, DEHP exposure for 10 days selectively decreased the 
mRNA levels of the inhibitory PI3K signaling factor Pten at doses that correspond to the 
acceleration of early folliculogenesis when compared to the vehicle control group. Importantly, 
DEHP exposure for 30 days also decreased the mRNA levels of Pten at a dose that corresponds 
to the acceleration of early folliculogenesis when compared to the vehicle control group. 
Interestingly, DEHP exposure for 30 days also selectively altered the mRNA levels of 
stimulatory, Kit and Rps6, and inhibitory, Tsc1, PI3K signaling factors, but DEHP did so at doses 
in which early folliculogenesis was unaffected. Further, DEHP exposure altered the mRNA 
levels of factors outside the PI3K signaling pathway that also are involved in primordial follicle 
recruitment. In the 30 day dosing study, DEHP exposure decreased the mRNA levels of Foxl2 
when compared to the vehicle control group. Thus, although we provide evidence that DEHP 
disrupts folliculogenesis by dysregulating the PI3K signaling pathway, the additive effects of 
other factors/signaling pathways in contribution to PI3K signaling cannot be discounted and 
should be examined in future studies. 
Based on the selective ability of DEHP to aberrantly alter the mRNA levels of PI3K 
signaling factors that are associated with early folliculogenesis and that several PI3K signaling 
factors are translationally and post-translationally regulated, we decided to expand upon the gene 
expression findings by measuring protein levels of pAKT and PTEN. These proteins were 
chosen because they serve as integral regulators of PI3K signaling and are associated with 
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primordial follicle recruitment. Specifically, the phosphatase PTEN negatively regulates the 
PI3K-induced activation of the secondary messenger AKT; thus, PTEN lies upstream of AKT 
[45, 46]. Further, the loss of Pten in oocytes leads to global acceleration of all primordial 
follicles in the ovary via increased AKT-regulated PI3K signaling [44]. In the 10 day dosing 
study, DEHP exposure increased the staining of pAKT and decreased the staining of PTEN in 
the whole ovary at all selected doses of DEHP when compared to the vehicle control group. In 
confirmation that these effects were evident in the follicles of interest, DEHP exposure increased 
pAKT staining in primordial follicles at all selected doses of DEHP and in primary follicles at 
the 20 and 200 µg/kg/day doses, and the 20 mg/kg/day dose when compared to the vehicle 
control group. Thus, the mRNA and protein data provide evidence that DEHP may first 
downregulate PTEN leading to the overactivation of the PI3K/pAKT signaling cascade. Similar 
effects of DEHP-induced dysregulation of PI3K signaling have been noted in other tissues [64-
66]. Our data expand upon these previous findings by showing DEHP-induced PI3K 
dysregulation in the ovary. Additionally, our data are consistent with our follicle count data in 
that increased pAKT and decreased PTEN would favor an environment conducive for primordial 
follicle recruitment. Furthermore, these data are fairly consistent with the mRNA data; however, 
not all of the gene expression changes correlate with the phenotypic changes in folliculogenesis. 
Additionally, the effects of DEHP exposure on gene expression exhibit a non-monotonic dose 
response. Thus, the protein data are more definitive than the mRNA data in that all doses that 
cause the acceleration of primordial follicle recruitment contain significant protein data.  
Collectively, these data provide evidence that relatively low levels of DEHP alter estrous 
cyclicity and accelerate primordial follicle recruitment, which potentially can interfere with 
normal reproductive function and appropriate timing of reproductive senescence. Further, our 
data show that the DEHP-induced defects in early folliculogenesis may be mediated by 
dysregulation of the PI3K signaling pathway. This study is novel because we provide 
mechanistic evidence by which a ubiquitous endocrine disrupting chemical disrupts 
folliculogenesis, an essential ovarian process necessary for normal reproductive and non-
reproductive health. However, further work is needed to completely elucidate the mechanism of 
DEHP-induced acceleration of primordial follicle recruitment. Additionally, although early 
folliculogenesis is aberrantly regulated in our dosing windows, it is of great interest to 
investigate if the primordial follicle pool is depleted at an accelerated rate in response to DEHP 
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exposure over an extended period of time or if DEHP exposure compromises oocyte quality in 
accelerated follicles, thus leading to the potential of premature ovarian failure and infertility.  
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3.6 Tables, Figures, and Legends 
Table 3.1 Sequences of primer sets used for gene expression analysis  
 
Specific primer sequences used for qPCR analysis of gene expression.  
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Table 3.2 Effect of DEHP exposure on body and organ weights 
 
 
 
 
 
 
 
 
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-750 mg/kg/day) daily for 10 and 30 days. Following dosing, percent body weight 
change, whole organ weights, and relative organ weights were calculated and compared in each 
treatment group. (n=8 mice/treatment group). Asterisks (*) represent significant difference from 
vehicle control (p ≤ 0.05). 
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Figure 3.1 Effect of DEHP exposure on estrous cyclicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-750 mg/kg/day) daily for 10 (panel A) and 30 (panel B) days. Vaginal swabs were 
taken daily using phosphate buffered saline administered from a pipet tip. Stage of estrus was 
recorded based on previously defined criteria using a light microscope. Percentage of days in 
estrus and metestrus/diestrus were calculated and compared in each treatment group. Graph 
represents means ± SEM (n=8 mice/treatment group). Asterisks (*) represent significant 
difference from vehicle control (p ≤ 0.05). 
 
  
87 
Figure 3.2 Effect of DEHP exposure on folliculogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-750 mg/kg/day) daily for 10 (panel A) and 30 (panel B) days. Following dosing, 
ovaries were processed for histological evaluation of follicle counts. Percentages of each follicle 
type were calculated and compared in each treatment group. Graph represents means ± SEM 
(n=3-8 ovaries/treatment group). Asterisks (*) represent significant difference from vehicle 
control (p ≤ 0.05). 
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Figure 3.3 Effect of DEHP exposure for 10 days on the mRNA expression of key factors in 
the PI3K signaling pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-750 mg/kg/day) daily for 10 days. Following dosing, whole ovaries were subjected to 
qPCR for Mtorc1 (panel A), Pdk1 (panel B), and Pten (panel C). All values were normalized to 
Actb. Graph represents means ± SEM (n=4-5 ovaries/treatment group). Asterisks (*) represent 
significant difference from vehicle control (p ≤ 0.05). 
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Figure 3.4 Effect of DEHP exposure for 30 days on the mRNA expression of key factors in 
the PI3K signaling pathway 
 
 
 
 
 
 
 
 
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-200 mg/kg/day) daily for 30 days. Following dosing, whole ovaries were subjected to 
qPCR for Kit (panel A), Pten (panel B), Rps6 (panel C), and Tsc1 (panel D). All values were 
normalized to Actb. Graph represents means ± SEM (n=3-4 ovaries/treatment group). Asterisks 
(*) represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 3.5 Representative images of immunohistochemistry and pseudocolored protein 
quantification 
 
 
 
 
 
 
 
 
 
 
 
Panels A-H exhibit pAKT staining in the whole ovary (panels A-D) and in selected primordial 
and primary follicles (panels E-H). Panels I-L exhibit PTEN staining in the whole ovary. Panels 
A, B, E, F, I, and J were from vehicle control treated ovaries and follicles. Panels C, D, G, H, K, 
and L were from 20 µg/kg/day DEHP treated ovaries and follicles. Black arrow heads represent 
positive staining in the immunohistochemistry images, which translate to the yellow/orange 
pseudocolored pixels represented by red arrow heads. Scale bars are set as 500 µm for whole 
ovary images (panels A-D and I-L) and 100 µm for follicle images (panels E-H) and the same 
scale bars should be used across each row.  
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Figure 3.6 Effect of DEHP exposure on protein levels of PI3K signaling factors associated 
with early folliculogenesis  
 
Adult CD-1 mice were orally dosed with vehicle (tocopherol-stripped corn oil) or DEHP (20 
µg/kg/day-750 mg/kg/day) daily for 10 days. Following dosing, ovaries were subjected to 
immunohistochemistry for quantification of pAKT (panels A, C, and D) and PTEN (panel B) 
staining. Digital images were converted to 8-bit grayscale images and then converted to 
pseudocolored images. Colors were based on relative stain intensity. Percentage of positively 
stained pixels in the whole ovary (panels A and B) and in follicles (panels C and D) were 
calculated and compared in each treatment group. Graph represents means ± SEM (n=3/group). 
Asterisks (*) represent significant difference from vehicle control (p ≤ 0.05). 
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CHAPTER IV 
Di(2-ethylhexyl) Phthalate Inhibits Antral Follicle Growth, Induces Atresia, and Inhibits 
Steroid Hormone Production in Cultured Mouse Antral Follicles3 
4.1 Abstract  
Di(2-ethylhexyl) phthalate (DEHP) is a ubiquitous environmental toxicant found in 
consumer products that causes ovarian toxicity. Antral follicles are the functional ovarian units 
and must undergo growth, survival from atresia, and proper regulation of steroidogenesis to 
ovulate and produce hormones. Previous studies have determined that DEHP inhibits antral 
follicle growth and decreases estradiol levels in vitro; however, the mechanism by which DEHP 
elicits these effects is unknown. The present study tested the hypothesis that DEHP directly 
alters regulators of the cell cycle, apoptosis, and steroidogenesis to inhibit antral follicle 
functionality. Antral follicles from adult CD-1 mice were cultured with vehicle control or DEHP 
(1-100μg/ml) for 24-96 hr to establish the temporal effects of DEHP on the follicle. Following 
24-96 hr of culture, antral follicles were subjected to gene expression analysis, and media were 
subjected to measurements of hormone levels. DEHP increased the mRNA levels of cyclin D2, 
cyclin dependent kinase 4, cyclin E1, cyclin A2, and cyclin B1 and decreased the levels of 
cyclin-dependent kinase inhibitor 1A prior to growth inhibition. Additionally, DEHP increased 
the mRNA levels of BCL2-associated agonist of cell death, BCL2-associated X protein, BCL2-
related ovarian killer protein, B-cell leukemia/lymphoma 2, and Bcl2-like 10, leading to an 
increase in atresia. Further, DEHP decreased the levels of progesterone, androstenedione, and 
testosterone prior to the decrease in estradiol levels, with decreased mRNA levels of side-chain 
cleavage, 17α-hydroxylase-17,20-desmolase, 17β-hydroxysteroid dehydrogenase, and aromatase. 
Collectively, DEHP directly alters antral follicle functionality by inhibiting growth, inducing 
atresia, and inhibiting steroidogenesis.   
3 Reprinted, with permission, from PR. Hannon et al. Di(2-ethylhexyl) phthalate inhibits antral follicle growth, 
induces atresia, and inhibits steroid hormone production in cultured mouse antral follicles. Toxicology and Applied 
Pharmacology 2015 (in press). 
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4.2 Introduction 
Di(2-ethylhexyl) phthalate (DEHP) is the most commonly used phthalate ester, and it is 
predominantly used in the manufacturing of a wide range of polyvinyl chloride consumer, 
medical, and building products to impart flexibility [1, 2]. Because of its incorporation in 
numerous commonly used consumer products, DEHP is produced in vast quantities. Domestic 
production of dioctyl phthalates, a subgroup of phthalate esters in which DEHP is classified, 
exceeds 300 million pounds annually [2]. Humans are exposed to DEHP on a daily basis via oral 
ingestion, inhalation, and dermal contact [1]. This is because DEHP is non-covalently bound to 
the plastic, allowing the chemical to frequently leach out into the environment and in the 
products that humans consume on a daily basis [1]. In fact, it is estimated that the range of daily 
human exposure to DEHP is between 3-30 μg/kg/day [3, 4]. Continuous, daily exposure to 
DEHP is a major concern because DEHP and its metabolite mono(2-ethylhexyl) phthalate 
(MEHP) have been identified in human blood samples [5, 6], urine samples [1, 5-9], amniotic 
fluid samples [10-12], cord blood samples from newborns [13, 14], breast milk samples [6], and 
in ovarian follicular fluid samples tested [15], indicating the ability of these chemicals to reach 
the ovary. 
Important for public health, DEHP is a known endocrine disrupting chemical and 
reproductive toxicant [1, 2]. In women, chronic occupational exposure to phthalates is associated 
with an increased risk of miscarriage and a decreased rate of pregnancy [1]. In laboratory 
animals, DEHP causes pregnancy complications, including reduced implantations, increased 
resorptions, and decreased fetal weights of offspring [16, 17].  
The mechanisms by which DEHP disrupts these endocrine and reproductive events 
remain unknown, but interestingly, antral follicles from the ovary are critical regulators of these 
processes. Follicles are the functional units of the ovary, and the antral follicle is the most mature 
follicle type. Antral follicles are the major sources of sex steroid hormone production in the 
female and are the only follicle type capable of ovulation [18]. Normal antral follicle function 
requires follicle growth, survival from atresia, and appropriate regulation of steroidogenesis [18]. 
Antral follicle growth is predominantly regulated by proliferation of granulosa cells and 
theca cells, which are somatic cells located in the follicle [18]. Proliferation of these cells, like 
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most mammalian cells, is regulated by cyclins, cyclin dependent kinases, and cyclin dependent 
kinase inhibitors [19-21]. Although some antral follicles are rescued from atresia and ovulate in a 
female’s reproductive lifespan, the vast majority of follicles (99%) are lost via atretic demise [18, 
22]. The regulation of follicular atresia involves a balance of pro- and anti-apoptotic factors that 
signal through the B cell leukemia/lymphoma 2 (BCL2) signaling pathway promoting caspase-
induced apoptosis [23-28]. Antral follicle production of sex steroid hormones, a process termed 
ovarian steroidogenesis, is also essential for reproductive and non-reproductive health [29-46]. 
Steroidogenesis is the enzymatic conversion of cholesterol to 17β-estradiol and other necessary 
sex steroid hormones.  
Interestingly, recent work also suggests that DEHP targets the ovary and adversely 
affects antral follicle functionality. Specifically, in vivo studies using oral exposure to DEHP 
have shown that DEHP decreases serum estradiol levels, decreases aromatase levels, decreases 
antral follicle size, causes anovulation, and disrupts estrous cyclicity [47-51]. Further, studies 
using ovarian granulosa cell cultures and minced ovary cultures show that DEHP also decreases 
estradiol and aromatase levels [52, 53]. Our group has also reported that DEHP inhibits antral 
follicle growth and decreases estradiol and aromatase levels in a whole antral follicle culture 
system following 96 hrs of culture [54]. However, few studies have investigated the effects of 
DEHP on the precursor hormones and enzymes upstream of estradiol and aromatase. Further, the 
direct effect of DEHP on antral follicle atresia is unclear. Additionally, the mechanisms by which 
DEHP disrupts antral follicle growth, health, and steroidogenesis remain unknown.   
The present study was designed to conduct a time-course study using an antral follicle 
culture system to investigate the initial and time specific DEHP-induced defects in antral follicle 
growth, atresia, and steroidogenesis upstream of the previously reported effects on estradiol. 
Specifically, we tested the hypothesis that DEHP directly alters regulators of the cell cycle, 
apoptosis, and steroidogenic pathway to inhibit antral follicle growth, induce atresia, and inhibit 
steroid production. To test this hypothesis, antral follicles were cultured with vehicle or DEHP 
for 24, 48, 72, and 96 hrs. Following culture, antral follicles were collected for histological 
evaluation of atresia and the measurements of mRNA levels of regulators of the cell cycle 
(Ccnd2, Cdk4, Ccne1, Ccna2, Ccnb1, and Cdkn1a), apoptosis (Bad, Bax, Bok, Bcl2, Bcl2l10, 
Casp8, and Casp3), and the enzymes responsible for generating estradiol (Star, Cyp11a1, 
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Hsd3b1, Cyp17a1, Hsd17b1, and Cyp19a1). Further, media were collected for the measurements 
of antral follicle produced progesterone, DHEA, androstenedione, testosterone, estrone, and 
estradiol.  
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4.3 Materials and Methods  
Chemicals 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions 
of DEHP were prepared using dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) as 
the vehicle in various concentrations (1.33, 13.3, and 133 mg/ml). This allowed for an equal 
volume of each stock to be added to the culture wells to control for vehicle concentration. Final 
concentrations of DEHP in culture were 1, 10, and 100 μg/ml, which is approximately equivalent 
to 2.77, 27.7, and 277 μM respectively.  
The concentrations of DEHP were chosen based their ability to cause inhibition of antral 
follicle growth, decreased estradiol production from antral follicles, and decreased antral follicle 
Cyp19a1 expression [54, 55]. These concentrations of DEHP also have been determined to be 
clinically relevant in reproductive and non-reproductive cell and tissue cultures [56-58]. 
Additionally, the selected concentrations of DEHP are environmentally relevant. Plasma 
concentrations of DEHP in healthy women have been reported to be 0.18 μg/ml, and peritoneal 
fluid concentrations of DEHP in these women were reported to be 0.46 μg/ml, which are close to 
the lowest concentration in this study [59]. The no-observed-adverse-effect level (NOAEL) for 
DEHP is 5.8 mg/kg/day which equates to 14.3 μM [2]. In addition, patients undergoing 
consistent medical care have markedly higher levels of DEHP than healthy people due to the 
extensive use of DEHP in medical care products [60, 61]. In intensive neonatal care units, 
patients receiving blood transfusions have plasma levels of DEHP at 11.1 μg/ml [62]. Further, 
the lowest-observed-adverse-effect level (LOAEL) of DEHP is 140 mg/kg/day, which equates to 
344.6 μM [2]. Each of the selected concentrations of DEHP falls below the LOAEL 
concentration.  
Animals 
Cycling, adult CD-1 female mice (34-37 days of age) were obtained from Charles River 
Laboratories (Wilmington, MA). The mice were housed in groups of 4 in the College of 
Veterinary Medicine Animal Facility at the University of Illinois at Urbana-Champaign and were 
allowed to acclimate to the facility prior to experimentation. The mice were housed in a 
controlled animal room environment (temperature at 22 ± 1 °C and 12-hour light–dark cycles) 
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and were provided food and water ad libitum. The Institutional Animal Use and Care Committee 
at the University of Illinois at Urbana-Champaign approved all procedures involving animal 
care, euthanasia, and tissue collection. 
In vitro antral follicle culture 
Unprimed, female CD-1 mice were euthanized and their ovaries were aseptically 
removed for antral follicle isolation. Antral follicles were isolated from the ovary based on 
relative size (250-400 μm) and were cleaned of interstitial tissue using watchmaker’s forceps 
[63, 64]. At least 2-3 mice were used in each experiment, in which we could obtain 
approximately 20-30 antral follicles per mouse. Each treatment group contained 10-16 follicles. 
Isolated antral follicles were randomly and individually plated in wells of a 96-well culture plate 
containing unsupplemented α-minimal essential medium (α-MEM, Life Technologies, Grand 
Island, NY) prior to treatment.  
Treatment groups included DMSO (vehicle control) and DEHP (1, 10, and 100 μg/ml) 
and were prepared in supplemented α-MEM. Supplemented α-MEM contained 1% ITS (10 
ng/ml insulin, 5.5 ng/ml transferrin, 5.5 ng/ml selenium, Sigma-Aldrich, St. Louis, MO), 100 
U/ml penicillin (Sigma-Aldrich, St. Louis, MO), 100 mg/ml streptomycin (Sigma-Aldrich, St. 
Louis, MO), 5 IU/ml human recombinant follicle-stimulating hormone (FSH; Dr. A. F. Parlow, 
National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, CA), and 5% 
fetal calf serum (Atlanta Biologicals, Lawrenceville, GA) as described previously [63, 64]. An 
equal volume of chemical (0.75 µl/ml of media) was added for each dose to control for the 
amount of vehicle in each preparation (final concentration of DMSO=0.075%). Each follicle was 
cultured in 150 μl of medium for 24–96 hr in an incubator at 37°C supplying 5% CO2. Following 
each 24 hr culture window, media were collected for measurements of the levels of sex steroid 
hormones and follicles were collected, snap-frozen, and stored at −80°C for gene expression 
analysis. Further, follicles were collected following 96 hr of culture and processed for 
histological analysis of atresia. A time-course was conducted to observe when the effects of 
DEHP on antral follicle growth, atresia, and steroidogenesis begin and to determine which 
enzymes and/or hormones cause the inhibition of growth and reduction of estradiol production 
from antral follicles following 96 hr as reported previously [54]. 
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Histological analysis of antral follicle atresia 
 Following 96 hr of culture, antral follicles were collected and processed for histological 
evaluation of atresia as described previously (n=10-16 follicles/3 separate experiments) [65, 66]. 
Briefly, each section of the follicle was observed for the presence of apoptotic bodies, which is a 
morphological sign of apoptosis. Based on the abundance of apoptotic bodies, the follicles were 
scored on a 1-4 scale. A rating of 1 indicated a healthy follicle without apoptotic bodies, a rating 
of 2 indicated the presence of apoptotic bodies encompassing 1-10% of the follicle section, a 
rating of 3 indicated the presence of apoptotic bodies encompassing 11-30% of the follicle 
section, and a rating of 4 indicated the presence of apoptotic bodies encompassing >30% of the 
follicle section. Atresia ratings were reported based on the average of all ratings throughout the 
follicle sections.  
Analysis of gene expression  
 After  24, 48, 72, and 96 hr of culture, antral follicles were snap frozen in liquid nitrogen, 
and stored at -80°C for quantitative real-time polymerase chain reaction (qPCR) analysis (n=10-
16 follicles/3-9 separate experiments). We elected to focus on mRNA gene expression analysis 
based on the limited amount of sample that can be retrieved from antral follicles. Total RNA 
(200 ng) was extracted from the follicles using the RNeasy Micro Kit (Qiagen, Inc., Valencia, 
CA) according to the manufacturer’s protocol, and was then reverse transcribed to 
complementary DNA (cDNA) using the iScript RT kit (Bio-Rad Laboratories, Inc., Hercules, 
CA) according to the manufacturer’s protocol. Each cDNA sample was diluted 1:4 using 
nuclease-free water prior to qPCR analysis. Analysis of qPCR was conducted using the CFX96 
Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA) and 
accompanying CFX Manager Software according to the manufacturer’s protocol. All qPCR 
reactions were done in triplicate using 1 μl cDNA, forward and reverse primers (5 pmol) for 
Ccnd2, Cdk4, Ccne1, Ccna2, Ccnb1, Cdkn1a, Bad, Bax, Bok, Bcl2, Bcl2l10, Casp8, Casp3, Star, 
Cyp11a1, Hsd3b1, Cyp17a1, Hsd17b1, Cyp19a1, Cyp1b1, or Actb, in addition to a 
SsoFastEvaGreen Supermix for a final reaction volume of 10 μl. Specific qPCR primers 
(Integrated DNA Technologies, Inc., Coralville, IA) for the genes of interest as well as the 
reference gene, beta-actin (Actb), which did not differ across treatment groups, can be found in 
Table 4.1. The genes tested were chosen because they are regulators of cell cycle (Ccnd2, Cdk4, 
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Ccne1, Ccna2, Ccnb1, and Cdkn1a) [19, 20, 67, 68], apoptosis (Bad, Bax, Bok, Bcl2, Bcl2l10, 
Casp8, and Casp3) [23-26, 69], and ovarian steroidogenesis (Star, Cyp11a1, Hsd3b1, Cyp17a1, 
Hsd17b1, and Cyp19a1) [70-73].  
The CFX96 machine quantifies the amount of PCR product generated by measuring 
SsoFastEvaGreen dye (Bio-Rad Laboratories, Inc., Hercules, CA) that fluoresces when bound to 
double-stranded DNA. The qPCR program consisted of an enzyme activation step (95°C for 1 
min), an amplification and quantification program (40 cycles of 95°C for 10 sec, 60°C for 10 sec, 
single fluorescence reading), a step of 72°C for 5 min, a melt curve (65°C−95°C heating 0.5°C 
per sec with continuous fluorescence readings), and a final step at 72°C for 5 min as per the 
manufacturer’s protocol. Expression data were generated using the mathematical standard 
comparative (ΔΔCt) method. The ΔCt was calculated by subtracting the Actb Ct value from the 
gene of interest Ct value. The ΔΔCt was calculated as the difference between the ΔCt between 
the treatment groups and the DMSO groups. The relative fold-change of expression was then 
equaled to 2(-ΔΔCt) for each sample.  
Analysis of sex steroid hormone levels 
 After 24, 48, 72, and 96 hr of culture, media were subjected to enzyme-linked 
immunosorbent assays (ELISAs) for the measurements of the levels of dehydroepiandrosterone 
(DHEA), progesterone, androstenedione, testosterone, estrone, and 17β-estradiol. ELISA kits 
were purchased from Diagnostics Research Group (DRG, Mountainside, NJ) (n=10-16 wells of 
pooled media containing follicles/3-9 separate experiments). The analytical sensitivity of each kit 
was 0.044 μg/ml for DHEA, 0.1 ng/mL for progesterone, 0.019 ng/mL for androstenedione, 
0.083 ng/mL for testosterone, 6.3 pg/mL for estrone, and 9.71 pg/mL for estradiol. The assays 
were performed following the manufacturer’s protocol. All samples were run in duplicate and all 
intra- and inter-assay coefficients of variability were less than 10%. Some samples were diluted 
to match the dynamic range of each ELISA kit. Mean values for each sample were used in this 
analysis. These steroid hormones were chosen because of their necessity for normal female 
reproductive function and endocrinology. Further, these hormones serve as precursors for 
estradiol production, and estradiol production has been shown to be reduced in response to 
DEHP treatment [54].   
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Statistical analysis  
 All data were analyzed using SPSS statistical software (SPSS, Inc., Chicago, IL). Data 
were expressed as means ± standard error of the means (SEM), and at least three separate 
experiments were conducted for each treatment group prior to data analysis. Multiple 
comparisons between normally distributed experimental groups were made using one-way 
analysis of variance (ANOVA) followed by Tukey post-hoc comparison. Multiple comparisons 
between non-normally distributed experimental groups were made using the Kruskal Wallis test 
when appropriate. Statistical significance was assigned at p ≤ 0.05. 
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4.4 Results  
Effect of DEHP on antral follicle growth and the mRNA levels of key regulators of the cell 
cycle 
 As previously reported, DEHP exposure for 72 and 96 hr inhibits antral follicle growth in 
vitro [54, 55]. To confirm this, antral follicles were cultured with vehicle control (DMSO) or 
DEHP (1-100µg/ml) for 96 hr, and follicle diameters were measured on a perpendicular axis 
every 24 hr. Similar to the previous reports, DEHP exposure for 72 hr inhibited antral follicle 
growth by roughly 10% at the 10 and 100µg/ml doses when compared to the vehicle control 
group (data not shown). Also comparable to the previous studies, DEHP exposure for 96 hr 
inhibited antral follicle growth by roughly 15% at all selected doses of DEHP when compared to 
the vehicle control group (data not shown).  
Because DEHP has been shown to inhibit antral follicle growth in vitro beginning at 72 
hr, we investigated the initial effects and potential mechanisms by which DEHP inhibits antral 
follicle growth. Specifically, we subjected antral follicles to qPCR following 24, 48, and 72 hr of 
culture to investigate the direct effects of DEHP on the mRNA levels of key cyclins, cyclin 
dependent kinases, and cyclin dependent kinase inhibitors, which are heavily involved in 
follicular cell proliferation and ultimately antral follicle growth [18-20]. Cyclins (Ccnd2, Ccne1, 
Ccna2, and Ccnb1) and cyclin dependent kinases (Cdk4) promote progression through the cell 
cycle, whereas cyclin dependent kinase inhibitors (Cdkn1a, also known as p21) promote cell 
cycle arrest.  
DEHP exposure for 24 hr significantly increased the mRNA levels of Ccnd2 at the 
1µg/ml dose when compared to the vehicle control group (Fig. 4.1A, n=3, p≤0.05). Similarly, 
DEHP exposure for 72 hr significantly increased the mRNA levels of Ccnd2 at the 10µg/ml dose 
when compared to the vehicle control group (Fig. 4.1A, n=5-9, p≤0.05). DEHP exposure for 72 
hr also increased the mRNA levels of Cdk4 at the 10µg/ml dose when compared to the vehicle 
control group (Fig. 4.1B, n=5-9, p≤0.05). Further, DEHP exposure for 48 and 72 hr increased the 
mRNA levels of Ccne1 at the 100µg/ml dose when compared to the vehicle control group (Fig. 
4.1C, n=5-9, p≤0.05). The mRNA levels of Ccna2 were significantly increased following 24 hr  
at the 1µg/ml dose and following 72 hr at the 10µg/ml dose when compared to the vehicle 
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control group (Fig. 4.1D, n=3-9, p≤0.05). Strikingly, DEHP exposure for 48 and 72 hr 
significantly increased the mRNA levels of Ccnb1 at all selected doses when compared to the 
vehicle control group (Fig. 4.1E, n=5-9, p≤0.05). The mRNA levels of the inhibitor Cdkn1a were 
significantly decreased by the 1 and 100µg/ml doses following 48 hr when compared to the 
vehicle control group (Fig. 4.1F, n=5-8, p≤0.05). 
Effect of DEHP on antral follicle atresia 
 An important aspect of antral follicle health and functionality is survival from atresia, 
which is an apoptotic process. Although we have previously determined that DEHP exposure 
inhibits antral follicle growth and decreases antral follicle-produced estradiol levels [54, 55], the 
direct effects of DEHP on antral follicle atresia were unknown. Thus, we cultured antral follicles 
with vehicle control (DMSO) or DEHP (1-100µg/ml) for 96 hr and processed the follicles for 
histological evaluation of atresia. Atresia was rated by the presence of apoptotic bodies. A 
representative image of a DMSO treated follicle is displayed in Fig. 4.2A, whereas a 
representative image of a DEHP 100µg/ml treated follicle is exhibited in Fig. 4.2B. 
Qualitatively, it appears that DEHP treatment increased the presence and abundance of apoptotic 
bodies within the follicular unit when compared to the vehicle control treated follicles. When 
quantified, DEHP exposure for 96 hr significantly increased the number of apoptotic bodies, 
represented by a higher atresia rating, at the 10 and 100µg/ml doses when compared to the 
vehicle control group (Fig. 4.2C, n=3, p≤0.05). 
Effect of DEHP on the antral follicle mRNA levels of key regulators of apoptosis   
 Although atresia is a natural occurrence in antral follicles, an increase in atresia can have 
negative impacts on ovarian and reproductive health [18, 22]. Because we observed an increase 
in antral follicle atresia following 96 hr of DEHP exposure, we investigated the initial effects and 
potential mechanisms by which DEHP induces atresia, or apoptosis, in the antral follicle. 
Specifically, antral follicles were cultured with vehicle control (DMSO) or DEHP (1-100µg/ml) 
for 24-72 hr. Following 24, 28, and 72 hr of culture, we subjected antral follicles to qPCR to 
investigate the direct effects of DEHP on the mRNA levels of factors that drive apoptosis to 
promote atresia (Bad, Bax, and Bok) and factors that inhibit apoptosis to promote follicle survival 
(Bcl2 and Bcl2l10). DEHP exposure significantly increased the mRNA levels of pro-apoptotic 
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Bad following 24 hr at the 1µg/ml dose and following 48 hr at the 100µg/ml dose when 
compared to the vehicle control group (Fig. 4.3A, n=3-8, p≤0.05). DEHP exposure also 
significantly increased the mRNA levels of pro-apoptotic Bax following 24 hr at all selected 
doses of DEHP and following 72 hr at the 1 and 10µg/ml doses when compared to the vehicle 
control group (Fig. 4.3B, n=3-9, p≤0.05). The mRNA levels of pro-apoptotic Bok were 
significantly increased following 24 hr at the 1µg/ml dose and following 72 hr at the 10µg/ml 
dose when compared to the vehicle control group (Fig. 4.3C, n=3-9, p≤0.05). Interestingly, 
DEHP exposure for 24, 48, and 72 hr significantly increased the mRNA levels of anti-apoptotic 
Bcl2 at the 1 and 10µg/ml doses when compared to the vehicle control group (Fig. 4.3D, n=3-9, 
p≤0.05). Similarly, the mRNA levels of anti-apoptotic Bcl2l10 were significantly increased 
following 48 hr at all selected doses of DEHP and following 72 hr at the 10 and 100µg/ml doses 
when compared to the vehicle control group (Fig. 4.3E, n=5-9, p≤0.05).  
 Apoptosis and cell survival rely on the balance of pro- and anti-apoptotic factors, and 
often the Bax/Bcl2 ratio is used to determine susceptibility to apoptosis [74, 75]. Following 
qPCR analysis, we calculated the Bax/Bcl2 ratio at 24, 48, and 72 hr of culture. Interestingly, 
DEHP exposure significantly decreased the Bax/Bcl2 ratio following 48 hr at the 1µg/ml dose 
when compared to the vehicle control group (Fig. 4.3F, n=5-8, p≤0.05).   
Effect of DEHP on the antral follicle mRNA levels of downstream apoptosis factors 
 The present study indicates that DEHP exposure induced atresia in cultured mouse antral 
follicles; however, DEHP exposure also increased the mRNA levels of both pro- and anti-
apoptotic BCL2 regulators of apoptosis. In addition, the Bax/Bcl2 ratio is relatively unchanged in 
response to DEHP exposure. In order to confirm the histological presence of atresia in the antral 
follicles, we measured the levels of key downstream facilitators of apoptosis. Specifically, we 
subjected antral follicles to qPCR following 24, 48, and 72 hr of culture to measure the mRNA 
levels of Casp8 and Casp3. These caspases are known executors of apoptosis that initiate the 
disassembly and degradation of the cell in response to pro-apoptotic BCL2 signaling [27, 28]. 
DEHP exposure significantly increased the mRNA levels of Casp8 following 72 hr at the 10 and 
100µg/ml doses when compared to the vehicle control group (Fig. 4.4A, n=5-9, p≤0.05). 
Interestingly, DEHP exposure significantly increased the mRNA levels of Casp3 following 24 hr 
at the 1 and 100µg/ml doses when compared to the vehicle control group, but this effect was not 
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observed following 48 hr of exposure (Fig. 4.4B, n=3-9, p≤0.05). However, following 72 hr of 
exposure, DEHP significantly increased the mRNA levels of Casp3 at all selected doses of 
DEHP when compared to the vehicle control group (Fig. 4.4B, n=5-9, p≤0.05).  
Effect of DEHP on antral follicle-produced sex steroid hormone levels 
 Previous studies have determined that DEHP exposure decreases estradiol levels both in 
vivo [47-50] and in vitro [52, 53]. Similar to previous studies, we have reported that DEHP 
exposure for 96 hr decreases estradiol levels in an in vitro antral follicle culture system [54]. 
However, the direct effects of DEHP at earlier time-points of exposure and on the estradiol 
precursor sex steroid hormones are relatively unknown. Thus, we conducted a time-course 
experiment to investigate the effects of DEHP upstream of estradiol production and to observe 
the initial effects of DEHP on antral follicle steroidogenesis. DEHP exposure significantly 
decreased the levels of progesterone following 48 and 72 hr at all selected doses of DEHP when 
compared to the vehicle control group (Fig. 4.5A, n=5-9, p≤0.05). DEHP exposure also 
significantly decreased the levels of DHEA following 72 hr at the 10µg/ml dose when compared 
to the vehicle control group (Fig. 4.5B, n=5-9, p≤0.05). Similarly, androstenedione levels were 
significantly decreased following 48 hr at all selected doses of DEHP, following 72 hr at the 10 
and 100µg/ml doses, and following 96 hr at the 100µg/ml dose when compared to the vehicle 
control group (Fig. 4.5C, n=5-9, p≤0.05). Likewise, DEHP exposure significantly decreased the 
levels of testosterone  following 48 hr at all selected doses of DEHP, following 72 hr at the 10 
and 100µg/ml doses, and following 96 hr at all selected doses of DEHP when compared to the 
vehicle control group (Fig. 4.5D, n=5-9, p≤0.05). Similar to our previously published study [54], 
DEHP exposure significantly decreased estradiol levels following 96 hr at the 10 and 100µg/ml 
doses when compared to the vehicle control group; but interestingly and not previously reported, 
DEHP exposure for 72 hr also decreased estradiol levels at all selected doses of DEHP when 
compared to the vehicle control group (Fig. 4.5F, n=5-9, p≤0.05). In contrast, DEHP exposure 
had no effect on the levels of estrone at each time-point tested when compared to the vehicle 
control group (Fig. 4.5E, n=3-9).     
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Effect of DEHP on the antral follicle mRNA expression of key steroidogenic enzymes 
 Previous studies have determined that DEHP exposure decreases the ovarian mRNA 
levels of Cyp19a1, also known as aromatase, in vivo [47, 76] and in an in vitro antral follicle 
culture system following 96 hr [54]. Similar to the effects on the levels of steroid hormones, not 
much is known about the direct effects of DEHP on the steroidogenic enzymes upstream of 
Cyp19a1. Because we observed decreases in the levels of estradiol and its precursor sex steroid 
hormones across multiple time-points, we investigated the initial effects and potential 
mechanisms by which DEHP inhibits steroidogenesis. Specifically, antral follicles were cultured 
with vehicle control (DMSO) or DEHP (1-100µg/ml) for 24-96 hr. Following each 24 hr time-
point, antral follicles were subjected to qPCR to investigate the direct effects of DEHP on the 
estradiol biosynthesis enzymes (Star, Cyp11a1, Hsd3b1, Cyp17a1, Hsd17b1, and Cyp19a1), 
which convert cholesterol to estradiol in a step-wise manner. DEHP exposure significantly 
decreased the mRNA levels of Cyp11a1 following 72 hr at the 10 and 100µg/ml doses when 
compared to the vehicle control group (Fig. 4.6B, n=5-9, p≤0.05). Beginning at 48 hr, DEHP 
exposure significantly increased the mRNA levels of Hsd3b1 at the 100µg/ml dose when 
compared to the vehicle control group (Fig. 4.6C, n=5-8, p≤0.05). Further, DEHP exposure 
significantly decreased the mRNA levels of Cyp17a1 following 96 hr at the 100µg/ml dose when 
compared to the vehicle control group (Fig. 4.6D, n=5-9, p≤0.05). Meanwhile, there was a trend 
for a significant decrease in the mRNA levels of Cyp17a1 following 72 hr at the 100µg/ml dose 
and following 96 hr at the 1µg/ml dose when compared to the vehicle control group (Fig. 4.6D, 
n=5-9). Beginning at 48 hr, there was a trend for a significant increase in the mRNA levels of 
Hsd17b1 at all selected doses tested, and this trend persists through 72 hr with statistical 
significance at the 10µg/ml dose (Fig. 4.6E, n=5-9, p≤0.05). However, by 96 hr, the mRNA 
levels of Hsd17b1 were significantly decreased at the 100µg/ml dose when compared to the 
vehicle control group (Fig. 4.6E, n=5-9, p≤0.05). Similarly, there was a trend for a significant 
increase in the mRNA levels of Cyp19a1 at all selected doses tested following 48 hr, with a 
statistical significance at the 1µg/ml dose when compared to the vehicle control group (Fig. 4.6F, 
n=5-8, p≤0.05). By 96 hr, there was a significant decrease in the mRNA levels of Cyp19a1 at the 
100µg/ml dose (Fig. 4.6F, n=5-9, p≤0.05). In contrast, DEHP exposure had no effect on the 
mRNA levels of Star at each time-point tested when compared to the vehicle control group (Fig. 
4.6A, n=3-9).   
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4.5 Discussion  
 We utilized an in vitro antral follicle culture system to investigate the effects of DEHP, a 
ubiquitous endocrine disrupting chemical, on antral follicle growth, atresia, and steroidogenesis. 
Our main findings suggest that DEHP exposure alters the follicular mRNA levels of cyclins, a 
cyclin dependent kinase, and a cyclin dependent kinase inhibitor to potentially impact the 
previously observed effect of DEHP-induced inhibition of antral follicle growth [54, 55]. 
Further, our work demonstrates that DEHP exposure directly induces antral follicle atresia as 
evident via histological evaluation and increased mRNA levels of caspases, and that alterations 
in the mRNA levels of BCL2 family members may be responsible for the DEHP-induced onset 
of atresia. Additionally, we have shown that DEHP directly impacts the production of sex steroid 
hormones upstream of estradiol and alters the mRNA levels of the estradiol biosynthesis 
enzymes upstream of Cyp19a1. Importantly, we have established a time-course of the DEHP-
induced defects on antral follicles, and we have determined the initial effects of DEHP on antral 
follicle growth, atresia, and steroidogenesis.  
 The use of this antral follicle culture system is vital in understanding the direct effects of 
DEHP on the most mature, and only, follicle type that is capable of ovulation and synthesis of 
steroid hormones. Previous work has investigated the effects of DEHP exposure on antral follicle 
growth and steroidogenesis in vivo showing that DEHP decreased antral follicle diameter, and 
decreased the levels of serum estradiol produced by the antral follicles [47-50]. The limitation of 
these previous studies is that they did not determine whether the effects on antral follicle size and 
estradiol production were direct effects on the follicle or were indirect effects caused by toxicity 
in other organ systems, namely the hypothalamus-pituitary axis. To combat this limitation, 
previous studies have shown that DEHP and MEHP decreased estradiol production and Cyp19a1 
levels in murine and human granulosa cell cultures in vitro [53, 77-80]. However, the limitation 
of these studies is that they only utilized one somatic follicular cell type. Antral follicle growth, 
survival from atresia, and steroidogenesis rely on the multi-directional communication between 
the oocyte, granulosa cells, and theca cells [18, 22, 72, 73]. Thus, although previous studies have 
been instrumental in understanding the defects caused by DEHP, the in vitro whole antral follicle 
culture system has proved to be a novel approach in understanding the direct effects of DEHP on 
antral follicle functionality [57, 81].  
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Our results indicate that DEHP directly inhibits antral follicle growth and dysregulates 
the expression of cell cycle regulators. We have previously reported that DEHP exposure 
decreased the antral follicle mRNA levels of Ccnd2 and Cdk4 following 96 hr [54]. Expanding 
upon these findings, we have established the time-course effects of DEHP on the antral follicle 
levels of several cyclins, Cdk4, and Cdkn1a. Contrary to the findings at 96 hr, DEHP exposure 
prior to 96 hr increased the mRNA levels of Ccnd2, Cdk4, Ccne1, Ccna2, and Ccnb1. Further, 
DEHP exposure decreased the mRNA levels of the inhibitor Cdkn1a. The earliest effect of 
DEHP on the regulators of the cell cycle was observed following 24 hr of exposure, where 
DEHP exposure increased the mRNA levels of Ccnd2 and Ccna2, but only at the lowest dose. 
The most striking finding is that DEHP exposure increased Ccnb1 following 48 and 72 hr at all 
selected doses. That, as well as the increases in the other cyclins and Cdk4, and decreases in 
Cdkn1a suggests that early exposure to DEHP may result in an initial push for cell cycle 
progression and proliferation to combat the toxicity of DEHP. This potentially is why we do not 
observe growth inhibition prior to 72 hr of DEHP exposure. This compensatory response, 
however, is not enough to prevent the DEHP-induced inhibition of growth following 72 hr, and 
this compensation is completely ablated by 96 hr of exposure because follicle growth is further 
inhibited and the mRNA levels of Ccnd2 and Cdk4 are decreased in response to DEHP treatment 
[54]. This compensation, nevertheless, may explain why we do not observe complete antral 
follicle growth inhibition, but rather the growth of the DEHP treated follicles is inhibited by 
roughly 15% of control treated follicles [55]. Interestingly, the 1µg/ml dose of DEHP is the only 
dose that does not inhibit antral follicle growth following 72 hr. This is likely because the 1µg/ml 
dose is the only dose to have compensatory increases in cyclins at the earliest time-point tested, 
while both the 10 and 100µg/ml doses show no signs of compensation at 24 hr of exposure.      
For an antral follicle to function properly, it must remain viable by escaping atresia [18]. 
Atresia is a natural process by which follicles undergo demise via apoptosis [22]. Following 96 
hr of treatment, DEHP exposure at the 10 and 100µg/ml doses directly increased the number of 
apoptotic bodies found in the antral follicles leading to an increase in the atresia rating. This 
increase in atresia dramatically affects the health of the antral follicle and possibly can have 
lasting impacts on reproductive and non-reproductive health. This expands upon previous 
studies, where exposure to DEHP and its metabolite MEHP induced apoptosis in ovarian cells in 
vivo [82, 83] and in vitro [84-86].  
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Follicular atresia is primarily regulated by the balance of pro-apoptotic factors (such as 
Bad, Bax, and Bok) and anti-apoptotic factors (such as Bcl2 and Bcl2l10) [23-26, 69]. Our 
findings that DEHP exposure may affect the expression of pro-apoptotic and anti-apoptotic 
factors expand upon previous studies that suggest DEHP causes oxidative stress in antral 
follicles following 24 hr of exposure [55]. Further, oxidative stress has been shown to be a 
regulator of atresia [87-92]. Therefore, it appears that DEHP exposure initially induces oxidative 
stress and increases pro-apoptotic factors or congruently induces oxidative stress and increases 
pro- and anti-apoptotic factors following 24 hr of exposure. Following 48 hr of exposure, the two 
anti-apoptotic factors tested are elevated to combat the initial increase in pro-apoptotic factors, 
and this occurs in the general absence of an increase in pro-apoptotic factors. However, pro-
apoptotic factors again became elevated following 72 hr of exposure. It appears that the 
compensatory increases in Bcl2 and Bcl2l10 occur after the onset of oxidative stress and 
increases in pro-apoptotic factors, and this compensation is not enough to alleviate the atresia 
observed at the 10 and 100µg/ml doses following 96 hr of exposure. However, increases in 
BCL2 can potentially have pro-apoptotic implications. When BCL2 is cleaved by caspases, 
studies have reported that BCL2 may acquire pro-apoptotic properties [93]. In support of this 
hypothesis, both Casp8 and Casp3 are increased following DEHP treatment in the present study. 
Thus, even though DEHP increases anti-apoptotic factors, it is possible that these factors have 
pro-apoptotic activities, and DEHP increased downstream apoptotic caspases further suggesting 
an increase in apoptosis. Interestingly, atresia is not observed at the 1µg/ml dose, and this is 
likely attributed to the decrease in the Bax/Bcl2 ratio following 48 hr of exposure and the 
absence of DEHP-induced oxidative stress in the previously mentioned study at the 1µg/ml dose 
[55].  
Proper regulation of antral follicle steroidogenesis is essential for reproductive and non-
reproductive health because defects in hormone production, even upstream of estradiol, can lead 
to anovulation, infertility, premature ovarian failure, cardiovascular disease, osteoporosis, mood 
disorders, and even premature death [29-46]. We have previously reported that DEHP exposure 
directly decreased estradiol levels in the antral follicle culture system following 96 hr at the 10 
and 100µg/ml doses, but few studies have investigated the effects of DEHP upstream of 
estradiol. [54]. Expanding upon previous findings and to understand the mechanism by which 
DEHP disrupts steroidogenesis, we established the time-course effects of DEHP on the levels of 
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antral follicle-produced sex steroid hormones. Prior to the observed decrease in estradiol levels, 
DEHP exposure decreased the levels of several precursor steroid hormones. The earliest time-
point of the inhibition of steroidogenesis occurs following 48 hr of exposure, where DEHP 
decreased the levels of progesterone, androstenedione, and testosterone at all selected doses 
tested. This decrease persists following 72 hr, where DEHP exposure decreased the levels of 
progesterone, DHEA, androstenedione, testosterone, and even estradiol. Similarly, DEHP 
exposure following 96 hr decreased the levels androstenedione, testosterone, and estradiol. 
Estradiol production requires the presence of these upstream steroid hormones to be converted to 
downstream hormones and ultimately estradiol [18, 72, 73]. Thus, it is likely the lack of 
precursor hormones following 48 hr of exposure that leads to the decrease in estradiol levels 
following 72 hr and ultimately 96 hr of exposure.  
Estradiol biosynthesis involves the strict coordination of the steroidogenic enzymes 
present in the theca and granulosa cells that convert the precursor sex steroid hormones to 
estradiol [72, 73]. We have previously reported that DEHP exposure directly decreased the antral 
follicle mRNA levels of Cyp19a1, which is the downstream enzyme that converts androgens to 
estrogens [54]. However, few studies have investigated the effects of DEHP upstream of 
Cyp19a1. Thus, we established the time-course effects of DEHP on the mRNA levels of each 
steroidogenic enzyme responsible for generating estradiol. The initial effects of DEHP exposure 
on the mRNA levels of the steroidogenesis occurred following 48 hr of exposure. DEHP 
exposure increased the mRNA levels of Hsd3b1 (which converts pregnenolone to progesterone 
and DHEA to androstenedione) at the 100µg/ml dose and Cyp19a1 at the 1µg/ml dose. 
Interestingly, DEHP increased the mRNA levels of Hsd17b1 (which converts androstenedione to 
testosterone and estrone to estradiol) following 72 hr of exposure at the 10µg/ml dose. Also 
following 72 hr of exposure, DEHP decreased the mRNA levels of Cyp11a1 (which converts 
cholesterol to pregnenolone). Following 96 hr of exposure, DEHP decreased the mRNA levels of 
Cyp17a1 (which converts pregnenolone to DHEA and progesterone to androstenedione), 
Hsd17b1, and Cyp19a1 at the 100µg/ml dose. 
 Initially, it appears that selected steroidogenic enzymes increase transcription to 
compensate for the decrease in steroid hormones following 48 hr of exposure. This 
compensation, however, is not adequate to restore the levels of androstenedione, testosterone, 
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and estradiol to control levels. Although there is not a difference in the levels of progesterone 
following 96 hr, it is not because the toxicity of DEHP on progesterone production is alleviated. 
In fact, progesterone levels remain constant throughout culture, and it is the vehicle control 
group that decreases production of progesterone from 72 to 96 hr of exposure. A similar 
phenomenon occurs with DHEA and androstenedione, where the levels of the hormones in the 
vehicle control group decrease from 72 to 96 hr of exposure. At this time-point in culture, it is 
likely that the antral follicles are shifting production of these precursor hormones to favor the 
production of the downstream hormones, testosterone, estrone, and estradiol. This effect was also 
seen in previous studies that investigated the time-course effects of bisphenol A on mouse antral 
follicles in vitro [94, 95]. Following 96 hr of exposure, the compensatory increase in the 
steroidogenic enzymes is lost at the 100µg/ml dose because of a decrease in the rate limiting 
enzymes, Cyp17a1, Hsd17b1, and Cyp19a1. However, this does not explain the decrease in 
estradiol levels at the 10µg/ml dose. It is most likely that the absence of precursor hormones 
leads to the decrease in estradiol following 96 hr of exposure at the 10µg/ml dose, whereas it is 
both the absence of precursor hormones and decrease in steroidogenic enzyme levels that lead to 
the decrease in estradiol levels following 96 hr of exposure at the 100µg/ml dose. Further, in the 
general absence of decreased steroidogenic enzyme expression, it is possible that ongoing 
apoptosis in the granulosa cells contributes to a loss of steroidogenically active cells, potentially 
leading to a decrease in precursor hormone levels. Conversely, even though the levels of 
precursor hormones are decreased at the 1µg/ml dose, the moderate increases in the mRNA 
levels of Hsd17b1 and Cyp19a1 following 48 and 72 hr of exposure at the 1µg/ml dose appear to 
be adequate in restoring estradiol levels to control levels following 96 hr of exposure.  
In conclusion, we have utilized the novel antral follicle culture system to establish the 
direct and temporal effects of DEHP on antral follicle growth, atresia, and steroidogenesis. 
Collectively, our results indicate that DEHP inhibits follicle growth potentially via dysregulation 
of the cell cycle, induces atresia potentially via dysregulation of apoptosis, and inhibits 
steroidogenesis potentially via the lack of upstream sex steroid hormones and disruption of the 
steroidogenic enzymes. These effects of DEHP are of concern because they can negatively 
impact ovulation, initiation and maintenance of pregnancy, estrous cyclicity, maintenance of the 
reproductive tract, and non-reproductive health [29-46]. Although the processes of growth, 
atresia and steroidogenesis are linked in certain aspects, the mechanism of the temporal 
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relationship of the three aspects of follicular function has yet to be elucidated [18, 73]. Further, 
studies should be done to explore the reasons for the non-monotonic dose responses observed for 
some endpoints in response to DEHP.  
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4.6 Tables, Figures, and Legends  
Table 4.1 Sequences of primer sets used for gene expression analysis 
 
Specific primer sequences used for qPCR analysis of gene expression.  
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Figure 4.1 Effect of DEHP on the antral follicle mRNA expression of key regulators of the 
cell cycle 
 
 
 
 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 24-72 hr. Following each 24 hr time-point, antral follicles were pooled 
per treatment group and were subjected to qPCR for the measurements of Ccnd2 (panel A), Cdk4 
(panel B), Ccne1 (panel C), Ccna2 (panel D), Ccnb1 (panel E), and Cdkn1a (panel F). All values 
were normalized to Actb. Graph represents means ± SEM from 3-9 separate experiments, with 
10-16 follicles/treatment group in each experiment. Asterisks (*) represent significant difference 
from vehicle control (p ≤ 0.05).  
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Figure 4.2 Effect of DEHP on antral follicle atresia  
 
 
 
 
 
 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 96 hr. Following 96 hr, antral follicles were processed for histological 
evaluation of atresia. A representative image of a DMSO treated follicle is found in panel A. A 
representative image of a DEHP 100 µg/ml treated follicle is found in panel B. Atresia ratings 
were assigned based on the presence of apoptotic bodies. A rating of 1 indicated a healthy 
follicle without apoptotic bodies, a rating of 2 indicated the presence of apoptotic bodies 
encompassing 1-10% of the follicle section, a rating of 3 indicated the presence of apoptotic 
bodies encompassing 11-30% of the follicle section, and a rating of 4 indicated the presence of 
apoptotic bodies encompassing >30% of the follicle section. Graph represents means ± SEM 
from 3 separate experiments, with 10-16 follicles/treatment group in each experiment. Asterisks 
(*) represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 4.3 Effect of DEHP on the antral follicle mRNA expression of key regulators of 
apoptosis 
 
 
 
 
 
 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 24-72 hr. Following each 24 hr time-point, antral follicles were pooled 
per treatment group and were subjected to qPCR for the measurements of Bad (panel A), Bax 
(panel B), Bok (panel C), Bcl2 (panel D), Bcl2l10 (panel E). All values were normalized to Actb. 
Further, ratios of Bax values/Bcl2 values were calculated (panel F). Graph represents means ± 
SEM from 3-9 separate experiments, with 10-16 follicles/treatment group in each experiment. 
Asterisks (*) represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 4.4 Effect of DEHP on the antral follicle mRNA expression of downstream apoptosis 
factors 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 24-72 hr. Following each 24 hr time-point, antral follicles were pooled 
per treatment group and were subjected to qPCR for the measurements of Casp8 (panel A) and 
Casp3 (panel B). All values were normalized to Actb. Graph represents means ± SEM from 3-9 
separate experiments, with 10-16 follicles/treatment group in each experiment. Asterisks (*) 
represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 4.5 Effect of DEHP on antral follicle-produced sex steroid hormone levels 
 
 
 
 
 
 
 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 24-96 hr. Following each 24 hr time-point, media were pooled per 
treatment group and were subjected to ELISAs for the measurements of progesterone (panel A), 
dehydroepiandrosterone (panel B), androstenedione (panel C), testosterone (panel D), estrone 
(panel E), and estradiol (panel F). Graph represents means ± SEM from 3-9 separate 
experiments, with medium from 10-16 wells/treatment group in each experiment. Hormones 
with ND (not detectable) at certain time-points had levels of that hormone below threshold 
detection. Asterisks (*) represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 4.6 Effect of DEHP on the antral follicle mRNA expression of key steroidogenic 
enzymes 
 
 
 
 
 
 
 
 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
DEHP (1-100µg/ml) for 24-96 hr. Following each 24 hr time-point, antral follicles were pooled 
per treatment group and were subjected to qPCR for the measurements of Star (panel A), 
Cyp11a1 (panel B), Hsd3b1 (panel C), Cyp17a1 (panel D), Hsd17b1 (panel E), and Cyp19a1 
(panel F). All values were normalized to Actb. Graph represents means ± SEM from 3-9 separate 
experiments, with 10-16 follicles/treatment group in each experiment. Asterisks (*) represent 
significant difference from vehicle control (p ≤ 0.05).  
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CHAPTER V 
Mono(2-ethylhexyl) Phthalate Accelerates Early Folliculogenesis and Inhibits 
Steroidogenesis in Cultured Mouse Whole Ovaries and Antral Follicles 
5.1 Abstract 
Humans are ubiquitously exposed to di(2-ethylhexyl) phthalate (DEHP), which is an 
environmental toxicant present in common consumer products. DEHP potentially targets the 
ovary through its metabolite mono(2-ethylhexyl) phthalate (MEHP). However, the direct effects 
of MEHP on ovarian folliculogenesis and steroidogenesis, two processes essential for 
reproductive and non-reproductive health, are unknown. The present study tested the hypotheses 
that MEHP directly accelerates early folliculogenesis via over-activation of phosphatidylinositol 
3-kinase (PI3K) signaling, a pathway that regulates primordial follicle quiescence and activation, 
and inhibits the synthesis of steroid hormones by decreasing steroidogenic enzyme levels. 
Neonatal ovaries from CD-1 mice were cultured for six days with vehicle control, DEHP, or 
MEHP (0.2-20μg/ml) to assess the direct effects on folliculogenesis and PI3K signaling. Further, 
antral follicles from adult CD-1 mice were cultured with vehicle control or MEHP (0.1-10μg/ml) 
for 24-96hr to establish the temporal effects of MEHP on steroid hormones and steroidogenic 
enzymes. In the neonatal ovaries, MEHP, but not DEHP, decreased phosphatase and tensin 
homolog levels and increased phosphorylated protein kinase B levels, leading to a decrease in 
the percentage of germ cells and an increase in the percentage of primary follicles. In the antral 
follicles, MEHP decreased the mRNA levels of 17α-hydroxylase-17,20-desmolase, 17β-
hydroxysteroid dehydrogenase, and aromatase leading to a decrease in testosterone, estrone, and 
estradiol levels. Collectively, MEHP mediates the effect of DEHP on accelerated 
folliculogenesis via over-activating PI3K signaling and inhibits steroidogenesis by decreasing 
steroidogenic enzyme levels.  
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5.2 Introduction  
Di(2-ethylhexyl) phthalate (DEHP) is a widely used synthetic plasticizer incorporated in 
the manufacturing of common polyvinyl chloride consumer, medical, and building products in 
order to impart flexibility [1, 2]. DEHP is produced in vast quantities, up to 300 million pounds 
annually, to account for its high demand in products ranging from carpeting and roofing to food 
and beverage packaging [2]. This is of concern because DEHP is non-covalently bound to the 
plastic, meaning DEHP frequently leaches from the plastics into the environment and products 
that humans consume [1]. Based on its high production volumes, use in common items, and 
ability to leach out from the items, humans are exposed to DEHP on a daily basis via oral 
ingestion, inhalation, and dermal contact [1]. Specifically, the estimated range of daily human 
exposure to DEHP is 3-30 μg/kg/day [3, 4]. Exposure to DEHP represents a public health 
concern because DEHP and its metabolite, mono(2-ethylhexyl) phthalate (MEHP), have been 
identified as top contaminants in human tissues such as blood [5, 6], urine [1, 5-9], amniotic fluid 
[10-12], umbilical cord blood [13, 14], breast milk [6], and ovarian follicular fluid [15]. 
Important from a toxicological standpoint, it is hypothesized that the toxicity of DEHP is 
mediated by the bioactive metabolite MEHP in many organ systems, including the ovary [16-
21].  
Also important for public health, DEHP and MEHP are known endocrine disrupting 
chemicals and reproductive toxicants that potentially target the ovary [1, 2, 16-21]. 
Understanding the effects of these chemicals on normal ovarian function is crucial because the 
ovary is responsible for the maturation of follicles for ovulation, a process termed 
folliculogenesis, and for the synthesis of sex steroid hormones, a process termed steroidogenesis 
[22]. Defects in folliculogenesis and steroidogenesis, including accelerated depletion of follicles 
within the ovary and decreased estradiol production, can cause reproductive and non-
reproductive complications, such as infertility, premature ovarian failure, cardiovascular disease, 
osteoporosis, mood disorders, and even premature death [23-34].  
Interestingly, DEHP and MEHP have been shown to disrupt ovarian folliculogenesis. 
Specifically, we have previously reported that oral exposure to DEHP in adult mice accelerates 
primordial follicle recruitment following 10 and 30 days of dosing [35]. Primordial follicle 
recruitment is a gonadotropin-independent process involving strict regulation of intrinsic ovarian 
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growth factors [36-39]. Factors within the phosphatidylinositol 3-kinase (PI3K) signaling 
pathway have recently been implemented as regulators of primordial follicle survival, dormancy, 
and recruitment, where inhibition of PI3K signaling maintains primordial follicle dormancy and 
over-activation of signaling leads to primordial follicle recruitment [38, 40-45]. We have also 
previously reported that the DEHP-induced acceleration of primordial follicle recruitment is 
likely via over-activation of PI3K signaling, indicated by a decrease in ovarian phosphatase and 
tensin homolog (PTEN) levels, an inhibitor of PI3K signaling that maintains primordial follicle 
dormancy, and an increase in ovarian phosphorylated protein kinase B (pAKT) levels, a 
stimulator of PI3K signaling that promotes primordial follicle recruitment [35]. However, the 
limitation of that study is that we did not determine whether the effects on primordial follicle 
recruitment and PI3K signaling were direct effects on the ovary, or the effects were a secondary 
response caused by toxicity in other organ systems following exposure in vivo.  
Additionally, DEHP and MEHP have been shown to disrupt ovarian steroidogenesis. 
Specifically, DEHP exposure has been shown to decrease estradiol levels and aromatase levels in 
vivo [46-48] and in vitro [16, 49, 50]. We have reported that the inhibition of steroidogenesis 
may be via a direct effect on antral follicle functionality, because DEHP exposure in cultured 
mouse antral follicles directly decreased the availability of precursor sex steroid hormone levels 
at time-points prior to decreasing estradiol levels [51]. This toxicity of DEHP may be mediated 
by MEHP, and MEHP exposure has also been shown to inhibit steroidogenesis in vitro [19-21, 
52, 53]. Specifically, we have reported that MEHP exposure directly decreased the levels of 
estradiol and the mRNA levels of aromatase, Cyp19a1, in cultured mouse antral follicles 
following 96 hr of exposure [16]. Steroidogenesis is primarily conducted by the mature antral 
follicle and is a step-wise process involving the enzymatic conversion of cholesterol to estradiol 
and other necessary precursor steroid hormones that are essential for reproductive and non-
reproductive health [54, 55]. However, few studies have investigated the effects of MEHP on the 
precursor steroid hormones and the steroidogenic enzymes upstream of estradiol and aromatase. 
Additionally, the temporal effects by which MEHP directly inhibits steroidogenesis in the antral 
follicle remain unknown.   
The present study was designed to investigate the direct effects of DEHP and MEHP on 
early folliculogenesis and to compare the mechanisms by which these chemicals alter 
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folliculogenesis in vivo and in vitro. Further, the present study was designed to establish a time-
course of the initial and time specific effects of MEHP on antral follicle steroidogenesis 
upstream of estradiol and aromatase and to compare the mechanisms by which MEHP and 
DEHP inhibit steroidogenesis in cultured antral follicles. Specifically, we tested the hypotheses 
that MEHP mediates the DEHP-induced acceleration of primordial follicle recruitment, and 
MEHP does so via a mechanism involving over-activation of PI3K signaling, which is the 
mechanism observed in vivo. Additionally, we hypothesized that MEHP directly inhibits the 
synthesis of sex steroid hormones to ultimately lead to a decrease in estradiol levels.  
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5.3 Materials and Methods  
Chemicals 
DEHP (99% purity) was purchased from Sigma-Aldrich (St. Louis, MO), and MEHP (99% 
purity) was purchased from AccuStandard (New Haven, CT). Stock solutions of DEHP and 
MEHP were prepared using dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) as the 
vehicle in various concentrations (0.133, 0.267, 1.33, 2.67, 13.3, and 26.7 mg/ml). This allowed 
for an equal volume of each stock to be added to the culture wells to control for vehicle 
concentration. Final concentrations of DEHP in culture were 0.2, 2, and 20 μg/ml which is 
approximately equivalent to 0.54, 5.4, and 54 μM respectively. Final concentrations of MEHP in 
culture were 0.1, 0.2, 1, 2, 10, and 20 μg/ml, which is approximately equivalent to 0.34, 0.68, 
3.4, 6.8, 34, and 68 μM respectively.   
The concentrations of DEHP and MEHP were chosen based their ability to disrupt 
ovarian steroidogenesis and folliculogenesis. Specifically, concentrations of these chemicals 
cause inhibition of antral follicle growth, decreased estradiol production from antral follicles, 
decreased antral follicle Cyp19a1 expression, and increased antral follicle atresia [16, 17, 56]. 
We have also previously determined that oral exposure to DEHP for 10 and 30 days accelerates 
primordial follicle recruitment at doses ranging from 200 μg/kg/day-20 mg/kg/day [35]. These 
doses are approximately equivalent to 0.492-49.2 μM, which encompasses the doses ranging 
from 0.2-20 μg/ml. The concentrations of DEHP and MEHP selected in these experiments have 
also been determined to be clinically relevant [20, 52, 57-59]. Importantly, plasma 
concentrations of DEHP and MEHP in healthy women have been reported to be 0.18 μg/ml and 
0.58 μg/ml respectively, and peritoneal fluid concentrations of DEHP and MEHP in these 
women were reported to be 0.46 μg/ml and 0.37 μg/ml respectively, which encompasses the 
lower selected concentrations [60]. In addition, the extensive use of DEHP in medical equipment 
leads to markedly higher levels of DEHP and MEHP in patients undergoing consistent medical 
care when compared to healthy people [61, 62]. Neonatal patients in intensive care units that 
receive blood transfusions have plasma levels of DEHP and MEHP at 11.1 μg/ml and 15.1 μg/ml 
respectively, which encompasses the higher selected concentrations [63]. Further, the lowest-
observed-adverse-effect level (LOAEL) of DEHP is 140 mg/kg/day which is approximately 
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equivalent to 344.6 μM [2]. The selected concentrations of DEHP and MEHP in these 
experiments fall below the LOAEL concentration.  
Animals  
For the experiments investigating the direct effects of DEHP and MEHP on early 
folliculogenesis, cycling, adult CD-1 female mice (40-50 days of age) and mature, adult CD-1 
male mice (40-50 days of age) were obtained from Charles River Laboratories (Wilmington, 
MA). Breeding groups (one male with two females) were housed in the College of Veterinary 
Medicine Animal Facility at the University of Illinois at Urbana-Champaign to serve as a source 
for post-natal day (PND) 4 ovaries for culture. Once pregnant, the mice were individually placed 
in separate cages and allowed to give birth. On PND4, female pups were removed from the dam 
and used in the neonatal ovary cultures described below. For the experiments investigating the 
effects of MEHP on antral follicles, cycling, adult CD-1 female mice (35-39 days of age) were 
obtained from Charles River Laboratories (Wilmington, MA). The mice were housed in groups 
of four in the College of Veterinary Medicine Animal Facility at the University of Illinois at 
Urbana-Champaign and were allowed to acclimate to the facility prior to experimentation. All 
animals in these experiments were housed in a controlled animal room environment (temperature 
at 22 ± 1 °C and 12-hour light–dark cycles) and were provided food and water ad libitum. The 
Institutional Animal Use and Care Committee at the University of Illinois at Urbana-Champaign 
approved all procedures involving animal care, euthanasia, and tissue collection. 
In vitro neonatal ovary cultures  
Whole ovaries were aseptically collected from CD-1 pups on PND4 and were used for 
ovarian culture as described previously [64, 65]. Briefly, each ovary was removed on PND4 and 
cleaned of excess fat, oviductal, and interstitial tissue under a light microscope. The ovaries were 
placed in media droplets on a piece of Millicell culture plate inserts (Millipore, Billercia, MA) 
that was floating on 500 μl of equilibrated (37°C) supplemented ovary culture media in a four-
well culture plate. The treatment groups for the neonatal ovary culture experiments included 
vehicle control (DMSO), DEHP (0.2, 2, and 20 μg/ml), and MEHP (0.2, 2, and 20 μg/ml). The 
supplemented media contained DMEM/Ham F12 minus phenol red medium (Life Technologies, 
Grand Island, NY) with 1 mg/ml BSA (Sigma-Aldrich, St. Louis, MO), 1 mg/ml Albumax (Life 
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Technologies, Grand Island, NY), 50 μg/ml ascorbic acid (Sigma-Aldrich, St. Louis, MO), 5 
U/ml penicillin per 5 μg/ml streptomycin (Life Technologies, Grand Island, NY), and 27.5 μg/ml 
transferrin (Sigma-Aldrich, St. Louis, MO) per well. Each ovary was cultured for 6 days until 
PND10 in an incubator at 37°C supplying 5% CO2. The media were replaced daily with fresh, 
treated supplemented media, and one drop of medium was placed on the ovary to prevent the 
ovary from drying. Following culture, one ovary was collected for histological evaluation of 
follicle numbers, and the other ovary was subjected to immunohistochemistry as described 
below.  
The neonatal ovary culture system and PND4-PND10 time-points were chosen because 
the neonatal ovary is enriched in primordial and primary follicles that are naturally undergoing 
the initial stages of folliculogenesis [66]. Since DEHP exposure (approximately equivalent to 
0.492-49.2 μM or 0.2-20 μg/ml) for 10 and 30 days accelerates primordial follicle recruitment in 
vivo [35], this culture system provides a direct tool to assess the effects of DEHP and MEHP on 
early folliculogenesis. Specifically, At PND4, the neonatal ovary is completing germ cell nest 
breakdown; therefore, the ovary contains a population of follicles that are primarily in the 
primordial stage. At PND10, some primordial follicles naturally begin to undergo recruitment to 
the primary stage of development both in vivo and in vitro, and these follicles are structurally and 
functionally identical to those in the adult [22, 66].  
Histological evaluation of follicle numbers 
Following 6 days of culture, some PND10 neonatal ovaries were fixed in Dietrich’s 
fixative for at least 24 hrs for histological evaluation of follicle numbers (n=4-6 ovaries/group). 
The ovaries were then transferred to 70% ethanol, embedded in paraffin wax, and serial 
sectioned (5 µM) using a microtome. The serial sections were mounted on a glass slide and 
stained with hematoxylin and eosin. The numbers of oocyte containing follicles and germ cells 
were counted in every fifth serial section using a light microscope, and the percentage of each 
follicle type was calculated by dividing the number of follicles of each specific type by the total 
number of follicles counted and multiplying that value by 100. Stage of follicular development 
was assessed using previously defined criteria [67, 68]. Briefly, germ cells were identified by the 
presence of a single oocyte or group of oocytes without a defined granulosa cell layer 
encapsulating them, primordial follicles contained the oocyte surrounded by a single layer of 
squamous granulosa cells, and primary follicles contained the oocyte surrounded by a single 
141 
layer of cuboidal granulosa cells. Very few preantral and antral follicles are present at PND10; 
therefore, these follicle types were not included in the analysis. All germ cells, primordial and 
primary follicles with oocytes, regardless of nuclear material in the oocytes, were counted. 
Immunohistochemistry  
Following 6 days of culture, some PND10 neonatal ovaries were fixed in 4% 
paraformaldehyde overnight and transferred to 70% ethanol for immunohistochemical analysis 
for PTEN and pAKT (Ser473) (the active form of the protein) as described previously 
(n=3/group) [35]. Briefly, the ovaries were embedded in paraffin wax, serial sectioned (5 µM), 
and three representative sections that span the entire length of the ovary were mounted on a glass 
slide. Some tissue sections were subjected to staining for PTEN (1:200) (Cell Signaling 
Technology, Inc., Boston, MA), while other tissue sections were subjected to staining for pAKT 
(1:50) (Cell Signaling Technology, Inc., Boston, MA). The tissues were then incubated with a 
secondary biotinylated goat anti-rabbit antibody (Vector Laboratories, Inc., Burlingame, CA), 
followed by an incubation with an avidin biotin complex solution (Vector Laboratories, Inc., 
Burlingame, CA). ImmPACT NovaRED peroxidase substrate solution (Vector Laboratories, 
Inc., Burlingame, CA) was then applied until color optimally developed. Each sample was 
exposed to the chromogen for equal amounts of time. The slides were then rinsed, counter-
stained with a 1:10 dilution of hematoxylin, and coverslipped. A negative control was used in 
each experiment and was subjected to the same methods listed above, except instead of primary 
antibody, the negative control tissues were incubated with a negative control rabbit 
immunoglobulin fraction (Dako, Carpinteria, CA) at the same concentration of each primary 
antibody. Negative controls were confirmed to have no positive staining after exposure to the 
chromogen for equal amounts of time as the samples. Both PTEN and pAKT were chosen 
because they are integral regulators of PI3K signaling and have been associated with the 
regulation of primordial follicle recruitment [38, 43, 69-71]. Specifically, PTEN inhibits PI3K 
signaling and ultimately maintains primordial follicle dormancy [38, 43, 69-71]. Additionally, 
pAKT drives PI3K signaling and ultimately promotes primordial follicle recruitment [38, 43, 69-
71]. Further, 10 day oral exposure to DEHP decreases ovarian PTEN and increases ovarian 
pAKT potentially driving the acceleration of primordial follicle recruitment that was observed in 
that study [35].  
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Analysis of the levels of protein staining  
Following immunohistochemistry, the levels of PTEN and pAKT staining in the neonatal 
ovaries were quantified using published methods [35, 72-74]. Briefly, images of ovaries were 
digitally captured using a Leica DFC 290 camera and analyzed using the ImageJ software 
(http://rsb.info.nih.gov/nih-image/). For analysis, three representative sections from each ovary 
were assessed from three separate animals per treatment group. Digital images were converted to 
8-bit grayscale images and then converted to pseudocolored images. Colors were based on 
relative stain intensity, as defined digitally. Areas with no staining appeared black and blue, 
while areas with the most intense staining appeared deep yellow to orange. Percentages of 
positively stained PTEN and pAKT pixels in the whole ovary and percentages of positively 
stained PTEN and pAKT primordial follicle oocytes were compared across treatment groups. For 
whole ovarian analysis, the pixels of positively stained PTEN and pAKT areas were divided by 
the total amount of pixels in the whole ovary, and that value was multiplied by 100. For 
primordial follicle oocyte analysis, positively stained PTEN and pAKT primordial follicle 
oocytes were quantified, divided by the total amount of primordial follicle oocytes, and that 
value was multiplied by 100.  
In vitro antral follicle cultures 
Unprimed, female CD-1 mice were euthanized and their ovaries were aseptically 
removed for antral follicle isolation. Antral follicles (250-400 μm) were isolated from the ovary 
and were cleaned of interstitial tissue using watchmaker’s forceps [75, 76]. At least 2-3 mice 
were used in each experiment, in which approximately 20-30 antral follicles per mouse were 
obtained. Each treatment group contained 8-16 follicles. Isolated antral follicles were randomly 
and individually plated in wells of a 96-well culture plate containing unsupplemented α-minimal 
essential medium (α-MEM, Life Technologies, Grand Island, NY) prior to treatment.  
The treatment groups for the follicle culture experiments included vehicle control 
(DMSO) and MEHP (0.1, 1, and 10 μg/ml), and they were prepared in supplemented α-MEM. 
Supplemented α-MEM was prepared as described previously [75, 76]. Briefly, supplemented α-
MEM contained 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 ng/ml selenium, Sigma-
Aldrich, St. Louis, MO), 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO), 100 mg/ml 
streptomycin (Sigma-Aldrich, St. Louis, MO), 5 IU/ml human recombinant follicle-stimulating 
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hormone (FSH; Dr. A. F. Parlow, National Hormone and Peptide Program, Harbor-UCLA 
Medical Center, Torrance, CA), and 5% fetal calf serum (Atlanta Biologicals, Lawrenceville, 
GA). An equal volume of chemical (0.75 µl/ml of media) was added for each dose to control that 
the amount of vehicle in each preparation was 0.075%. Each follicle was cultured in 150 μl of 
medium for 24–96 hr in an incubator at 37°C supplying 5% CO2. Following each 24 hr culture 
window, media from cultured follicles were collected for measurements of the levels of sex 
steroid hormones, and cultured follicles were collected, snap-frozen, and stored at −80°C for 
gene expression analysis. A time-course was conducted to observe when the effects of MEHP on 
steroidogenesis begin, to determine which hormone/enzyme is causing the reduction of estradiol 
production from antral follicles following 96 hr as reported previously [16].  
Analysis of sex steroid hormone levels 
Following each 24 hr antral follicle culture window, culture media were subjected to 
enzyme-linked immunosorbent assays (ELISAs) for the measurements of the levels of sex 
steroid hormones. Levels of progesterone, dehydroepiandrosterone (DHEA), androstenedione, 
testosterone, estrone, and 17β-estradiol were measured following the manufacturer’s protocol 
using ELISA kits purchased from Diagnostics Research Group (DRG, Mountainside, NJ) (n=8-
16 wells of pooled media containing follicles from 3-9 separate experiments). The analytical 
sensitivity of each kit was 0.044 μg/ml for DHEA, 0.1 ng/mL for progesterone, 0.019 ng/mL for 
androstenedione, 0.083 ng/mL for testosterone, 6.3 pg/mL for estrone, and 9.71 pg/mL for 
estradiol. All samples were run in duplicates and all intra- and inter-assay coefficients of 
variability were less than 10%. Some samples were diluted to match the dynamic range of each 
ELISA kit. Mean values for each sample were used in this analysis. 
Analysis of antral follicle gene expression  
 Following each 24 hr antral follicle culture window, antral follicles were snap frozen in 
liquid nitrogen, and stored at -80°C for quantitative real-time polymerase chain reaction (qPCR) 
analysis (n=8-16 follicles/3-9 separate experiments). Total RNA (200 ng) was extracted from the 
follicles using the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) according to the 
manufacturer’s protocol, and was then reverse transcribed to complementary DNA (cDNA) 
using the iScript RT kit (Bio-Rad Laboratories, Inc., Hercules, CA) according to the 
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manufacturer’s protocol. Prior to qPCR analysis, each cDNA sample was diluted 1:4 using 
nuclease-free water. The CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., 
Hercules, CA) and accompanying CFX Manager Software was used for analysis of qPCR 
according to the manufacturer’s protocol. All qPCR reactions were done in triplicate using 1 μl 
cDNA, forward and reverse primers (5 pmol), and a SsoFastEvaGreen Supermix for a final 
reaction volume of 10 μl. Specific qPCR primers (Integrated DNA Technologies, Inc., 
Coralville, IA) for the genes of interest as well as the reference gene, beta-actin (Actb), can be 
found in Table 5.1. Beta-actin was chosen as the reference gene because its expression did not 
differ across treatment groups. The genes tested were steroidogenic acute regulatory protein 
(Star), cytochrome P450 cholesterol side-chain cleavage (Cyp11a1), 3β-hydroxysteroid 
dehydrogenase (Hsd3b1), 17α-hydroxylase-17,20-desmolase (Cyp17a1), 17β-hydroxysteroid 
dehydrogenase (Hsd17b1), and aromatase (Cyp19a1). These genes were chosen because they 
synthesize estradiol and its precursor sex steroid hormones in the ovary.  
The CFX96 machine quantifies the amount of PCR product generated by measuring 
SsoFastEvaGreen dye (Bio-Rad Laboratories, Inc., Hercules, CA) that fluoresces when bound to 
double-stranded DNA. The qPCR program consisted of an enzyme activation step (95°C for 1 
min), an amplification and quantification program (40 cycles of 95°C for 10 sec, 60°C for 10 sec, 
single fluorescence reading), a step of 72°C for 5 min, a melt curve (65°C−95°C heating 0.5°C 
per sec with continuous fluorescence readings), and a final step at 72°C for 5 min as per the 
manufacturer’s protocol. Expression data were generated using the mathematical standard 
comparative (ΔΔCt) method. The ΔCt was calculated by subtracting the Actb Ct value from the 
gene of interest Ct value. The ΔΔCt was calculated as the difference between the ΔCt between 
the treatment groups and the DMSO groups. The relative fold-change of expression was then 
equaled to 2(-ΔΔCt) for each sample.  
Statistical analysis 
Analysis of data was conducted using SPSS statistical software (SPSS, Inc., Chicago, IL). 
Data were expressed as means and error bars represent the standard error of the means (SEM). 
Multiple comparisons between normally distributed experimental groups were made using one-
way analysis of variance (ANOVA) followed by Tukey post-hoc comparison. Multiple 
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comparisons between non-normally distributed experimental groups were made using Kruskal 
Wallis tests when appropriate. Statistical significance was assigned at p ≤ 0.05. 
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5.4 Results 
Effect of DEHP and MEHP on early folliculogenesis 
Proper regulation of ovarian folliculogenesis is essential for fertility and the maintenance 
of appropriately timed reproductive senescence. Previously, we have shown that daily oral 
exposure to DEHP for 10 and 30 days disrupts folliculogenesis by accelerating primordial 
follicle recruitment to the primary stage of development [35]. However, that study utilized an in 
vivo dosing regimen and was unable to test if the effects on primordial follicle recruitment were 
due to direct ovarian toxicity caused by DEHP or the bioactive metabolite MEHP. Therefore, the 
direct effects of DEHP and MEHP on follicular dynamics were evaluated in this study. 
Following 6 days of culture, DEHP exposed ovaries had similar percentages of germ cells, 
primordial follicles, and primary follicles counted when compared to the vehicle control group 
(Fig. 5.1A, n=5-6/group). However, following 6 days of culture, MEHP exposure significantly 
decreased the percentage of germ cells counted at all selected doses when compared to the 
vehicle control group (Fig. 5.1B, n=4-6/group, p ≤ 0.05). MEHP exposure did not significantly 
alter the percentage of primordial follicles counted, but it significantly increased the percentage 
of primary follicles counted at all selected doses when compared to the vehicle control group 
(Fig. 5.1B, n=4-6/group, p ≤ 0.05).  
Effect of DEHP and MEHP on protein levels of PI3K signaling factors 
We have previously shown that the DEHP-induced acceleration of primordial follicle 
recruitment following 10 and 30 days of exposure may involve over-activation of the PI3K 
signaling pathway [35], but it was unknown if the DEHP-induced dysregulation of PI3K 
signaling was due to a direct ovotoxic effect of DEHP and/or MEHP. Thus, this study tested 
whether DEHP or MEHP directly alter the levels of PTEN and/or pAKT in the neonatal ovaries. 
Qualitatively, it appears that MEHP exposure decreased the staining of PTEN in the whole 
neonatal ovary (Fig. 5.2, A-D), decreased the percentage of PTEN positive oocytes (Fig. 5.2, E 
and F), and increased the percentage of pAKT positive oocytes (Fig. 5.2, G and H). When 
quantified, MEHP significantly decreased the levels of PTEN staining in the whole neonatal 
ovary at the 2 and 20 µg/ml doses when compared to the vehicle control group, while all selected 
doses of DEHP had comparable levels of PTEN staining to the vehicle control group (Fig. 5.3A, 
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n=3/group, p ≤ 0.05). Conversely, both MEHP and DEHP had comparable levels of pAKT 
staining in the whole ovary when compared to the vehicle control group (Fig. 5.3A, n=3/group). 
To ensure that the levels of the PI3K proteins were altered in the follicles of interest, the 
percentages of positively stained PTEN and pAKT oocytes in primordial follicles were 
quantified. MEHP significantly decreased the percentage of PTEN and significantly increased 
the percentage of pAKT positive oocytes in primordial follicles at all selected doses of MEHP 
when compared to the vehicle control group (Fig. 5.3B, n=3/group, p ≤ 0.05). Meanwhile, DEHP 
had comparable percentages of PTEN and pAKT positive oocytes to the vehicle control group 
(Fig. 5.3B, n=3/group).  
Effect of MEHP on sex steroid hormone production by antral follicles 
 Previous studies have determined that DEHP exposure decreases estradiol levels in vivo 
[46-48] and in cultured ovarian cell types and follicles in vitro [16, 49-51]. Likewise, MEHP 
exposure has also been shown to decrease estradiol levels in cultured ovarian cell types and 
follicles in vitro [16, 19-21, 53]. However, the mechanism by which MEHP decreases estradiol 
levels is unknown. We have previously reported that MEHP exposure for 96 hr decreases 
estradiol levels produced by cultured mouse antral follicles [16]; but, the direct effects of MEHP 
on antral follicle steroidogenesis at earlier time-points of exposure and on the precursor steroid 
hormones upstream of estradiol are unknown. Thus, the temporal effects of MEHP on the levels 
of sex steroid hormones produced by the antral follicle were investigated by utilizing time-course 
culture experiments. Beginning with the most upstream precursor steroid hormones measured, 
MEHP exposure did not significantly alter the levels of progesterone or DHEA at any time-point 
tested when compared to the vehicle control group (Fig. 5.4, A and B, n=3-9/group). However, 
MEHP exposure significantly decreased the levels of androstenedione at the 10 µg/ml dose 
following 24 and 72 hr of exposure when compared to the vehicle control group (Fig. 5.4C, n=3-
9/group, p ≤ 0.05). Further, MEHP exposure significantly decreased the levels of testosterone at 
the 10 µg/ml dose following 24 hr of exposure when compared to the vehicle control group (Fig. 
5.4D, n=3/group, p ≤ 0.05). Likewise, MEHP exposure significantly decreased the levels of 
testosterone at all selected doses following 96 hr of exposure when compared to the vehicle 
control group (Fig. 5.4D, n=4-9/group, p ≤ 0.05). Further down the steroidogenesis pathway, 
MEHP exposure significantly decreased the levels of estrone at the 0.1 and 10 µg/ml doses  
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following 96 hr of exposure when compared to the vehicle control group (Fig. 5.4E, n=4-
9/group, p ≤ 0.05). Additionally, MEHP exposure significantly decreased the levels of estradiol 
at all selected doses following 96 hr of exposure when compared to the vehicle control group 
(Fig. 5.4F, n=4-9/group, p ≤ 0.05).  
Effect of MEHP on steroidogenic enzyme gene expression in antral follicles 
 Previous studies have hypothesized that one potential mechanism by which DEHP and 
MEHP decrease estradiol levels is through a decrease in the ovarian mRNA levels of Cyp19a1, 
also known as aromatase, following exposure in vivo [46, 77] and in vitro [16, 19-21, 51]. 
However, not much is known about the direct effects of MEHP on the steroidogenic enzyme 
levels upstream of Cyp19a1 in the antral follicle. Further, not much is known about the direct 
effects of MEHP on the enzyme levels prior to 96 hr of exposure. In addition, MEHP decreased 
the levels of sex steroid hormones upstream of estradiol across multiple time-points in the 
present study (Fig. 5.4). Thus, the temporal effects and potential mechanisms by which MEHP 
inhibits steroidogenesis were investigated. Following 48 hr of exposure, MEHP significantly 
decreased the mRNA levels of Star and Cyp11a1 at the 1 and 10 µg/ml doses when compared to 
the vehicle control group (Fig. 5.5, A and B, n=3-5/group, p ≤ 0.05). Following 24 hr of 
exposure, MEHP significantly decreased the mRNA levels of Hsd3b1 at the 10 µg/ml dose when 
compared to the vehicle control group (Fig. 5.5C, n=3/group, p ≤ 0.05). Following 96 hr of 
exposure, MEHP significantly decreased the mRNA levels of Cyp17a1 at all selected doses 
when compared to the vehicle control group (Fig. 5.5D, n=4-9/group, p ≤ 0.05). Following 72 hr 
of exposure, MEHP significantly increased the mRNA levels of Hsd17b1 at all selected doses 
when compared to the vehicle control group (Fig. 5.5E, n=4-9/group, p ≤ 0.05). However, 
following 96 hr of exposure, MEHP significantly decreased the mRNA levels of Hsd17b1 at all 
selected doses when compared to the vehicle control group (Fig. 5.5E, n=4-9/group, p ≤ 0.05). 
MEHP exposure significantly increased the mRNA levels of Cyp19a1 at the 0.1 and 1 µg/ml 
doses following 48 hr of exposure and at all selected doses following 72 hr of exposure when 
compared to the vehicle control group (Fig. 5.5F, n=3-9/group, p ≤ 0.05). However, following 96 
hr of exposure, MEHP significantly decreased the mRNA levels of Cyp19a1 at all selected doses 
when compared to the vehicle control group (Fig. 5.5F, n=4-9/group, p ≤ 0.05).  
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5.5 Discussion  
 We utilized a neonatal whole ovarian culture system and an antral follicle culture system 
to investigate the direct effects of DEHP and MEHP on early folliculogenesis and to investigate 
the direct and temporal effects of MEHP on steroidogenesis. Our main findings suggest that 
MEHP, but not DEHP, has a direct effect on over-activating PI3K signaling in the ovary to 
potentially lead to the acceleration of primordial follicle recruitment. Additionally, we have 
shown that MEHP directly inhibits the production of estradiol and upstream sex steroid 
hormones and alters the mRNA levels of Cyp19a1 and upstream estradiol biosynthesis enzymes. 
We have also established the initial and time specific effects of MEHP on antral follicle 
steroidogenesis. Importantly, we have determined that DEHP and MEHP have differential 
effects on the initial stages of folliculogenesis and on steroidogenesis.  
 The use of the whole neonatal ovarian culture system is essential for understanding the 
direct effects of chemicals on the earliest stages of folliculogenesis [64, 66]. Previous studies 
have shown that DEHP and MEHP accelerate primordial follicle recruitment in vivo [35, 78, 79]. 
The limitation of these studies is that they did not determine if these chemicals act directly on the 
ovary to elicit this response. A further study has shown that DEHP also affects early 
folliculogenesis in vitro, but that study only focused on germ cell nest breakdown and primordial 
follicle assembly [80]. Although these studies are influential in understanding the effects of 
DEHP and MEHP on early folliculogenesis, the effects of these chemicals on the activation of 
the dormant and already established primordial follicle pool remain unknown. Thus, we 
investigated the effects of DEHP and MEHP from PND4-PND10 on the neonatal ovary, a time-
span when the follicular reserve is nearly established and primordial follicles naturally begin to 
undergo activation to the primary stage of development [22, 66]. Importantly, at PND10, the 
neonatal ovary contains a population of follicles that are primarily in the primordial and primary 
stages of development. Thus, we were able to primarily focus on the populations of follicles in 
which we observed DEHP-induced effects in vivo [35]. 
 In the present study, MEHP, but not DEHP, directly decreased the percentage of germ 
cells counted and increased the percentage of primary follicles counted when compared to the 
vehicle control group. We have previously reported that oral exposure to DEHP for 10 and 30 
days in adult mice decreased the percentage of primordial follicles counted and increased the 
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percentage of primary follicles counted at doses similar to the 0.492-49.2 μM range (0.2-20 
µg/ml) used in this study [35]. Although we did not observe a change in primordial follicle 
numbers in the present study, we likely missed the time-point in which MEHP altered primordial 
follicle numbers. Our follicle count data represent a single “snap-shot” following 6 days of 
exposure; therefore, future studies should investigate the effects of MEHP on primordial follicle 
numbers prior to and after 6 days of exposure. However, our primary follicle count data correlate 
to those obtained in the in vivo studies [35]. Thus, these data suggest that MEHP has a direct 
effect on the ovary indicating that the observed effect in vivo is likely via a direct mechanism of 
action. 
 We have previously reported that the DEHP-induced acceleration of primordial follicle 
recruitment in vivo is likely via over-activation of the PI3K signaling pathway [35]. Primordial 
follicle recruitment is a tightly regulated process involving a balance between the factors that 
maintain primordial follicle quiescence and promote primordial follicle activation [36-39]. 
Interestingly, factors within the PI3K signaling pathway regulate primordial follicle survival, 
quiescence, and recruitment. Specifically, PTEN, an inhibitor of PI3K signaling, maintains 
primordial follicle quiescence, and pAKT, a stimulator of PI3K signaling, promotes development 
to the primary stage [38, 40-45]. Following 10 days of oral exposure to adult mice, DEHP at 
similar μM doses to those used in this study decreased the staining of PTEN in whole ovary and 
increased the staining of pAKT in the whole ovary and in the primordial and primary follicles 
[35]. Similarly, DEHP exposure decreased the mRNA levels of Pten in the whole adult ovary 
following 30 days of oral exposure [35]. In the present study, DEHP had no statistically 
significant effect on follicle numbers or PI3K signaling factors. However, MEHP exposure 
directly decreased PTEN staining in the whole ovary, decreased the percentage of PTEN positive 
primordial follicle oocytes, and increased the percentage of pAKT positive primordial follicle 
oocytes, again at doses that mimic those used in the in vivo studies. Thus, MEHP has a direct 
effect on over-activating ovarian PI3K signaling to promote an environment conducive for the 
acceleration of primordial follicle recruitment, and this mechanism is similar to the mechanism 
by which DEHP accelerates primordial follicle recruitment in vivo [35].  
 The antral follicle culture system used for the steroidogenesis experiments is an essential 
method to investigate the direct effects of MEHP on the antral follicle, which is the most mature 
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follicle type capable of ovulation and is the major producer of sex steroid hormones in the 
female. Previous studies have determined that MEHP exposure decreases estradiol levels in 
vitro; however, these studies utilized secondary follicles or murine/human granulosa cells [19-
21, 53]. Ovarian steroidogenesis is primarily conducted by the mature antral follicle, and it 
involves the strict coordination of theca and granulosa cells. Thus, the antral follicle culture 
system used in the present study expands upon the previously published data by using a more 
direct and sensitive approach [58, 81].  
We have previously reported that MEHP exposure decreases estradiol levels and the 
mRNA levels of Cyp19a1 in cultured mouse antral follicles following 96 hr of exposure. 
However, the temporal effects of MEHP upstream of estradiol and CYP19A1 and the mechanism 
by which MEHP decreases estradiol levels were not known. Further, we have previously 
reported that DEHP exposure decreases estradiol levels following 72 and 96 hr of exposure in 
cultured mouse antral follicles via a mechanism involving depletion of available precursor 
steroid hormones beginning at 48 hr of exposure [51]. However, it was unknown if DEHP and 
MEHP exhibited similar mechanisms of steroidogenesis inhibition.  
The initial effect of steroidogenesis was observed following 24 hr of exposure, where 
MEHP decreased the levels of androstenedione and testosterone at the 10 µg/ml dose, and this is 
likely attributed to the decrease in the mRNA levels of Hsd3b1 at that same time-point and dose. 
Interestingly, these effects were ablated and no changes in the levels of steroid hormones were 
observed following 48 hr of exposure. However, MEHP decreased the mRNA levels of Star and 
Cyp11a1 at that time-point, and a compensatory increase in the mRNA levels of Cyp19a1 was 
observed. The compensatory increase in Cyp19a1 levels persisted following 72 hr of exposure, 
and also at this time-point, a compensatory increase in the levels of Hsd17b1 was observed. 
Perhaps these compensatory increases in the levels of steroidogenic enzymes are present to 
combat the toxicity of MEHP; however, these increases do not lead to increases in steroid 
hormone levels. The increase in the levels of Hsd17b1 at the 72 hr time-point likely explains 
why we do not observe a statistically significant decrease in testosterone levels following 72 hr 
of exposure. Following 96 hr of exposure, the compensatory increases in the steroidogenic 
enzymes were ablated, and MEHP exposure decreased the mRNA levels of Cyp17a1, Hsd17b1, 
and Cyp19a1. It is likely this decrease in steroidogenic enzyme levels led to the decrease in the 
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levels of testosterone, estrone, and estradiol following 96 hr of exposure. Thus, MEHP decreased 
the levels of immediate precursor hormones and estradiol via a mechanism involving depletion 
of the enzymes responsible for generating these hormones. 
These findings on steroidogenesis also add to the existing literature that MEHP disrupts 
antral follicle functionality. Normal follicle function includes antral follicle growth, survival 
from apoptosis-induced atresia, and production of steroid hormones [22]. Previously, MEHP 
exposure for 72 and 96 hr has been shown to inhibit antral follicle growth in vitro, likely via 
disruption of cell cycle regulators [16, 17]. Additionally, MEHP exposure for 96 hr induced 
antral follicle atresia in vitro, likely via disruption of pro- and anti-apoptotic factors following 48 
hr of exposure [56]. Further, MEHP exposure for 72 hr decreased the activity of glutathione 
peroxidase in antral follicles, which led to oxidative stress in the cultured follicles [17]. In the 
present study, it appears that that major defects in steroidogenesis begin following 96 hr of 
exposure. Thus, the defects in antral follicle growth, atresia, and oxidative stress prior to 96 hr of 
exposure may promote the compensatory increases in Hsd17b1 and Cyp19a1. Further, it appears 
that these defects in antral follicle functionality precede and may cause the decreases in 
Cyp17a1, Hsd17b1, and Cyp19a1, ultimately leading to the decreases in testosterone, estrone, 
and estradiol levels. Future studies should address how MEHP interferes with the cross-talk 
between antral follicle growth, atresia, and steroidogenesis.       
Interestingly, DEHP and MEHP appear to exert toxicity differently depending on the 
system used. For the folliculogenesis studies, MEHP, but not DEHP, had a direct effect on 
accelerating primordial follicle recruitment via over-activation of the PI3K signaling pathway. 
For the steroidogenesis studies, both DEHP and MEHP have direct effects on the antral follicle. 
Specifically, we previously reported that DEHP exposure directly decreases precursor steroid 
hormones following 48 hr of exposure, and it is likely this decrease in the availability of 
precursor hormones that lead to the decrease in estradiol levels following 72 and 96 hr of 
exposure [51]. This is because the levels of the steroidogenic enzymes are relatively unchanged 
in response to 24-96 hr DEHP treatment [51]. However, in the present study, MEHP exposure 
decreased the levels of the steroidogenic enzymes following 96 hr of exposure, likely leading to 
the decrease in steroid hormone levels. We hypothesize that the differences between DEHP and 
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MEHP on folliculogenesis and steroidogenesis are attributed to ovarian metabolism of the 
chemicals.  
The ovary contains enzymes, specifically aldehyde dehydrogenases, alcohol 
dehydrogenases, and lipoprotein lipases, responsible for converting DEHP to MEHP and MEHP 
to further metabolic derivatives [82-86]. Importantly, the levels and activity of these metabolic 
enzymes increase with age, meaning the metabolic capacity of the neonatal ovary is much lower 
than the adult [84-87]. Thus, the reason that we likely do not observe direct effects of DEHP on 
folliculogenesis in our neonatal ovary culture system is because the neonatal ovaries do not have 
the metabolic capacity or possess the enzymes needed to convert DEHP to the toxic metabolite 
MEHP. However, these metabolic enzymes are present in the antral follicles [84-87], and 
perhaps differential metabolism explains why we observe differences in the DEHP and MEHP 
steroidogenesis studies. Thus, the composition of the mixture between parent compound and 
metabolites is likely different between our DEHP and MEHP treated follicles, and it is possible 
that this composition dictates toxicity in the antral follicle. However, it is plausible that the 
parent compound and metabolite simply exert toxicity in different ways. Future studies should 
investigate the metabolic capacity of the antral follicle to shed insight into the differential 
mechanisms of DEHP- and MEHP-induced inhibition of steroidogenesis.  
In conclusion, we have utilized the novel neonatal ovary and antral follicle culture 
systems to elucidate the mechanisms by which MEHP disrupts ovarian folliculogenesis and 
steroidogenesis. Collectively, our results indicate that MEHP has a direct effect on the neonatal 
ovary to accelerate primordial follicle recruitment, potentially via over-activation of ovarian 
PI3K signaling. Importantly, this mechanism in vitro is similar to the mechanism by which 
DEHP accelerates primordial follicle recruitment in vivo [35]. Additionally, our results indicate 
that MEHP has a direct effect on decreasing the levels of the steroidogenic enzymes responsible 
for generating estradiol and its immediate precursor steroid hormones. Interestingly, this 
mechanism is different than the mechanism by which DEHP inhibits steroidogenesis in vitro 
[51]. These effects of MEHP on folliculogenesis and steroidogenesis are of concern because 
ovarian controlled reproductive and non-reproductive processes have the potential to be 
compromised.  
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5.6 Tables, Figures, and Legends 
Table 5.1 Sequences of primer sets used for gene expression analysis 
 
Specific primer sequences used for qPCR analysis of gene expression.  
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Figure 5.1 Effect of DEHP and MEHP on early folliculogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ovaries from CD-1 mice were cultured from PND 4-PND 10 with vehicle (DMSO), DEHP (0.2-
20 µg/ml) (panel A), or MEHP (0.2-20 µg/ml) (panel B). Following culture, ovaries were 
processed for histological evaluation of germ cell and follicle counts. Percentages of each stage 
of folliculogenesis were calculated and compared in each treatment group. Graph represents 
means ± SEM (n=4-6 ovaries/treatment group). Asterisks (*) represent significant difference 
from vehicle control (p ≤ 0.05). 
  
156 
Figure 5.2 Representative images of immunohistochemistry and pseudocolored protein 
quantification 
 
 
Panels A-F exhibit PTEN staining in the whole ovary (panels A-D) and at 20x magnification to 
observe staining in primordial follicles (panels E and F). Panels G and H exhibit pAKT staining 
at 20x magnification to observe staining in primordial follicles. Panels A, B, E, and G were from 
vehicle control treated neonatal ovaries, and panels C, D, F, and H were from MEHP (2 µg/ml) 
treated neonatal ovaries. In panels A-D, the black arrow heads represent positive staining in the 
immunohistochemistry images, which translate to the yellow/orange pseudocolored pixels 
represented by red arrow heads. In panels E-H, the black arrow heads represent positively stained 
oocytes in primordial follicles.  
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Figure 5.3 Effect of DEHP and MEHP on protein levels of PI3K signaling factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ovaries from CD-1 mice were cultured from PND4-PND10 with vehicle (DMSO), DEHP (0.2-2 
µg/ml), or MEHP (0.2-20 µg/ml). Following culture, ovaries were subjected to 
immunohistochemistry for quantification of PTEN (the left side of panels A and B) and pAKT 
(the right side of panels A and B) staining. Digital images were converted to 8-bit grayscale 
images and then converted to pseudocolored images. Colors were based on relative stain 
intensity. Percentage of positively stained pixels in the whole ovary (panel A) and percentage of 
positively stained oocytes in primordial follicles (panel B) were calculated and compared in each 
treatment group. Graph represents means ± SEM (n=3/group). Asterisks (*) represent significant 
difference from vehicle control (p ≤ 0.05). 
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Figure 5.4 Effect of MEHP on the antral follicle-produced sex steroid hormone levels 
 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
MEHP (0.1-10 µg/ml) for 24-96 hr. Following each 24 hr time-point, media were pooled per 
treatment group and were subjected to ELISAs for the measurements of progesterone (panel A), 
dehydroepiandrosterone (panel B), androstenedione (panel C), testosterone (panel D), estrone 
(panel E), and estradiol (panel F). Graph represents means ± SEM from 3-9 separate 
experiments, with medium from 10-16 wells/treatment group in each experiment. ND indicates 
that hormone levels were not detectable because they were below the threshold level for 
detection. Asterisks (*) represent significant difference from vehicle control (p ≤ 0.05). 
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Figure 5.5 Effect of MEHP on the antral follicle mRNA levels of the steroidogenic enzymes 
 
Antral follicles were isolated from adult CD-1 mice and were cultured with vehicle (DMSO) or 
MEHP (0.1-10 µg/ml) for 24-96 hr. Following each 24 hr time-point, antral follicles were pooled 
per treatment group and were subjected to qPCR for the measurements of the mRNA levels of 
Star (panel A), Cyp11a1 (panel B), Hsd3b1 (panel C), Cyp17a1 (panel D), Hsd17b1 (panel E), 
and Cyp19a1 (panel F). All values were normalized to Actb. Graph represents means ± SEM 
from 3-9 separate experiments, with 10-16 follicles/treatment group in each experiment. 
Asterisks (*) represent significant difference from vehicle control (p ≤ 0.05).  
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CHAPTER VI 
Summary, Conclusions, and Future Directions 
6.1 Summary, Conclusions, and Future Directions 
 The goal of my doctoral dissertation work was elucidate the mechanisms by which DEHP 
and MEHP disrupt ovarian folliculogenesis and steroidogenesis. DEHP is a highly produced 
plasticizer in widely used consumer, medical, and building products [1, 2]. DEHP frequently 
leaches out of the products that humans consume on a daily basis. Thus, DEHP and its 
metabolite MEHP are identified as top contaminants present in human tissues, including the 
ovary [1, 3-13]. This is a public health concern because DEHP and MEHP are known endocrine 
disrupting chemicals and reproductive toxicants [1, 2]. However, few studies have investigated 
the effects of DEHP and MEHP on ovarian folliculogenesis and steroidogenesis. Understanding 
the effects of these chemicals on these ovarian processes is crucial because proper regulation of 
folliculogenesis is needed for appropriate reproductive and non-reproductive health [14-31]. 
Collectively, my studies show that environmentally relevant levels of DEHP and MEHP 
accelerate primordial follicle recruitment, inhibit antral follicle growth, induce antral follicle 
atresia, and inhibit antral follicle steroidogenesis. A model of the effects on folliculogenesis 
(Figure 6.1) and steroidogenesis (Figure 6.2) can be found in Chapter 6 section 2.  
 In Chapter 3, I first hypothesized that environmentally relevant levels of DEHP disrupt 
folliculogenesis by accelerating primordial follicle recruitment in vivo. I found that DEHP 
exposure for 10 days decreased the percentage of primordial follicles at the 20 and 200 
mg/kg/day doses and increased the percentage of primary follicles at all selected doses. Further, 
DEHP exposure for 30 days increased the percentage of primary follicles at the 200 μg/kg/day 
and 20 mg/kg/day doses with a trend for a decrease in the percentage of primordial follicles at 
those doses. The decrease in primordial follicles accompanied by an increase in primary follicles 
suggests that DEHP exposure accelerates primordial follicle recruitment in vivo. Because the 
female is born with a finite reserve of primordial follicles, acceleration of primordial follicle 
depletion can cause infertility and/or premature ovarian failure. Future studies should investigate 
if the effects of 10 and 30 day exposure to DEHP on primordial follicle recruitment are 
permanent. Further studies should investigate if chronic exposure to DEHP results in a similar 
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acceleration of primordial follicle recruitment. In addition, future studies should investigate if the 
effects on folliculogenesis cause infertility and/or premature ovarian failure.  
 In Chapter 3, I further hypothesized that DEHP exposure accelerates primordial follicle 
recruitment via over-activation of the PI3K signaling pathway. Factors within this signaling 
pathway are regulators of primordial follicle survival, quiescence, and recruitment [32-37]. 
Specifically, factors that inhibit PI3K signaling, such as PTEN, maintain primordial follicle 
quiescence, while factors that drive PI3K signaling, such as pAKT, promote primordial follicle 
recruitment [38]. I found that DEHP exposure at doses that accelerated primordial follicle 
recruitment altered the mRNA levels of PI3K signaling factors that are associated with 
folliculogenesis. Importantly, DEHP exposure at doses that accelerated primordial follicle 
recruitment decreased PTEN levels and increased pAKT levels in the whole ovary, primordial 
follicles, and primary follicles. Since the factors involved in PI3K signaling are heavily regulated 
translationally and post-translationally, the protein data expand upon the mRNA data. Further, I 
found that these signaling factors were altered in the primordial and primary follicle populations. 
Interestingly, increased levels of DEHP metabolites in serum and urine are associated with an 
earlier age of menopause in women [39]. Further, accelerated primordial follicle recruitment via 
over-activation of PI3K signaling is a mechanism also conserved in humans [33, 40]. Thus, the 
findings in these studies may be translational for women’s public health. Future studies should 
investigate the cross-talk between the PI3K signaling pathway and other signaling pathways 
associated with folliculogenesis to confirm if the effects on primordial follicle recruitment in the 
present study are direct effects on PI3K signaling.  
 In Chapter 4, I hypothesized that DEHP directly alters regulators of the cell cycle, 
apoptosis, and the steroidogenic pathway in antral follicles in vitro to inhibit growth, induce 
atresia, and inhibit steroidogenesis. The studies conducted in Chapter 4 provide the initial and 
time specific events by which DEHP induces toxicity in the antral follicle. I found that DEHP 
exposure initially increased the mRNA levels of cell cycle regulators perhaps in a compensatory 
manner to combat the toxicity of DEHP on the antral follicle. Specifically, DEHP increased the 
mRNA levels of Ccnd2, Cdk4, Ccne1, Ccna2, and Ccnb1 and decreased the levels of Cdkn1a 
prior to growth inhibition. However, following 72 hr of exposure, DEHP inhibited antral follicle 
growth, and by 96 hr of exposure, DEHP decreased the mRNA levels Ccnd2 and Cdk4 [41]. 
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Although there is an initial compensatory alteration in these factors that control the cell cycle, the 
compensation is not adequate enough to rescue the growth inhibition. Perhaps, this is also why I 
did not observe complete inhibition of antral follicle growth, but rather, DEHP exposure 
inhibited antral follicle growth by 15% compared to controls.  
Further, I found that DEHP exposure induces antral follicle atresia by increasing the 
levels of pro-apoptotic factors that regulate atresia. Specifically, DEHP increased the mRNA 
levels of Bad, Bax, and Bok prior to the observation of atresia at 96 hr of exposure. The increases 
in these pro-apoptotic factors were accompanied by increases in the mRNA levels of Bcl2 and 
Bcl2l10, which are anti-apoptotic factors. The increases in anti-apoptotic factors may be 
compensatory to combat DEHP toxicity; however, studies have shown that BCL2 can achieve 
pro-apoptotic properties in an apoptotic environment [42]. In addition, DEHP exposure increased 
the mRNA levels of Casp8 and Casp3, which are downstream regulators of apoptosis. In the 
ovary, 99% of all follicles undergo atresia [43, 44]. Thus, an increase in the incidence of antral 
follicle atresia can decrease sex steroid hormone levels and can cause infertility [45, 46]. The 
DEHP-induced increase in atresia can possibly have lasting effects of fertility and non-
reproductive health. Future studies should investigate if DEHP exposure in vivo increases atresia, 
and these studies should investigate if the increase in atresia causes anovulation and defects in 
the brain, cardiovascular, and skeletal systems.  
In addition to the defects in antral follicle growth and atresia, I found that DEHP 
exposure inhibits steroidogenesis by decreasing the levels of precursor sex steroid hormones 
available to be converted to estradiol. Specifically, DEHP exposure decreased the levels of 
progesterone, androstenedione, and testosterone following 48 hr of exposure, which is prior to 
the decrease in the levels of estradiol. These hormones serve as precursors to the generation of 
estradiol, but they are also required for reproductive and non-reproductive processes. The 
decrease in these hormones occurs in the general absence of a decrease in the levels of the 
steroidogenic enzyme, even though DEHP at 100 μg/ml decreased the mRNA levels of Cyp17a1, 
Hsd17b1, and Cy19a1. Thus, it is likely that the depletion of precursors at 48 hr of exposure led 
to the decrease in estradiol production following 96 hr of exposure. An inhibition of 
steroidogenesis can have lasting effects on reproductive and non-reproductive health [45, 46]. 
Specifically, decreasing these hormones can inhibit ovulation, disrupt the hypothalamus-
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pituitary-ovarian axis, inhibit the maintenance of the reproductive tract, and cause mood 
disorders, osteoporosis, and cardiovascular disease [14-31]. Future studies should address if the 
inhibition of steroidogenesis is present following exposure in vivo, and if the DEHP-induced 
inhibition of steroidogenesis causes anovulation and non-reproductive disorders. Further, future 
studies should supplement progesterone in the antral follicle culture media, since progesterone is 
the most upstream hormone affected by DEHP exposure. These studies would provide insight 
into whether the effects of DEHP on steroidogenesis are treatable.     
In Chapter 4, I provided evidence that DEHP directly alters antral follicle functionality. 
Antral follicles must undergo growth, survive atretic demise, and produce steroid hormones to 
remain viable for ovulation. DEHP exposure directly inhibits growth by altering cell cycle 
regulators, induces atresia by increasing pro-apoptotic factors, and inhibits steroidogenesis by 
depleting precursor steroid hormones. Interestingly, these effects occur rather congruently, so it 
is unknown which process is targeted first and whether the defects in one process promotes the 
defects in the others. Future studies should further investigate the time-specific effects of DEHP 
on growth, atresia, and steroidogenesis to determine which process is altered first.  Additionally, 
future studies should investigate the cross-talk between antral follicle growth, atresia, and 
steroidogenesis in order to ascertain the interrelationship of these processes. 
In Chapter 5, I first hypothesized that MEHP directly mediates the DEHP-induced 
acceleration of primordial follicle recruitment in vitro. I found that MEHP exposure at doses 
similar to those used in the in vivo experiments decreased the percentage of germ cell and 
increased the percentage of primary follicles in a whole neonatal ovary culture system. The 
neonatal ovary culture system was used because neonatal ovaries are enriched in primordial and 
primary follicles, which are the populations in which an effect is observed in vivo. Meanwhile, 
DEHP treated neonatal ovaries had comparable percentages of germ cells, primordial follicles, 
and primary follicles to control treated ovaries. These data suggest that MEHP directly 
accelerates primordial follicle recruitment, which is similar to the effect observed following 
DEHP treatment in vivo. I further hypothesized that MEHP directly accelerates primordial 
follicle recruitment via over-activation of the PI3K signaling pathway. I found that MEHP, but 
not DEHP, decreased the levels of PTEN in the whole ovary, decreased the percentage of 
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positively stained PTEN primordial follicle oocytes, and increased the percentage of positively 
stained pAKT primordial follicle oocytes.  
These findings suggest that MEHP has a direct effect on over-activating ovarian PI3K 
signaling to potentially lead to the acceleration of primordial follicle recruitment. The 
mechanism by which MEHP accelerates primordial follicle recruitment is the same in which 
DEHP accelerates primordial follicle recruitment in vivo. Thus, the effects on early 
folliculogenesis are direct on the ovary, and it is MEHP that mediates the effects of DEHP on 
accelerated primordial follicle recruitment. As previously mentioned, accelerated depletion of 
primordial follicles can cause infertility and premature ovarian failure. Further, increased levels 
of DEHP metabolites are associated with an earlier age of menopause, and the PI3K-regulated 
control of primordial follicle recruitment is conserved in women [33, 39, 40]. Future studies 
should incorporate the use of PI3K inhibitors in the culture system to investigate if MEHP is 
working exclusively through the PI3K signaling pathway. These studies would provide 
therapeutical insight by potentially rescuing the MEHP-induced acceleration of primordial 
follicle recruitment. Further, these findings would aid in the understanding of the mechanisms of 
primordial follicle activation, and provide novel techniques to manipulate the follicular reserve.   
In Chapter 5, I further hypothesized that MEHP directly inhibits the synthesis of sex 
steroid hormones in antral follicles in vitro via a different mechanism than DEHP. Similar to 
DEHP treated follicles, I found that MEHP exposure decreased the levels of testosterone and 
estradiol following 96 hr of exposure. In contrast to the DEHP treated follicles, I found that 
MEHP exposure also decreased the levels of estrone following 96 hr of exposure. Again, defects 
in antral follicle steroidogenesis can cause infertility and other non-reproductive disorders [14-
31].  
Interestingly, MEHP appears to inhibit steroidogenesis via a different mechanism than 
DEHP. Initially, MEHP exposure increased the mRNA levels of Hsd17b1 and Cyp19a1 
following 48 and 72 hr of exposure. The increase in the levels of these steroidogenic enzymes is 
perhaps to compensate for the toxicity of MEHP; however, this compensatory increase did not 
lead to an increase in the levels of sex steroid hormones. Further, this compensatory increase is 
ablated following 96 hr of exposure where MEHP decreased the mRNA levels of Cyp17a1, 
Hsd17b1, and Cyp19a1. Thus, it is likely this decrease in steroidogenic enzyme levels that led to 
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the decrease in testosterone, estrone, and estradiol following 96 hr of exposure. This mechanism 
is in contrast to the DEHP-induced inhibition of steroidogenesis. In Chapter 4, I concluded that 
DEHP decreased the levels of precursor steroid hormones beginning at 48 hr of exposure, in the 
general absence of a decrease in steroidogenic enzyme levels, which led to a decrease in estradiol 
levels. MEHP, meanwhile, relatively did not decrease the levels of precursor hormones prior to 
96 hr of exposure. Thus, MEHP decreased the levels of the enzymes responsible for generating 
estradiol beginning at 96 hr of exposure.  
Future studies should investigate the differential mechanisms by which DEHP and 
MEHP inhibit steroidogenesis. It is possible that the antral follicle differentially metabolizes 
DEHP to MEHP and MEHP to its further oxidative derivatives. The adult ovary and antral 
follicles contain the enzymes capable of metabolizing DEHP to MEHP [47-50]. Thus, the 
composition of the mixture between parent compound and metabolites is likely different between 
the DEHP and MEHP treated follicles, and it is possible that this composition dictates toxicity in 
the antral follicle. Future studies should investigate how the antral follicle metabolizes DEHP 
and MEHP. Additionally, these studies should use a composition of the DEHP metabolite 
mixture to investigate which metabolite and what levels of metabolites are responsible for 
defects in steroidogenesis. Further, the level and activity of these metabolic enzymes increase 
with age [47-50]. Thus, this may explain why DEHP did not affect early folliculogenesis in the 
neonatal ovary culture system. Additional studies should confirm that the metabolic capacity of 
the neonatal ovary is not adequate enough to metabolize DEHP to its toxic metabolites. 
Understanding ovarian metabolism is important from a physiological and therapeutical stand 
point. Intervening in the ovarian metabolism of DEHP and MEHP may alleviate some of the 
toxic outcomes that were observed in my doctoral dissertation work.    
Overall, my doctoral dissertation work indicates that environmentally relevant levels of 
DEHP and MEHP disrupt ovarian folliculogenesis and steroidogenesis. Specifically, DEHP, 
through its bioactive metabolite MEHP, accelerates primordial follicle recruitment via over-
activation of PI3K signaling. Additionally, DEHP and MEHP differentially inhibit 
steroidogenesis in the antral follicle by decreasing the availability of precursor hormones and 
decreasing the levels of steroidogenic enzymes, respectively. These findings are important for 
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public health because humans are continuously exposed to these chemicals. Further, the ovary is 
an integral regulator of reproductive and non-reproductive health.  
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6.2 Figures and Legends 
Figure 6.1 Mechanism by which DEHP and MEHP alter folliculogenesis  
 
 
 
 
 
 
 
DEHP, through its bioactive metabolite MEHP, directly decreases PTEN and increases pAKT in 
the ovary to over-activate PI3K signaling. The over-activation of PI3K signaling leads to the 
acceleration of primordial follicle recruitment indicated by decreases in the percentages of germ 
cells and primordial follicles and increases in the percentage of primary follicles in vivo and in 
vitro. 
  
176 
Figure 6.2 Mechanisms by which DEHP and MEHP alter steroidogenesis 
 
 
 
 
 
 
 
DEHP and MEHP differentially inhibit the production of estradiol in cultured antral follicles. 
Specifically, DEHP decreases the precursors available to be converted to estradiol beginning at 
48 hr of exposure, and MEHP decreases the levels of the steroidogenic enzymes responsible for 
generating estradiol beginning at 96 hr of exposure.   
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